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ABSTRACT 
Cancer is the second biggest global killer,[1,2] with cancers of the brain and central nervous 
system accounting for a disproportionately high number of deaths.[3]  The most prolific cancer 
of the central nervous system is glioblastoma, for which prognosis is still very poor.  In this 
project, analogues of two lead compounds with known activity against glioblastoma cell lines 
(compounds 4 and 5, Figure 1) were produced in order to develop structure-activity 
relationships and discover compounds with superior activities against glioblastoma. 
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Figure 1 - The structures of the lead compounds 4 and 5 
Analogues of compound 4 were the result of a rigorous similarity search of the ZINC database,[4,5] 
as well as using chemical intuition to identify potential analogues.  A scaffold-hopping approach 
was undertaken, through which two new compound classes were identified as potentially 
superior lead compounds for future work (Figure 2). 
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Figure 2 - The structures of two analogues of compound 4 with different scaffolds and superior activity, 
compounds 168 and 214 
Compound 4 is known to induce cell death through the induction of elevated levels of cellular 
reactive oxygen species (ROS),[6] which may be formed via the radical form of compound 4 and 
its analogues.  The connection between the anticancer activity of 4 and its analogues with the 
propensity of these compounds to form radicals was also investigated.  Enthalpic values relevant 
to radical formation (BDE, AIP, PDE, PA and ETE) were calculated using a density functional 
theory (DFT) approach.  Although no strong correlation was found for the whole series of 
compounds, the data indicates that correlations may exist within certain structural classes. 
The anticancer activity of compound 5, a prodrug, was compared against 11 analogues of both 
the prodrug and active form of the compound (Scheme 1).  It was found that compound 9 has 
superior activity to that of the prodrug 5.  Substitutions at the N-position of 5 were also found 
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to have a significant effect on activity, with an N-tosyl analogue having significantly improved 
activity against glioblastoma cell lines and short term cultures.  The results obtained suggest that 
future work on this series should therefore be based around compound 9, a subclass of indoles 
that have wide ranging anticancer activity, but have not yet been reported against glioblastoma. 
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Scheme 1 - The degradation of 5 into its suspected active form (9) 
In conclusion, analogues were discovered within this project which improved upon the 
anticancer activity of both compounds 4 and 5.  For compound 4, two alternative scaffolds were 
identified as superior and novel lead compounds against glioblastoma, and there is some 
indication that there may be a correlation between radical formation and anticancer activity 
within specific structural classes of this functional class of compounds.  For prodrug 5, 
substituents at the N-positon were found to have a significant effect on activity, and the activity 
of the active form (9) was found to be superior to the activity of the prodrug.  
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1.1 Cancer 
Cancer is one of the biggest global killers, responsible for 8.2 million deaths in 2012,[1] the most 
recent year for which reliable data is available.  This makes cancer the second biggest global 
killer after cardiovascular disease.[2]  Reproductive, dietary, metabolic, hormonal and age-based 
factors are expected to drastically increase cancer incidences between now and 2030.[7] 
The most common types of cancer internationally are lung (13%), breast (12%) and colorectal 
(9.8%).[8]  Although relatively uncommon, cancers of the brain and central nervous system (1.7%) 
have disproportionately high mortality rates.  According to Cancer Research UK, cancers of the 
central nervous system accounted for 9,365 of the 331,487 cases (2.83%) in the UK in 2011 (with 
2011 being the most recent year for which such data is available), while accounting for 5,187 of 
the 161,823 deaths (3.21%).  The ten-year net survival of malignant brain tumours for patients 
diagnosed in 2011 is expected to be around 13.5%, comparing poorly with the predicted value 
of 49.8% for all cancer patients.[3]  As age is a major risk factor for many types of cancer including 
many cancers of the central nervous system,[9] incidence rates are expected to continue their 
upward trend as life expectancy continues to increase. 
Tumours found in the brain may or may not have originated there, and one main way to classify 
tumours is based on where the tumour originated.  A primary tumour is one which originated at 
the site, and a secondary tumour is one which originated elsewhere in the body, then 
metastasised to the brain.  Metastatic tumours have the properties of the original tumour, for 
example a tumour of the lung which metastasised to the brain would be made up of mutated 
lung cells, not of mutated brain cells. 
There are over 150 types and subtypes of tumours of the central nervous system,[10] which can 
be classified in a number of ways.  A common way of classifying tumours is based on its “tumour 
grade”, and brain tumours are often graded on a four-tier scale (going from Grade I to Grade 
IV).  Grading is done by inspecting the cancerous cells under a microscope for similarity to the 
healthy cell, and the more dissimilar the cancerous cell is to a healthy cell (referred to as a 
“poorly differentiated” or “anaplastic” cell), the higher the grade it is given.  The more similar a 
cancerous cell looks to its healthy counterpart, the slower the bulk tumour is likely to develop.  
The more abnormal the cancerous cell looks, the more likely the tumour is to grow aggressively.  
High-grade tumours (often called “malignant” tumours) are relatively fast growing, have a larger 
chance of recurrence (more likely to come back after removal), are more likely to metastasise, 
are more difficult to treat and are therefore more dangerous to the patient.  Low-grade tumours 
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(often called “benign” tumours) are relatively slow growing, are less likely to recur, are less likely 
to metastasise, are typically easier to treat and therefore pose much less of a danger to the 
patient. 
1.1.1 Glioblastoma 
Of the 155 types and subtypes of tumours of the central nervous system, the most prolific is 
glioblastoma.  Glioblastomas begin in the brain as mutated astrocytes, a type of glial cell named 
after their star-like appearance.  They were first described as glioblastoma multiforme (GBM) in 
1926,[11] with the name alluding to the belief that the tumour originated from a glioblast, an 
undifferentiated glial cell.  The “multiforme” component of the name was due to the variation 
in appearance between cells within the same tumour, making them appear to have multiple 
forms. 
Glioblastomas are a WHO Grade IV tumour,[10] the most aggressive grade.  Coupled with the 
difficulty in treating these tumours and their sensitive location, the prognosis for patients 
diagnosed with glioblastoma is often very poor.  Prognoses have improved steadily over recent 
years due to improvements in surgical methods, radiotherapy and the creation and 
development of better chemotherapies, but are still very poor. 
The standard treatment procedure is currently maximal safe surgical resection followed by 
simultaneous radiotherapy to the resection site and chemotherapy with temozolomide, in what 
is sometimes known as the “Stupp protocol” after Roger Stupp, who first described this 
method.[12]  The Stupp protocol leads to a mean survival of 14.6 months and a two year survival 
of 26.5%.[12]  Glioblastomas are however largely considered to be currently incurable. 
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Figure 3 - The structures of temozolomide (left) and mitozolomide (right), two imidazotetrazines that 
were shown to have broad-spectrum antitumour activity 
Temozolomide, the current first line therapy for glioblastomas, was first published by the 
Stevens group at the University of Aston in Birmingham (now simply called “Aston University”) 
in 1984 alongside a series of other imidazotetrazines that showed broad-spectrum antitumour 
activity (Figure 3)[13].  Temozolomide was actually the second compound from this publication 
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to make it to clinical trials, but after the similarly structured mitozolomide showed unacceptable 
toxicity in phase II trials,[14–16] temozolomide was entered into phase I trials in 1992.[17]  FDA 
approval for the use of temozolomide was originally given in 1999 for use on anaplastic 
astrocytomas, and in 2005 for use on newly diagnosed glioblastomas. 
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Scheme 2 - Guanine (left) and the products of O6 methylation (1) and N7 methylation (2) 
Temozolomide is a DNA alkylating agent, meaning it can damage DNA by adding alkyl groups to 
some residues.  In the case of temozolomide, it is known to add a methyl group typically at the 
O6 or N7 position of guanine residues of DNA (Scheme 2).  This is achieved because 
temozolomide is a prodrug, and degrades under physiological conditions to form 3-methyl-
(triazen-1-yl)imidazole-4-carboxamide (MTIC).  MTIC itself degrades into 5-aminoimidazole-4-
carboxamide (AIC) and the methyldiazonium ion (Scheme 3). 
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Scheme 3 - The degradation of temozolomide to MTIC and finally to AIC and the methyldiazonium ion 
This methyldiazonium ion is the species which is responsible for the actual methylation of DNA, 
as shown in Scheme 4. 
N
N
Me
:DNA Me-DNA N2+
 
Scheme 4 - Methylation of DNA by the methyldiazonium ion 
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1.1.2 The Blood-Brain Barrier 
Aside from the obviously sensitive nature of the surroundings of a glioblastoma tumour, a 
further issue to consider when designing chemotherapies is the blood-brain barrier (BBB, shown 
in Figure 4).  The BBB is a semi-permeable membrane separating brain cells (and by extension 
brain tumours) and the extracellular fluid from the blood stream, and exists solely in the central 
nervous system.  The BBB is predominantly composed of endothelial cells, much like the rest of 
the circulatory system, but in the brain, the endothelial cells are bound to one another with 
“tight junctions”, meaning that compounds can’t pass between the endothelial cells, as they can 
elsewhere in the circulatory system.  The BBB also includes pericytes, which cover around a third 
of the surface of the capillary, and have roles in the formation and maintenance of the BBB.  
Finally, the capillaries are kept structurally sound and held in place by the foot processes of 
astrocytes. 
 
Figure 4 - The structure of the blood-brain barrier * 
The task of the BBB is to prevent chemicals harmful to the brain (often called “neurotoxins”) 
from making it to the brain, while allowing water, certain gasses, sugars, amino acids and some 
lipid-soluble compounds including hormones through.  It is therefore highly selective, and poses 
a significant problem when attempting to administer drugs via a route that utilises the blood 
stream. 
                                                          
* Original graphic created solely for this thesis 
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Due to its small size and lipophilicity,[18] temozolomide readily permeates the blood-brain 
barrier.[19]  The same cannot be said for another glioblastoma chemotherapy carmustine (Figure 
5), although a workaround has been developed which bypasses the blood-brain barrier 
completely.  Carmustine, as part of a degradable polymer wafer, is applied directly to the 
resection site during surgery.  As the polymer breaks down, the drug is released in a controlled 
manner directly to the remaining cancer cells.[20] 
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Figure 5 - The structures of two glioblastoma chemotherapeutic drugs, temozolomide and carmustine 
1.1.3 Chemoresistance 
A further problem with chemotherapies that is especially pervasive with respect to treating 
glioblastomas is the tendency for cancer cells to become resistant to anticancer drugs, in a 
process known as chemoresistance.  Due to the apparent propensity for glioblastomas to 
become chemoresistant, a phenomenon that is still not fully understood,[21] more 
chemotherapies will always be required. 
The primary form of chemoresistance with the current first line chemotherapy temozolomide is 
that the DNA methylation shown in Scheme 4 can be undone by the protein O6-methylguanine-
DNA methyltransferase (MGMT).  The MGMT protein is essential in humans for maintaining 
genomic stability, as it can repair the naturally occurring O6-methylguanine back to guanine, thus 
preventing transcription errors.  However, as mentioned earlier, temozolomide’s mode of action 
is to induce this mutation in order to damage cancerous cells.  There are two potential solutions 
to this form of chemoresistance. 
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Figure 6 - O6-Methylguanine (1) and the inactivator of MGMT O6-benzylguanine (3) 
The first potential solution is to prevent the action of MGMT.  This is an active area of research, 
and the most promising method discovered thus far is using O6-benzylguanine (Figure 6) to 
inactivate MGMT by irreversibly binding to it, thus meaning that guanine residues alkylated at 
the O6 position remains alkylated.[22]  By coadministering O6-benzylguanine with an alkylating 
agent, chemoresistance due to MGMT can be prevented,[23] and this method has made it all the 
way to clinical testing with promising results.[24,25] 
The second potential solution to chemoresistance is simply to have more and varied therapies.  
So far, alkylating agents are the best therapy for glioblastomas, but in the cases where MGMT-
based chemoresistance is problematic, there is currently very little that can be done.  By having 
diverse chemotherapies available, the potential for running out of options is decreased.  This is 
the ultimate justification for this thesis. 
Although the mechanisms of action for the prevailing standard chemotherapies for 
glioblastomas (temozolomide and carmustine) are as DNA alkylators, a growing number of 
active compounds are found to induce cell death via oxidative stress, by inducing the generation 
of reactive oxygen species.[26] 
1.2 Reactive Oxygen Species 
The term reactive oxygen species (ROS), though poorly technically defined, is often taken as a 
collective term for small oxygen-containing radicals such as superoxide (O2●-), the hydroxide 
radical (HO●), alkoxyl radicals (RO●) or peroxyl radicals (ROO●).  Small, non-radical oxygen-
containing compounds that are either oxidisers, or can easily be converted into radicals, are 
often also considered to be reactive oxygen species, such as ozone (O3), singlet oxygen (1O2) and 
hypochlorous acid (HOCl).[27,28]  Analogous nitrogen-containing radicals such as the nitric oxide 
radical (●NO) are referred to as reactive nitrogen species (RNS), but due to RNS being so 
physiologically similar to ROS, RNS are often implicitly included as ROS. 
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Physiologically, ROS are essential for healthy cell functions and maintaining homeostasis,[29,30] as 
well as being implicated in many diseases associated with the ageing process,[31–33] Alzheimer’s 
disease [34–36] and cancer.[37–40]  It is this paradox that makes ROS-based therapies both promising 
and challenging. 
Within the cell, ROS can be generated under either physiological or pathological conditions.  
Major physiological sources for ROS generation include the electron transport chain during 
oxidative phosphorylation in mitochondria, as a by-product of protein oxidation in the 
endoplasmic reticulum, and as a by-product from some oxidases in peroxizomes.[41]  Major 
pathological sources of ROS include oxidising water to a range of ROS via ionising radiation,[42,43] 
in inflamed tissues during a respiratory burst (also known as an oxidative burst),[44] or due to 
unbound metals in the body via the Fenton reaction (Scheme 5).[45] 
𝐹𝐹𝐹𝐹2+ + 𝐻𝐻2𝑂𝑂2  →  𝐹𝐹𝐹𝐹3+ + 𝐻𝐻𝑂𝑂● +  𝐻𝐻𝑂𝑂− 
Scheme 5 - The Fenton reaction, generating the hydroxyl reactive oxygen species 
Within the cell, a major deleterious effect of ROS is the autoxidation of unsaturated lipids 
(denoted as RH in Scheme 6), which is a natural process whereby a ROS initiates a radical chain 
reaction that results in the degradation of unsaturated lipids in a cell membrane, causing 
damage to the cell.  The initiation step of this chain reaction rarely happens spontaneously, but 
the hydrogen radical can be abstracted by a ROS or other radical species (labelled as “X●” in 
Scheme 6.I).  This chain reaction is so destructive because the termination steps (Scheme 6.IV, 
Scheme 6.V and Scheme 6.VI) rarely happen due to the high relative concentration of RH, 
meaning that the step shown in Scheme 6.III happens many times before the chain reaction is 
terminated. 
Initiation 
Propagation 
 
Termination 
 
RH + X●  R● + XH 
R● + O2  ROO● 
ROO● + RH  R● + ROOH 
R● + R●  RR 
R● + ROO●  ROOR 
ROO● + ROO●  ROOR + O2  
(I) 
(II) 
(III) 
(IV) 
(V) 
(VI) 
Scheme 6 - Steps in the radical chain reaction for the autoxidation of lipids 
1.2.1 Using ROS to kill cancer cells 
Cells are highly adaptive to their environment.  Although there is a “sweet spot” with regard to 
ROS levels within a cell, small deviations from these levels lead to low levels of oxidative stress.  
This oxidative stress can be redressed by the cell in the form of an adaption such as increased 
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proliferation[46] or the synthesis of mutant proteins beneficial for survival under the new 
conditions (also known as adaptive translation).[47]  More significant deviations in ROS levels 
leads to higher levels of oxidative stress, which can lead to cell senescence,[48] apoptosis,[49,50] 
necrosis [51] or autophagic cell death.[52,53]  It has been shown that ROS-based therapies can be 
more effective, or even selective, in cancerous cells that have naturally elevated ROS levels or 
naturally decreased antioxidant levels.[28] 
ROS-based therapies are far from novel, and have been in use since as early as 1969 when 
procarbazine was approved by the FDA.[54] There have since been many more examples of such 
drugs, including drugs that cause ROS-induced apoptosis (adenosine, doxorubicin, imexon),[55–
57] ROS-induced complement-dependant cytotoxicity (rituximab),[58] ROS-induced senescence 
(cisplatin)[59,60] and ROS-induced autophagy (gemcitabine/cannabinoid combination).[61] 
1.2.2 Antioxidants 
Antioxidants are chemicals that prevent oxidation reactions.  Although the term is typically 
associated with dietary or endogenous antioxidants, antioxidants have roles as diverse as 
preventing fats in packaged food going rancid,[62] stabilising fuels[63,64] and preventing the 
degradation of rubbers.[65]  In each of these roles, some sort of oxidation reaction (either a loss 
of electrons, loss of hydrogen or gain of oxygen) is prevented or preferentially occurs on a 
sacrificial antioxidant. 
As previously mentioned, ROS homeostasis (and by extension oxidative stress) is maintained 
both by regulating ROS generation and regulating antioxidant generation; higher levels of ROS 
production can be counteracted with higher antioxidant levels and vice versa.  Such antioxidants 
can act in three different ways, and are classified based on this. 
The first way in which antioxidants can act is as oxygen scavengers.  In food preservation, a 
modified atmosphere of reduced oxygen levels or an atmosphere that is absent of oxygen 
altogether leads to prevention of food rancidity and reduction in the levels of many bacteria and 
fungi.[66]  By employing a modified atmosphere within the packaging, the shelf life of the food 
can be drastically increased.  Although limiting oxygen levels in packaging is common practice 
within the packaged food industry, creating oxygen-free conditions in vitro would not be a 
beneficial property of a physiological antioxidant, so this mechanism of antioxidant activity is 
not relevant to this work. 
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The second way in which antioxidants can act is by chelating to unbound metals in the body.  
Free metals in the body, particularly free iron or free copper, can be responsible for generating 
ROS via the Fenton reaction,[67] as has been previously mentioned.  Conditions such as 
haemochromatosis or Wilson’s disease are caused by elevated levels of iron or copper 
respectively in the body, which leads to elevated ROS levels and tissue damage.  Compounds 
that can chelate these metal ions can act as preventative antioxidants by preventing the metals 
from generating ROS in the first place, and such therapies for conditions such as 
haemochromatosis and Wilson’s disease are known.[68–71] 
The final and most physiologically relevant way in which antioxidants can act is by acting as a 
free radical terminator.  Free radical terminators are sacrificial antioxidants, meaning a single 
antioxidant molecule can terminate a single radical chain reaction.  In the radical chain reaction 
shown in Scheme 6, this would mean quenching one of the two radical species (i.e. R● or ROO●), 
and the steps involved with radical chain reaction termination by an antioxidant (AH) is shown 
in Scheme 7. 
 
ROO● + AH  ROOH  + A● 
RO● + AH  ROH + A● 
ROO● + A●  ROOA 
RO● + A●  ROA 
(I) 
(II) 
(III) 
(IV) 
Scheme 7 - Termination of radicals by antioxidant AH 
As can be seen in Scheme 7.III and Scheme 7.IV, the radical form of the antioxidant (A●) appears 
as the quenching species.  If the antioxidant radical is stable enough, A● can also play the role of 
X● in Scheme 6.I.  In other words, these compounds can act as both pro-oxidants and 
antioxidants in a concentration-dependant manner.[72,73] 
Phenolic compounds can therefore act as pro-oxidants by forming their respective radical 
species.  This could hypothetically occur via a number of potential pathways, as shown in 
Scheme 8.  The simplest way that this could occur is by homolytic cleavage of the O-H bond, and 
subsequent loss of a hydrogen radical in a process known as “Hydrogen Atom Transfer” (HAT).  
This process therefore yields two compounds that could either terminate or initiate a radical 
chain reaction.  The next process, along the top of Scheme 8, is the sequential loss of a proton 
then an electron, and is known as “Sequential Proton Loss Electron Transfer” (SPLET).  It doesn’t 
produce a hydrogen radical, but it does produce a lone electron, which could generate a ROS 
(for example, the electron may partake in the partial reduction of O2 to superoxide, a known 
ROS).  The final pathway for phenolic radical formation is the loss of an electron followed by the 
loss of a proton, in a process known as “Sequential Electron Transfer Proton Transfer” (SET-PT).  
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Like with SPLET, it produces a phenolic radical and an electron capable of forming a ROS, but has 
a different intermediate. 
OH O
O
OH
HAT
PL ET
PTSET
- H+
- e-
H
-
- H+
- e-
 
Scheme 8 - Possible ways in which a phenolic compound could form its respective radical species.  
HAT = Hydrogen Atom Transfer.  PL = Proton Loss.  ET = Electron Transfer.  SET = Single Electron Transfer.  
PT = Proton Transfer 
When studying these mechanistic steps, the enthalpy of each step has a specific name; bond 
dissociation enthalpy (BDE) for HAT, proton affinity (PA) for PL, electron transfer enthalpy (ETE) 
for ET, adiabatic ionisation potential (AIP) for SET and proton dissociation enthalpy (PDE) for PT.  
These enthalpic values are often determined computationally, and are plotted against 
antioxidant activity in an attempt to find correlations.  BDE is often found to correlate with 
antioxidant activity,[74,75] and BDE and IP are occasionally found to correlate anticancer 
activity.[76] 
This project includes work on a lead compound which is known to promote the formation of 
ROS (which will be discussed later).  An attempt will therefore be made to correlate the activity 
of this lead compound and its analogues with the enthalpic values previously described in order 
to investigate if the class of compounds under investigation can be considered to be directly 
responsible for the generation of ROS. 
1.3 The Lead Compounds 
Indoles have long since been known to have anticancer properties through a variety of 
mechanisms including as topoisomerase inhibitors,[77–88] PKC inhibitors,[89–96] PDGF signal 
transduction inhibitors,[97] methuosis initiators,[98–100] G2/M abrogators,[101–104] Trk inhibitors,[105–
108] angiogenesis inhibitors,[109,110] PARP inhibitors[111,112] and casein kinase 2 inhibitors[113].  This 
project was born out of the work of Prabhu et al,[6] who found that the indole-based compounds 
4 and 5 (Figure 7) had reasonable activity against the glioblastoma cell line U87.  These structures 
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themselves were designed based on a review authored by Lal and Snape, which described the 
variety of biological properties that 2-phenylindoles have been implicated in.[114]  Due to their 
range of activities and their relatively simple structures, 2-phenylindoles make appealing lead 
structures for a medicinal chemistry research project. 
N
H NH
OHHO
N
H
4 5 2-phenylindole  
Figure 7 - The structures of compound 4 (left), compound 5 (centre) and 2-phenylindole (right) 
Prabhu et al. originally considered compounds 4 and 5 to be of the same pharmacological class 
of compounds, and indeed these two compounds do have structural similarities (Figure 8).  Both 
compounds contain a 2-phenylindole skeleton (shown in blue) and a hydroxide group that can 
be close in space (shown in red), combining into what would form a believable pharmacophore.  
However, to understand why this is now thought unlikely to be the case, the background of 5 
needs to be examined. 
N
H
OH
N
H
OH
N
H
HO
4 5
 
Figure 8 - Commonalities in the structures of 4 (top left) and 5 (top right) 
1.3.1 The Lead Compound 5 
N
H
OH
N
H
N
H
OH
5
II3C 2
-
-pheennylliinndoollee
 
Figure 9 - Compound 5 (below) was created as a hybrid structure of I3C (left) and 2-phenylindole (right) 
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Compound 5 was created as a hybrid structure between the naturally occurring compound 
indole-3-carbinol (I3C) and the known privileged structure 2-phenylindole (Figure 9).  I3C is 
found naturally in particularly high concentrations in cruciferous vegetables such as cabbage, 
kale, cauliflower and sprouts.  I3C is by far the most studied component of cruciferous 
vegetables, a class of vegetable that appears to contain many anticancer agents.[115]  In vitro, I3C 
forms many degradation products (Scheme 9),[116] which have been an active area of study for 
over 30 years,[117,118] during which time I3C has been shown to be active against a wide variety  
of cancers including cancer of the breast,[119] colon,[120–122] prostate[123–125] and, most recently, 
against glioblastomas of the brain.[6]  Many of the I3C metabolites have also been shown to have 
wide ranging effects in biological assays.[123–126] 
N
H
HN
OH
NH
N
H
H
N
HN NH
N
H
HN
NH
N
H
N
H
HN
NH
H
N
NH
H
N
HN
H
N
I3C
DIM
ICZ
LTr1
CTr
CTet
LTet
 
Scheme 9 - Indole-3-carbinol (I3C) and its metabolites 3,3′-diindolylmethane (DIM), a cyclic tetramer 
(CTet), the first linear trimer (LTr1), indolo[3,2-b]carbazole (ICZ), a cyclic trimer (CTr) and a linear 
tetramer (Ltet) 
The simplest and mostly widely studied I3C metabolite is 3,3’-diindolylmethane (DIM). The 
mechanism of the conversion of I3C to DIM is well known, and proceeds under even slightly 
acidic conditions (even CDCl3 in an NMR sample tube) via a 3-methyleneindolinium intermediate 
(6),[117] as shown in Scheme 10.  DIM, which is known to be an active form of the prodrug I3C,[127] 
is formed in a reaction that appears to occur within 60 minutes under the conditions of the 
stomach.[128]  Under normal physiological conditions, it is thought that I3C is converted almost 
exclusively into DIM,[118] whereas under the conditions of the stomach, DIM, CTr and LTr are the 
major products, and are thought to be produced in roughly equal quantities.[128] 
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DIMI3C
I3C
- CH2O
-
H
6  
Scheme 10 - Generation of DIM from I3C via a 3-methyleneindolinium intermediate[116] 
Although the ultimate fate of I3C is known, it is thought that there may be other chemical 
changes that occur while I3C is in the body.  One such example of this, as described by Bjeldanes 
et al, is that I3C appears to form adducts with cellular thiols such as glutathione, cysteine and 
other such proteins.  This has been shown to occur in cell culture media both in the presence 
and absence of cells, indicating that the conversion is not enzymatically controlled or 
facilitated.[129]  The formation of such adducts, as was the case with the formation of DIM, is 
believed to proceed via the 3-methyleneindolinium ion (6).  An example of such a formation is 
shown in Scheme 11 between I3C and the representative and common thiol cysteine to form 
the metabolite 7. 
N
H
OH
N
H
S
OH
O
NH2
N
H
HS
OH
O
NH2
I3C 6
7
 
Scheme 11 - Proposed pathway for the formation of I3C-cysteine adduct 
In the same paper by Bjeldanes et al,[129] the path that I3C can take through cultured MCF-7 
breast cancer cells was investigated.  The concentrations of I3C, the I3C-cysteine adduct 7 
(shown in Scheme 11) and DIM were determined in the free media, in the cytosol of the cells 
and in the nuclei of the cells.  It was found that the concentration of I3C in the media gradually 
decreased while the concentrations of its metabolites barely increased, indicating that either 
I3C or its metabolites were being taken up by the cells faster than I3C could be metabolised.  I3C 
or DIM was not detected in the cytosol in significant quantities, but the concentration of adduct 
7 was shown to steadily increase.  Within the nucleus, I3C again wasn’t detected in significant 
quantities, whereas the adduct 7 was detected initially, but was seemingly steadily converted to 
DIM.  These observations suggested that I3C was converted to the adduct 7 in the media, adduct 
7 was taken up by the cell, then passed into the nucleus where it was converted to DIM.  The 
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fact that I3C doesn’t seem to exist in significant concentrations inside the cells further suggests 
that I3C it not directly responsible for any biological effect, and instead it is a metabolite of I3C 
that is the active species. 
Due to considering I3C as a prodrug, and based on the mechanism of formation of DIM (as shown 
in Scheme 10), compound 5 (Figure 7) might be expected to metabolise in much the same way, 
thus forming an analogous pharmacologically active metabolite.  Scheme 12 suggests a 
formation of the 2-phenylindole analogue of DIM, compound 9, which proceeds via the 
3-methyleneindolinium intermediate 8. 
N
H
OH
N
H
N
H
H
N
H
5 8
9  
Scheme 12 - Hypothesised analogous mechanism of the degradation of compound 5 
Returning to Figure 8, it is now obvious that compounds 3 and 5 cannot be part of the same 
pharmacological class in this instance, as comparing the structure of the prodrug 5 to the 
structure of compound 4 is not comparing like for like.  What would be a more fair comparison 
would be to compare the structure of 4 with compound 9 or DIM, which obviously share very 
few structural features, and would therefore be unlikely to be considered as two members of 
the same chemical class. 
Compound 5 is a novel compound and therefore a novel anticancer compound, and has been 
shown to be a marked improvement over its lead compound of I3C.  Work within the group has 
found that against the U87 glioblastoma cell line and using the MTS assay, I3C has an IC50 of 
526 μM, whereas compound 5 has an IC50 of 176 μM.[6] 
Prior to this project, the compound 9 (Scheme 12) had yet to be tested as an anticancer 
compound.  It has previously been investigated along with a series of DIM analogues as 
antibacterial compounds, but was found to be inferior to DIM in this respect, and was not taken 
forwards for further development.[130] 
Overall, investigating the potential of both compound 5 and its metabolite compound 9 as 
glioblastoma therapies appears to be a novel area of research.  This seems unusual considering 
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how much attention has been directed at I3C and at 2-phenylindoles, but this work will hopefully 
lead to the development of a more potent subclass of an already well studied class of anticancer 
compounds. 
1.3.2 The Lead Compound 4 
The second lead compound, compound 4 (Figure 10), was also found by Prabhu et al. to have 
anticancer activity against the U87 glioblastoma cell line, albeit to a lesser extent (IC50 of 
compound 5 was 176 µM, compared to an IC50 of 379 µM for compound 4).[6]  Compound 4 was 
tested due to it being a 2-phenylindole, a subclass of indoles which have many biological effects 
including reported anticancer properties.[114]  Compound 4 appears to be a novel anticancer 
agent against glioblastoma cell lines, whilst its parent compound, 2-phenylindole, has been 
shown by Prabhu et al. to be inactive.  This suggests that compound 4 may be a novel fragment 
with respect to antiglioblastoma compounds, and may be the simplest example of this class of 
compounds. 
N
H
HO
4  
Figure 10 - The structure of compound 4 
The mode of activity of compound 4 has also been briefly investigated.  Using the Image-iT™ 
LIVE Green Reactive Oxygen Species Detection Kit, it was found that the addition of compound 
4 to cells causes the levels of cellular reactive oxygen species (ROS) to increase (Figure 11).  The 
Image-iT™ LIVE Green Reactive Oxygen Species Detection Kit determines quantities of cellular 
ROS fluorometrically; a ROS oxidises the molecular probe, and ROS levels can therefore be 
quantised using a plate reader.  Because elevated ROS levels are typically associated with 
oxidative stress,[131] is was therefore hypothesised that compound 4 induces cellular death by a 
mechanism which includes elevated ROS levels.  This hypothesis has literature precedents, as 
many phenol derivatives and phenol-containing compounds are known to act in this way.[132–135] 
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Figure 11 - Detected ROS levels in U87 cells upon addition of compound 4.  Black vertical bar indicates 
baseline ROS level, and a peak shift to the right indicates elevated ROS levels 
Compound 4 has also been shown to induce apoptosis in vitro.  Using the Annexin V-FITC 
apoptosis detection kit, 1321N1 and U87 cells were shown to have entered the early stages of 
apoptosis 24 hours after addition of compound 4, and were shown to have entered the late 
stages of apoptosis 48 hours after addition of compound 4. 
 
Graph 1 - Percentage of cells in early and late apoptosis in 1321N1 and U87 cells 24 and 48 hours after 
addition of compound 4 (200 𝜇𝜇M, darker bars) and the positive control cisplatin (100 𝜇𝜇M on 1321N1 cell 
line, 200 𝜇𝜇M on U87 cell line, lighter bars) 
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1.4 Project Structure 
In this project, a multifaceted approach to drug development is taken, whereby multiple 
different approaches to designing analogues of known active lead compounds are undertaken.  
First, the traditional approach of synthesising and testing analogues is carried out, whereby 
chemically relevant analogues are produced using nothing more than chemical intuition and 
literature precedents.   The second approach to determining potential functional analogues is 
to carry out a computational similarity search to discover a wider breadth of structural 
analogues.  A similarity search is a way of exploring otherwise unconsidered or unknown areas 
of chemical space, hopefully leading to some functional analogues which will help elucidate 
otherwise neglected aspects of a structure-activity relationship (SAR).   
Once the structural analogues have been determined and either procured or synthesised, a 
series of enthalpic values about their propensities to form radicals will be calculated.  These 
values will be calculated computationally based on energies determined using density functional 
theory (DFT). 
The anticancer activities of these structural analogues will also be established against 
glioblastoma cell lines and short term cultures.  In the case of compound 4, because current 
evidence suggests that the anticancer activity of this lead compound is related to ROS, the 
relationship between anticancer activities and the energies of the aforementioned ROS-forming 
steps for this series of analogues will be investigated.
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2.1 The Indole Privileged Structure 
Although nature tends to produce biologically active compounds that make full use of all three 
dimensions, the state of chemical synthesis currently strongly favours the synthesis of rather 
planar compounds.[136]  One outcome of this is the use of “scaffolds”, i.e. the use of a molecular 
framework at the centre of a drug molecule around which biologically relevant substituents can 
be added in order to add activity or affect properties such as solubility or cell permeability.  A 
2009 paper based on the ZINC database found that over 241,000 unique scaffolds are currently 
known,[137] with the most common and versatile of these scaffolds being known as “privileged 
structures” or “privileged scaffolds”. 
 
Graph 2 - Occurrence of the terms "privileged structure”, "privileged structures”, "privileged scaffold” or 
"privileged scaffolds” within the title or abstract of publications between 1988 and 2015, as found using 
Web of Science † 
The terms “privileged structures” and “privileged scaffolds” have been in use since the term was 
first mentioned in 1988,[138] and have rapidly gone from a niche term to part of the standard 
medicinal chemistry lexicon (Graph 2).  The specific definition has changed slightly over time, 
but perhaps the most widely accepted and succinct definition was given by Duarte et al, who 
described privileged structures as “molecular frameworks which are [capable] of providing 
useful ligands for more than one type of receptor or enzyme target by judicious structural 
modifications”.[139]  Privileged structures include 2-imidazoline,[140] quinoline,[141] indole,[142] 
                                                          
† Original graphic created solely for this thesis 
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isatin[143] and chromone[144] (Figure 12) all five of which are highly rigid, planar compounds 
(although these are not features which are necessarily inherent to being a privileged structure).  
This in part explains why much of the explored drug-like chemical space involves largely planar 
compounds. 
N
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2--iimmiidaazzoolliinnee quuiinnoolliinnee iinndoollee iissaattiinn cchrroommoonnee  
Figure 12 - The privileged structures 2-imidazoline, quinolone, indole, isatin and chromone.  The 
numbering system for indole is shown 
The indole privileged structure is of particular importance, and is believed to be the most 
ubiquitous privileged structure known.[114,145]  The indole structure contains seven positions 
where derivatisation can occur (described in Figure 12), is perfectly planar, and contains an NH 
group at the 1-position which is not capable of acting as a hydrogen bond acceptor, and is known 
to act as a poor hydrogen bond donor.  The classification of being a privileged structure is 
certainly earned in the case of indole, which makes up the structural core of compounds with 
incredible diversity in activity, including the psychedelic drug LSD, the antimigraine drug 
rizatriptan, the “happy” hormone serotonin and the amino acid tryptophan (Figure 13). 
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LSD rizatriptan serotonin tryptophan  
Figure 13 - From left to right, the indole containing compounds LSD, rizatriptan, serotonin and 
tryptophan 
2.2 Indole Syntheses 
Due in part to their wide-ranging uses, the development of indole syntheses has been ongoing 
for many years, and much progress has been made in our ability to synthesise increasingly 
complex indoles under more mild and generic conditions. 
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2.2.1 The Fischer Indole Synthesis 
N
N COOH
N
COOH
10 11  
Scheme 13 - The original Fischer indole synthesis 
The most widely researched method of synthesising indoles is the Fischer indole synthesis, 
which was first carried out by Herman Emil Fischer in 1883.[146]   Fischer discovered this synthesis 
while synthesising 1-methylindole-2-carboxylic acid (11) from the phenylhydrazone 10 using this 
procedure, shown in Scheme 13 (although the exact product of this reaction wasn’t identified 
until 1884)[147].  The Fischer indole synthesis involves cyclising a phenylhydrazone (13) to an 
indole (17) under acidic conditions, and has since been developed to allow for the synthesis of 
indoles with substituents at any of the seven substitutable positions. 
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Scheme 14 - The mechanism of the Fischer indole synthesis 
A major benefit of the Fischer indole synthesis is that, under the same reaction conditions, the 
hydrazone can be generated in situ from a hydrazine and a ketone, both of which are classes of 
chemicals with wide commercial availability.  The actual mechanism of this tandem reaction, 
shown in Scheme 14, has since been elucidated by Allen and Wilson in 1943,[148] and was based 
on a suggestion first postulated by Robinson and Robinson in 1918.[149]  Starting from the 
aforementioned phenylhydrazine, the mechanism involves a condensation reaction between 
the hydrazine and an aldehyde to form the hydrazone, followed by a [3, 3] sigmatropic 
rearrangement, cyclisation, and subsequent loss of ammonia to yield the product indole. 
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Scheme 15 - The Buchwald modification for generation of N-arylhydrazones, followed by cyclisation to 
the indole under Fischer conditions 
If the hydrazone can’t be synthesised under these classic conditions, an alternative and 
increasingly popular entry into the Fischer indole synthesis is the palladium-catalysed cross 
coupling of an aryl bromide (18) and a hydrazone (19), forming the N-arylhydrazone (20).  This 
so called “Buchwald modification” of the Fischer indole synthesis, shown in Scheme 15, was first 
published by Stephen Buchwald et al in 1998,[150] and helped confirm the proposed role of the 
hydrazone intermediate in Scheme 14.  
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Scheme 16 - The Japp-Klingemann synthesis of indoles from aryldiazonium salts 
Aside from substitutions at the N-position, the main limitation of the Buchwald modification is 
the stability of aryl hydrazines, making it unreliable for large-scale industrial use.  However, aryl 
hydrazines can be avoided altogether by employing the Japp-Klingemann synthesis of aryl 
hydrazones directly from an aryldiazonium salt (22) and a β-keto ester (23) or β-keto acid (26), 
as shown in Scheme 16.  The Japp-Klingemann synthesis was first reported in 1887 by Francis 
Japp and Felix Klingemann,[151] when a small range of hydrazones (compounds 24 and 27) were 
synthesised.  These hydrazones could then be cyclised to their respective indoles (compounds 
25 and 28) using classic Fischer conditions.  The commercial potential of this reaction was proven 
in 1999 by Reddy et al, when the Japp-Klingemann synthesis was included in the multistep 
Chapter 2 – Project Background 
56 
 
synthesis of the potential anticancer agent melatonin, which was synthesised on a 5-10kg scale 
(Scheme 17).[152] 
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Scheme 17 -Reddy's multi-kilogram scale synthesis of melatonin, employing the Japp-Klingemann 
hydrazone synthesis and the Fischer indole synthesis 
The Fischer synthesis is by far the most developed reaction for synthesising indoles, and as such 
has the broadest scope.  This reaction is particularly compatible with a wide range of 
substitutions on all possible carbons due to the wide range of conditions that have been 
developed,[153–157] and the new C-C and C-N bonds are produced with a reasonably high degree 
of atom economy.  Substitutions on the N-position are however much more difficult and less 
developed, and the procedure is obviously unsuitable for reagents or products that are acid 
sensitive. 
2.2.2 Synthesis of Indoles From 2-Alkynyl Anilines 
2-Alkynyl anilines (34) can be intramolecularly cyclised by a number of methods to form indoles, 
and are themselves commonly synthesised via Sonogashira coupling between 2-haloanilines 
(32) and a terminal alkyne (33), as shown in Scheme 18.  Methods for the cyclisation step are 
mostly differentiated based on the choice of catalyst. 
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Scheme 18 - Example synthesis of a 2-alkynyl aniline (34) via the Sonogashira reaction 
Alkoxides such as potassium tert-butoxide or sodium ethoxide can be used to cyclise 2-alkynyl 
anilines or their carbamate derivatives (35), although the carbamate group is cleaved off under 
reaction conditions.  This reaction is typically carried out in a protic solvent (often the 
corresponding alcohol of the alkoxide). 
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Scheme 19 - Alkoxide-mediated cyclisation of the carbamate derivative of a generic 2-alkynyl aniline (35) 
to form an indole (36) 
An alkoxide-mediated cyclisation of a 2-alkynyl aniline has been successfully used in the 
synthesis of an analogue of rebeccamycin (39), a potent antitumour agent, as shown in Scheme 
20. 
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Scheme 20 - The use of alkoxide-mediated cyclisation conditions in the synthesis of a rebeccamycin 
analogue 
Inorganic and organometallic catalysts can also be employed to cyclise 2-alkynyl anilines.  
Copper-mediated cyclisations, such as the Castro synthesis, are widely reported.  The Castro 
synthesis, first reported by Castro et al in 1963[158] and shown in Scheme 21, utilises an excess 
of copper (I) salts as a catalyst, and yields indoles with very high atom economy. 
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Scheme 21 - The standard Castro indole synthesis 
The standard Castro reaction begins with a 2-alkynyl aniline (40), however, a one-pot reaction 
beginning with carboxylated o-iodoanilines was developed by Cacchi et al to generate 2-aryl 
indoles (Scheme 22), potentially saving a reaction step in generating the 2-alkyl aniline.[159]  
These reactions were found to proceed with moderate to excellent yields for the synthesis of 
2-aryl indoles, and in poor yields for 2-alkyl indoles. 
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Scheme 22 - Cacchi's one-pot synthesis of 2-aryl indoles 
Although a mechanism for the Castro synthesis is yet to be conclusively proven, a reasonable 
proposal is shown in Scheme 23. 
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Scheme 23 - Proposed mechanism for the Castro synthesis 
The Castro synthesis has found use in complex multi-step syntheses, such as in the total 
synthesis of α-C-mannosyltrytophan,[160] a naturally occurring C-glycosylamino acid.  The step 
employing the Castro reaction, shown in Scheme 24, produces the indole 50 from the 2-alkynyl 
aniline 49, and was just one of 10 steps in this difficult synthetic project. 
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Scheme 24 - The Castro step in the total synthesis of α-C-mannosyltrytophan 
As well as copper-mediated cyclisations, palladium-mediated cyclisations of 2-alkynyl anilines 
have also been reported.  These reactions typically begin with 2-alkyl anilines, although some 
one-pot indole syntheses carried out under Sonogashira conditions and beginning at the 
o-iodoaniline have been developed.  Although typically less common due to the higher cost of 
palladium and the higher temperatures that these reactions typically require, considerable work 
has gone into the development of this class of indole syntheses. 
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The conditions developed by Larock et al are a good example of the potential of a one-pot, two 
step, palladium catalysed indole synthesis, although these conditions are not to be confused 
with the Larock indole synthesis, which is described later.  The first step is a coupling between 
an o-iodoaniline (51) and terminal alkyne (52) under solvent-free Sonogashira conditions and 
under gentle microwave heating.  The second step adds in an organoiodide (54) and some 
solvent, producing the target indole (54) in good to excellent yields.[161] 
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Scheme 25 - Larock's One-pot, two-step palladium-catalysed indole synthesis 
A catalytic cycle for this reaction was proposed (Scheme 26), which includes the palladium(0) 
catalyst oxidatively inserting into the oranoiodide bond of compound 54 and coordinating to the 
alkyne to form complex 56, followed by the aniline lone pair attacking the weakened alkyne 
bond and subsequent formation of a carbon-palladium bond to form compound 57, and finally 
the elimination and regeneration of the palladium(0) catalyst. 
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Scheme 26 - Proposed catalytic cycle for Larock's cyclisation of a 2-alkyl aniline 
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As well as many other palladium-catalysed heteroannulations of 2-alkyne anilines, there are also 
a number of less developed cyclisations mediated by other metals and metal complexes such as 
indium,[162] mercury,[163] silver[164] and iodine[165,166] compounds. 
2.2.3 Larock Indole Synthesis 
A major drawback of using 2-alkynyl anilines is that substituents at the 3- position are not 
possible.  A similar method to those mentioned above, and developed by the same group that 
developed the one-pot microwave synthesis of indoles from o-iodoanilines and terminal 
alkynes, is the so-called Larock synthesis.  This reaction was first described by Richard Larock in 
1991 (Scheme 27),[167] who made a range of indoles with substitutions at the 1-, 2- and 3-
positions (61) out of internal alkynes (60). 
II
NHR
RS
RL N
RS
RL
R
Pdd(OAcc)2
Baassee59 60 61  
Scheme 27 - The Larock indole synthesis.  RL is more sterically bulky than RS 
The mechanism is thought to proceed via insertion of palladium into the C-I bond to form 
complex 62, followed by coordination of the alkyne to the palladium to form complex 63, and 
subsequent formation of the indole 61, as shown in Scheme 28.[168]  The regioselectivity of this 
reaction can also be described by this catalytic cycle; in the reductive elimination step which 
forms complex 64, the RL group is directed adjacent to the palladium due to the relatively long 
Pd-C bond lowering the steric clash felt by the larger R group. 
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Scheme 28 - Catalytic cycle of the Larock indole synthesis. RL is more sterically bulky than RS 
As can be seen in the catalytic cycle, a major drawback of the Larock indole synthesis is that an 
iodine in the ortho-position of the aniline is essential.  This can be a tight limitation, especially 
during convergent syntheses of large molecules.  A further reason for the Larock indole synthesis 
having poor uptake industrially is that an excess of at least two equivalents of the alkyne is often 
required, severely reducing the efficiency of the reaction. 
2.2.4 Reductive Cyclisations 
Reductive cyclisations of ortho-substituted nitrophenyls have received much interest from those 
involved in synthesising indoles on a large scale due to how reliably these reactions can be scaled 
up.  o-Nitrotoluenes, common precursors to ortho-substituted nitrophenyls, also have the 
additional benefit of often being widely commercially available. 
The Leimgruber-Batcho synthesis of indoles, peculiarly, was widely used industrially before 
being published in any scientific journals.  Amongst the first publications on the topic was a 
review by Leimgruber and Batcho in 1985,[169] whereas the original patent for the reaction was 
filed in 1970.[170]  This synthesis converts an o-nitrotoluene (65) to an enamine (67) using 
N,N,-dimethylformamide dimethyl acetal (DMFDMA) and an optional amine (66), often 
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pyrrolidine.  This enamine is then reductively cyclised to the 1,2-unsubstituted indole (68), as 
shown in Scheme 29. 
 
Scheme 29 - The Leimgruber-Batcho indole synthesis 
The mechanism for this reaction occurs in two steps.  The first step, shown in Scheme 30, shows 
the role of the optional amine (pyrrolidine in this example) in the formation of a more reactive 
reagent (69).[171] 
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Scheme 30 – The formation of a more reactive reagent, with pyrrolidine used as an example amine 
After the in situ formation of this reagent, the deprotonated nitrotoluene (71) goes on to form 
an enamine (67), the nitrophenyl group of which can be reduced under a number of conditions 
to form an aniline (73), which subsequently cyclises to form the respective indole (68), as shown 
in Scheme 31.  The reaction is typically run at high temperatures for extended periods of time. 
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Scheme 31 - The mechanism of the Leimgruber-Batcho synthesis 
This synthesis has retained popularity industrially due to the availability of substituted 
o-nitrotoluenes, which the reaction is generally tolerant towards.[169]  Substitutions at the 2- and 
3-positions are less developed but possible.  Substitutions on the nitrogen are not possible 
within the Leimgruber-Batcho method without employing a separate step. 
This process has been employed in the synthesis of a number of biologically relevant indoles, 
including the synthesis of a series of indolopyrrolocarbazole alkaloids by Ohkubo et al (Scheme 
32).[172] 
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Scheme 32 - Ohkubo's synthesis of a series of a series of arcyriaflavins and an analogue 
Overall, the Leimgruber-Batcho indole synthesis is fairly well developed, but development and 
academic interest appears to be waning.  There are however a number of other reductive 
cyclisation options, such as the reductive cyclisation of o-nitrobenzylcarbonyls.  
o-Nitrobenzylcarbonyls, which can be synthesised from o-nitrotoluenes, can be reductively 
cyclised in a process known as the Reissert synthesis.  This synthesis can be traced back to 1897 
when Reissert cyclised ethyl o-nitrophenylpyruvate (79) to form indole-2-carboxylic acid (80), as 
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shown in Scheme 33.[173]  The Reissert synthesis involves the condensation of an o-nitrotoluene 
(77) with an oxalic ester (for instance diethyl oxalate, 78, as shown in Scheme 33) to form an 
o-nitrobenzylcarbonyl (ethyl o-nitrophenylpyruvate, 79, in Scheme 33).  Like the Leimgruber-
Batcho synthesis, this synthesis is tolerant of substitutions on the o-nitrotoluene starting 
material, but is less capable of producing indoles with substituents on the 3- position of the 
indole.  The product indole will always contain a carboxylic acid on the 2-position, which can be 
easily decarboxylated upon heating. 
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Scheme 33 - The original Reissert synthesis of an indole 
A much more versatile method of synthesising o-nitrobenzylcarbonyls is by employing the Truce-
Smiles rearrangement.  The Truce-Smiles rearrangement (Scheme 34),[174] a variant on the 
Smiles rearrangement,[175] is a particularly powerful C-C bond forming reaction, and lends itself 
well to the synthesis of o-nitrobenzylcarbonyls.  The Truce-Smiles rearrangement has recently 
been shown to be useful as the first step in a tandem synthesis of indoles.[176,177] 
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Scheme 34 - The Truce-Smiles rearrangement, where X is an electronegative group or atom 
The Truce-Smiles rearrangement requires the incoming nucleophile to be a carbanion, as seen 
in Scheme 34.  This can be achieved through the use of deprotonated conjugated functional 
groups such as acetyl groups or through the use of organolithium compounds.  This 
rearrangement has been utilised by the Snape group to form a range of o-nitrobenzylcarbonyls.  
The antitumour agent 2-(2'-hydroxyphenyl)indolen (4) was synthesised from one such 
o-nitrobenzylcarbonyl compound (86) formed using the Truce-Smiles method (Scheme 35).[176] 
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Scheme 35 - A Truce-Smiles rearrangement and subsequent cyclisation to form the anticancer compound 
2-(2'-hydroxyphenyl)indole (4) 
The Truce-Smiles rearrangement may soon also find use in industrial processes, as it was 
recently utilised in the multi-step synthesis of the antiviral compound 89, which was successfully 
synthesised on a 50 kg scale (Scheme 36).[178] 
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Scheme 36 - A Truce-Smiles rearrangement on a 50 kg scale 
2.2.5 The Bartoli Indole Synthesis 
The Bartoli indole synthesis (often simply called the Bartoli reaction) was first described by the 
Bartoli group in 1989,[179] and provides a simple way of synthesising 2- and 3-substituted indoles 
from commercially available o-nitrophenyl compounds (90) and a vinyl Grignard reagent (91), as 
shown in Scheme 37.  It does, however, require at least three equivalents of the Grignard 
reagent, so has poor atom economy, as well as being inefficient to carry out on scale. 
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Scheme 37 - The Bartoli indole synthesis 
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The mechanism of the Bartoli indole synthesis (Scheme 38) begins with one equivalent of the 
Grignard reagent 91 to convert the nitro compound 90 to the nitroso compound 94, a further 
equivalent of the Grignard reagent 91 to add an alkene to the nitroso group to form compound 
95, a Claisen rearrangement (96), a subsequent cyclisation (97) and a rearrangement to form 
the indoline 98, which reacts with the final equivalent of the Grignard reagent 91.  This 
N-substituted indoline 99, on an acid work-up, forms the product indole 92. 
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Scheme 38 - Mechanism of the Bartoli indole synthesis 
2.2.6 Summary of Indole Syntheses 
A large variety of syntheses have been described, and a summary of these syntheses is presented 
in Table 1. 
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SYNTHESIS STRENGTHS WEAKNESSES 
FISCHER INDOLE 
SYNTHESIS 
Most highly developed method 
Substituents at all positions are 
possible 
Unsuitable for acid-sensitive 
reagents or products 
FROM 
2-ALKYNYL 
ANILINES 
Reagents can be easily 
synthesised 
Wide variety of conditions have 
been developed 
Substituents at the 3-position are 
difficult 
Substituents at the 1-position are 
often difficult 
LAROCK INDOLE 
SYNTHESIS 
Substituents at the 2- and 3- 
positions are well tolerated 
Two equivalents of the alkyne are 
often required 
Stereocontrol of this reaction 
limits the use of this reaction 
REDUCTIVE 
CYCLISATIONS 
These reactions scale well 
A wide variety of conditions have 
been developed 
Generally poor atom economy 
Substituents at the 2- positions 
are less developed 
Substituents at the 3- position 
are very difficult 
BARTOLI INDOLE 
SYNTHESIS 
Reagents are easily synthesised 
Substituents at the 2- and 3- 
positions are particularly well 
tolerated 
A substituent at the 7-position is 
essential 
Three equivalents of Grignard 
reagent are required 
Table 1 - Summary of indole syntheses 
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These reactions allow for a large area of indolic chemical space to be accessed.  Although being 
able to access as wide an area of chemical space as possible is important, knowing which areas 
of chemical space are available and accessible or knowing which areas of chemical space are of 
synthetic interest is just as important. 
2.3 Developing Analogues 
The role of the medicinal chemist at the earliest stages of drug development is to establish a 
correlation between structural changes to a known lead compound and the effect that these 
changes have on the compound’s activity, developing what is known as a structure-activity 
relationship (SAR).  Although this general concept has remained consistent throughout the 
history of drug development, the specific approach to developing an SAR has changed 
considerably.  This is partially down to improvements in identifying and understanding how 
compounds interact with target sites, and partially due to the development of computational 
techniques. 
The traditional approach of finding active analogues, known as “analogue-based drug design”, 
can be broadly split into two classes.  The first approach is known as “structure-based drug 
design” (SBDD),[180,181] which requires the structure of the active site to be known (often 
determined via X-ray diffraction or NMR).  Drugs that have the potential to interact strongly with 
this active site can then be synthesised and tested.  This approach is heavily favoured if the 
structure of the active site is known, as it allows for a higher number of active compounds to be 
tested.  With the SBDD approach, the potential strength of a drug-receptor interaction is now 
almost exclusively determined computationally.  This is due to the recent improvements in 
docking software and the reduction in the cost of computational power. 
The second approach is useful in the cases where the active site is unknown or is difficult to 
structurally determine.  In these cases, an approach called “ligand-based drug design” (LBDD) 
can be employed.  LBDD begins with making structural analogues of a lead compound, each of 
which tends to add in or remove a single structural feature that is to be investigated.  This 
approach allows the medicinal chemist to highlight which structural features of the drug are 
required for activity, while also exploring the immediate chemical space of the lead compound.  
Based on how the SAR develops, this process can be continued iteratively, with finer detail about 
the structural requirements of the drug being determined. 
LBDD can lead to the determination of a pharmacophore, which is a description of the common 
structural properties of a class of drugs that hit a specific target with good efficacy.  Qualities of 
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the pharmacophore may include hydrogen bond acceptors in certain positions, structural rigidity 
in specific areas, planar areas, 3D areas etc.  It is conceptually similar to the SBDD method 
whereby appropriate fragments are assembled into compounds of interest, but LBDD takes 
much more trial and error to build up the relationship between structure and activity. 
On balance, when the target site of a compound is known, the SBDD approach is almost 
universally preferred.  As well as having a lower chance of producing inactive analogues due to 
the increased knowledge about the target site, the SBDD approach allows investigation of a 
wider breadth of chemical space due to not being limited to direct analogues of known active 
compounds. 
2.3.1 Chemical Space 
The purpose of both the SBDD and LBDD approaches is ultimately to test analogues of a known 
active compound with the intention of determining which chemical changes result in a change 
in activity, an approach often referred to as exploring chemical space. 
Chemical space is the term used to describe the hyperdimensional virtual space within which all 
possible chemical species exists, with each possible molecular property as an axis of this virtual 
space.  A more widely accepted and rigorous definition, published in 2015 by von Lilienfeld was 
given as “the combinatorial set of all compounds that can be isolated and constructed from 
possible combinations and configurations of NI atoms and Ne electrons in real space.”[182]  The 
aim of drug discovery is ultimately to explore as much chemical space as possible with the aim 
of finding pharmacologically active areas, and as a result building up a structure-activity 
relationship.  Due to the exploration of chemical space that is inherent within the field of drug 
discovery, the majority of the literature on the topic of chemical space is relevant to the 
medicinal chemist. 
Background on Chemical Space 
Due to its inherent hyperdimensional nature, visualisation of chemical space is an inherently 
difficult endeavour.  Each property of a molecule (e.g. mass, LogP, colour, number of rotatable 
bonds etc.) can be visualised as a separate axis of chemical space, meaning that a complete 
representation of chemical space will have countless dimensions.  A visual representation of 
these dimensions is obviously impossible, but there are a number of techniques that chemical 
cartographers can employ to circumvent this issue.  One such technique is to plot only the most 
important parameters for the particular situation, thus drastically reducing the number of 
necessary axes, in a process known as Principle Component Analysis (PCA).[183]  An example of 
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this is in the work of Ruddigkeit et al., who were trying to determine, amongst other things, how 
the 3D shapes of known drug-like molecules differed from the 3D shapes that would be expected 
to be found in general drug-like chemical space, and found that synthetic compounds are 
typically much flatter and rod-like than the more spherical compounds one would expect to find 
(Figure 14).[136] 
 
Figure 14 - Comparison of the 3D shapes of compounds found in general drug-like chemical space (left) 
and known drug-like compounds (right).  Taken from the work of Ruddigkeit et al.[136] 
Paraphrasing Douglas Adams, the famed chemistry blogger Derek Lowe once said “Chemical 
space is big.  Really big … You just won't believe how vastly, hugely, mindboggling big it is.”[184]  
An estimate of the total size of chemical space isn’t particularly useful from a drug discovery 
perspective; clusters of f-block elements are unlikely to be useful as drugs.  Estimating the size 
of chemical space of compounds currently known to be drug-like is a more meaningful 
endeavour, but values vary wildly.[185] Bohacek et al. estimates this value to be 1060 compounds 
(≤30 heavy atoms, with heavy atoms being C, N, O or S),[186] whereas Ertl et al. suggested a value 
of 1023 compounds (≤36 heavy atoms, with heavy atoms being C, N, O, S, P, Si, Se or a 
halogen),[187] but the most up to date estimate put the value at around 1033 drug-like compounds 
(≤ 36 heavy atoms, with heavy atoms being C, N, O, S or a halogen, a molecular mass of ≤500 Da 
and includes stable compounds only).[185]  Even the smallest of these values is beyond the realms 
of human comprehension.  The largest chemical database available, the CAS database, contains 
information not just on known drug-like compounds but on any known organic compound, as 
well as known alloys, minerals, polymers, salts and coordination complexes.  Despite this lack of 
limitation, it still only contains 113 million entries, 12 orders of magnitude fewer than the lowest 
estimate of drug-like chemical space. 
The entirety of chemical space couldn’t possibly be fully investigated on any realistic timeframe, 
let alone within the timeframe required for a drug discovery project.  Therefore, efficient ways 
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of investigating pharmacologically relevant areas of chemical space are of utmost importance to 
the modern medicinal chemist.  
Searching Chemical Space – Analogue-Based Drug Design 
As mentioned earlier, the traditional way of exploring chemical space is to simply make 
analogues of a lead compound.  This process is low-throughput, arduous and expensive, but due 
to its ease, it is still commonly carried out.  Representative examples of the two approaches to 
analogue-based drug design, SBDD and LBDD, are shown below. 
One approach to SBDD, known as molecular docking, involves taking a database of compounds 
and sequentially virtually fitting them into the known active site, and reporting their potential 
as active compounds based on the strength of the drug-receptor interaction.[188]  In this process, 
a known active site has a compound virtually inserted into a known active site (i.e. “docked”), 
and the drug-receptor interaction is calculated under the assumption that a strong interaction 
is an indicator for potential activity. 
 
Figure 15 - An example of molecular docking, showing four example compounds docked to an active site.  
(A) - compound has a poor fit due to being too large, (B) - compound has a poor fit due to being too 
small, (C) - compound has a poor fit due to interacting poorly with adjacent residues, (D) - compound has 
a good fit due to being an appropriate size and shape and interacting well with nearby residues‡ 
Another SBDD method, which approaches the problem of identifying compounds that interact 
strongly with an active site in a different way, is to generate a compound based on combining 
functional groups that interact well with key residues of the active site into a singular compound, 
which is often known as fragment-based drug design.  A hypothetical example of this process is 
                                                          
‡ Original graphic created solely for this thesis 
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shown in Figure 16, and shows the process broken down into four steps.  The steps are as 
follows: (1) determination of the active site, (2) the identification of key interacting residues 
such as serines, glutamines and phenylalinines, (3) determining what fragments will interact 
with these residues (e.g. by hydrogen bonding, pi stacking, hydrophobic interactions etc.), and 
(4) constructing or assembling these fragments into a drug that can be synthesised. 
 
Figure 16 - An approach to SBDD - Determine active site, identify interacting residues, choose fragments 
that interact with these residues, combine fragments into drugs§ 
As SBDD approaches such as those described above require knowledge of the active site.  If the 
active site is unknown or uncharacterised, an LBDD-based approach is required.  In this 
approach, it is typical for series of analogues of a known active compound to be produced in 
order to investigate the role of certain structural features.  This procedure can be roughly split 
into two separate approaches: depth first or breadth first. 
A depth-first approach focuses on making small changes to a compound which is typically known 
to already have high activity.  It may focus on improving qualities such as toxicology, solubility 
or blood-brain barrier permeability, or may just focus on further improving the activity of the 
lead compound.  This approach typically investigates a more local area of chemical space, but 
will investigate that area in depth.  The work is also often carried out in an iterative manner; the 
best compound from the first series of analogues will go on to be the lead compound for the 
next series. 
A good example of this approach is the work of Wasik et al., who made analogues of 
3,4-methylenedioxymethamphetamine, a psychoactive drug with known anti-lymphoma 
properties.[189]  Wasik et al. iteratively produced two series of analogues in order to reduce the 
                                                          
§ Original graphic created solely for this thesis 
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psychoactive qualities of the drug in order to make this class of compounds a viable therapy.  
The analogues produced, shown in Figure 17, show that substitutions at only one position of the 
lead compound was investigated.  In the first series, it was found that the phenyl analogue 106 
was the best candidate of the first series (based on anti-lymphoma activity and psychoactive 
levels).  The phenyl analogue was therefore used as the lead compound for the second series, 
which showed the bulkier aromatic substituents in analogues 116, 117 and 118 made for the 
best drug candidates. 
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Figure 17 - The two series of compounds produced by Wasik et al.,[189] showing the most active 
compound(s) of each series in a box 
An alternative approach to a depth-first analogue search is a breadth-first analogue search, in 
which a much broader area of chemical space is investigated, albeit investigated less thoroughly 
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than in a depth-first approach.  This often means that the effects of more structural features are 
investigated. 
One example of a breadth-first approach to finding functional analogues is to change the very 
core of the molecule, in an approach known as scaffold hopping.  In this approach, the core (or 
“scaffold”) of the molecule is changed, but an attempt is made to retain much of the surrounding 
derivatisation.  In small-molecule drug discovery, the scaffold of a molecule can simply be 
substituted for a similar scaffold (e.g. replacing an indole with a naphthalene), by opening or 
closing a ring (e.g. by breaking a C-C bond in a cyclohexane ring), or by replacing the scaffold 
with something that gives the same overall topology.[190]  A classic and very early example of 
successful scaffold hopping was the development of the pain relief medication tramadol from 
the opioid morphine.  Tramadol was developed by breaking three of the five rings of morphine, 
allowing for a more flexible molecule which could better fit the opioid receptors (Figure 18). 
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Figure 18 - Morphine (left) and its scaffold-hopped analogue tramadol (right) 
Typically, a breadth-first approach is carried out when the lead compound has reasonable but 
inadequate activity.  Qualities of the analogues of the lead compound such as solubility or 
toxicity are typically not considered at this stage, as these issues can be addressed later on in 
the drug development process. 
The depth-first and breadth-first approach are different ways of addressing the problem of 
searching chemical space.  Within a drug development programme, time is a finite resource, so 
only a finite number of analogues can be tested.  The depth-first approach focuses on the more 
immediate surrounding chemical space, potentially investigating as little as a single substituent 
of a drug.  The breadth-first approach allows a much wider area of chemical space to be 
investigated, but the level of detail that each structural feature is investigated to is inherently 
much lower. 
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Searching Chemical Space – Similarity Searching 
It is apparent that we are never going to run out of chemical space to explore, and we are never 
going to attain a comprehensive library of known drug-like compounds.  The method of drug 
discovery can therefore shift to finding efficient ways to virtually explore chemical space, which 
means moving away from the traditional method of synthesising compounds the chemist 
believes to be similar and moving towards testing compounds that some software considers to 
be similar.  This is of particular interest when one considers that humans are notoriously poor 
and inconsistent at identifying potential lead or drug-like compounds.[191,192] 
However, where the traditional chemist has chemical intuition and experience from where to 
draw inspiration when designing analogues, software needs to draw from databases.  There are 
many chemical databases which are differentiated based on their sizes and slightly different 
focuses. 
The smallest of the major databases is DrugBank,[193–195] which currently contains 8206 entries.  
This database contains over 2000 FDA-approved drugs (the vast majority of which are small 
molecules), some nutraceuticals, and over 6000 experimental drugs.  It is well curated, and each 
entry (known as a DrugCard) includes detailed information on both the physical properties of 
the drug, pharmacokinetic profiling and information on the drug’s target(s).  All compounds 
within the database are therefore known to have some biological activity.  The database is free 
for non-commercial use, and can be interrogated either through the browser, or downloaded 
and interrogated offline.  However, with only 8206 entries, it is a very small database that covers 
a tiny portion of chemical space. 
Next in order of size is BindingDB,[196–200] with over half a million entries for drug like molecules, 
as well as information on over 5000 proteins and over 1.2 million small molecule/protein 
interactions.  As the name suggests, it is a database of the interactions between small, drug-like 
molecules and druggable protein targets.  The database is free to use and is downloadable, and 
because the focus is on drug-protein interaction, it can be of particular use in projects that focus 
on such interactions. 
Considerably outside the realm of what could be tackled by a human, ChEMBL[201,202] contains 
over 1.5 million compounds (as well as data on over 11 thousand targets), along with data on 
calculated LogP values, polar surface area, hydrogen bond donors and acceptors and number of 
rotatable bonds.  It is free to use and the database is downloadable.  There are, however, no 
subsets of the database available if one wishes to search for, say, drug fragments rather than 
Chapter 2 – Project Background 
76 
 
drug-like molecules.  The result is that interrogating the database can be more computationally 
expensive, and that there are fewer relevant compounds available in the database. 
The ZINC database[4,5] contains over 22 million compounds, but can be split into database 
subsets such as “lead-like”, “fragment-like”, “drug-like” etc.  If one is carrying out a similarity 
search, this allows for a much more efficient methodology, as compounds of significantly 
different mass do not need to be included in the search.  In the case of this project, the lead 
compound is considered fragment-like due to having a molecular weight below 250 g mol-1 and 
fewer than five rotatable bonds,[203] so the fragment-like subset of over 800 thousand 
compounds would be used. Furthermore, ZINC’s novelty is that all compounds within the 
database are purchasable, meaning that in theory, compounds that are similar could be 
purchased and tested, drastically increasing throughput. 
The largest free database of known compounds is the PubChem database,[204,205] with over 89 
million compounds.  The focus of the PubChem database is to aid medical research, and to that 
end it includes the activities of the included compounds against biological assays through its 
BioAssay database,[206–209] which itself includes well over a million entries.  Although a limit of 
1000 atoms and 1000 bonds exists for entry into the database, this is more than sufficient for 
small drug development.  It is free to use and download, and can be interrogated online through 
a browser or offline. 
The Chemical Abstracts Service (CAS), run by the American Chemical Society (ACS), has a 
proprietary chemical database called CAS REGISTRY, currently containing over 114 million 
entries.  Although large, the database is not specific to drug-like compounds and also includes 
information on salts, polymers, alloys, minerals and other inorganic compounds.  The database 
is also not free to use, and cannot be downloaded, so has to be interrogated through other 
services such as SciFinder.[210]  The major advantage of CAS REGISTRY is that it is generated from 
literature mentions, so all compounds can be found in the scientific literature.  This often means 
that synthetic procedures for compounds are easy to find. 
By far the largest chemical database is the GDB-17 database,[136,211] which contains over 116 
billion entries, making it orders of magnitude larger than any other chemical database.  The GDB-
17 database was generated by enumerating molecules of up to 17 atoms of carbon, oxygen, 
nitrogen, sulfur and halogens, and then applying restrictions on chemical stability and synthetic 
feasibility, so therefore predominantly contains compounds that have never been characterised.  
The result is that the GDB-17 database is the most conclusive mapping of the chemical space 
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relevant to drug discovery.  This database does, however, have a number of drawbacks. 
Primarily, it is far too large to be conclusively interrogated using easily accessible computational 
hardware.  Secondly, the vast majority of the database is of previously uncharted chemical 
space.  This means that although the compounds in these regions may be synthetically accessible 
in theory, much of the database is practically inaccessible using current synthetic methods.  
Therefore, the GDB-17 database would be very likely to yield novel compounds when carrying 
out a similarity search, but the trade-off would be that the synthetic throughput would be very 
low and difficult. 
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3.1 Introduction 
As mentioned earlier, the generation of ROS, and therefore the propensity of a species to form 
a radical, may be related to the anticancer activity of a species.  The mechanistic steps involved 
in converting a neutral species to form a radical via various pathways are defined in Scheme 8 
(Section 1.2.2) as the bond dissociation enthalpy (BDE), proton affinity (PA), electron transfer 
enthalpy (ETE), adiabatic ionisation potential (AIP) and proton dissociation enthalpy (PDE).  To 
calculate the values of the BDE, PA, ETE, AIP and PDE, the neutral, radical, anionic and radical 
cationic species must first be conformationally optimised, and their energies calculated.  This is 
a routine computational problem that can be tackled by a large range of commercially and freely 
available software packages. 
3.2 The Schrödinger Equation 
The aim of geometry optimisation and energy calculations is to generate an approximate 
solution to the time-independent Schrödinger equation, an equation that relates the 
wavefunction of a system to its total energy.  The general form of the time-independent 
Schrödinger equation is given in Equation 1, where 𝛹𝛹 is the wavefunction, 𝐸𝐸 is the total system 
energy and 𝐻𝐻� is the total Hamiltonian. 
𝐻𝐻�𝛹𝛹 = 𝐸𝐸𝛹𝛹 
Equation 1 - General form of the time-independent Schrödinger equation 
The equation for the Hamiltonian 𝐻𝐻�, is given in Equation 2, where M and N refer to the nuclei 
and electrons respectively, μ refers to the mass of a particle, ħ is the reduced Planck’s constant, 
𝑅𝑅�⃗  and 𝑟𝑟 refer to the position of a nucleus and electron respectively, Z is the nuclear charge and 
𝜀𝜀0 is the vacuum permittivity. 
𝐻𝐻� =  −� ℏ22𝜇𝜇𝐴𝐴 ∇𝑅𝑅�⃗ 𝑖𝑖2𝑀𝑀𝐴𝐴 −� ℏ22𝜇𝜇𝑖𝑖 ∇𝑟𝑟𝑖𝑖2𝑁𝑁𝑖𝑖 + �� 𝑍𝑍𝐴𝐴𝑍𝑍𝐵𝐵𝐹𝐹24𝜋𝜋𝜀𝜀0�𝑅𝑅�⃗𝐴𝐴 − 𝑅𝑅�⃗ 𝐵𝐵�𝑀𝑀𝐵𝐵𝑀𝑀𝐴𝐴 + �� 𝐹𝐹24𝜋𝜋𝜀𝜀0�𝑟𝑟𝑖𝑖 − 𝑟𝑟𝑗𝑗�𝑁𝑁𝑗𝑗𝑁𝑁𝑖𝑖
−  �� 𝑍𝑍𝐴𝐴𝐹𝐹24𝜋𝜋𝜀𝜀0�𝑅𝑅�⃗𝐴𝐴 − 𝑟𝑟𝑖𝑖�𝑀𝑀𝐴𝐴𝑁𝑁𝑖𝑖  
Equation 2 - The Hamiltonian component of the Schrödinger equation 
Within this equation, the kinetic energy of the nuclei (𝑇𝑇𝑛𝑛𝑛𝑛𝑛𝑛) is given by the first term, the kinetic 
energy of the electrons (𝑇𝑇𝑒𝑒𝑒𝑒) is given by the second term, the potential energy of repulsion 
between nuclei (𝑉𝑉𝑛𝑛𝑛𝑛𝑛𝑛−𝑛𝑛𝑛𝑛𝑛𝑛) is given by the third term, the potential energy of repulsion between 
electrons (𝑉𝑉𝑒𝑒𝑒𝑒−𝑒𝑒𝑒𝑒) is given by the fourth term, and the potential energy of attraction between 
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each electron and nuclei (𝑉𝑉𝑛𝑛𝑛𝑛𝑛𝑛−𝑒𝑒𝑒𝑒) is given by the fifth term.  The Hamiltonian operator can 
therefore be written in a more simple form, as shown in Equation 3. 
𝐻𝐻� =  𝑇𝑇𝑛𝑛𝑛𝑛𝑛𝑛 + 𝑇𝑇𝑒𝑒𝑒𝑒 +  𝑉𝑉𝑛𝑛𝑛𝑛𝑛𝑛−𝑛𝑛𝑛𝑛𝑛𝑛 + 𝑉𝑉𝑒𝑒𝑒𝑒−𝑒𝑒𝑒𝑒 + 𝑉𝑉𝑛𝑛𝑛𝑛𝑛𝑛−𝑒𝑒𝑒𝑒 
Equation 3 - The simplified form of the Hamiltonian operator 
Since exact solutions to the Schrödinger equation are not available for systems consisting of 
more than two particles, only approximate solutions may be obtained.  The only option is to 
approximate a solution to the Schrödinger equation, and there are a number of potential 
methods for doing this.  The upcoming section will describe these methods, and explain the 
justifications for selecting the methodology employed. 
3.3 The Born-Oppenheimer Approximation 
The first major approximation employed is the Born-Oppenheimer approximation.  This states 
that due to the large difference in mass and mobility between the nuclei and electrons within a 
molecule, the nuclei can be considered stationary.  The justification for this is that a nucleus is 
often several thousand times greater in mass than an electron.  As a result, the nuclei moves 
much slower and much less than the electrons.  The motion of the nuclei can therefore be 
neglected when considering the motion of electrons. 
When using the Born-Oppenheimer approximation, we can consider the nuclei stationary (often 
referred to as “clamped nuclei”) with the electrons moving around them.  The outcome of this 
approximation is that the Hamiltonian operator of the Schrödinger equation can also be 
separated out into a Hamiltonian for the electrons (𝐻𝐻�𝑒𝑒𝑒𝑒) and Hamiltonian for the nuclei (𝐻𝐻�𝑁𝑁), as 
shown in Equation 4. 
𝐻𝐻�𝑒𝑒𝑒𝑒 =  𝑇𝑇𝑒𝑒𝑒𝑒 +  𝑉𝑉𝑒𝑒𝑒𝑒−𝑒𝑒𝑒𝑒 +  𝑉𝑉𝑛𝑛𝑛𝑛𝑛𝑛−𝑒𝑒𝑒𝑒=  −� ℏ22𝜇𝜇𝑖𝑖 ∇𝑟𝑟𝑖𝑖2𝑁𝑁𝑖𝑖 + �� 𝐹𝐹24𝜋𝜋𝜀𝜀0�𝑟𝑟𝑖𝑖 − 𝑟𝑟𝑗𝑗�𝑁𝑁𝑗𝑗𝑁𝑁𝑖𝑖 −  �� 𝑍𝑍𝐴𝐴𝐹𝐹24𝜋𝜋𝜀𝜀0�𝑅𝑅�⃗𝐴𝐴 − 𝑟𝑟𝑖𝑖�𝑀𝑀𝐴𝐴𝑁𝑁𝑖𝑖  
𝐻𝐻�𝑛𝑛𝑛𝑛𝑛𝑛 =   𝑇𝑇𝑛𝑛𝑛𝑛𝑛𝑛 +  𝑉𝑉𝑛𝑛𝑛𝑛𝑛𝑛−𝑛𝑛𝑛𝑛𝑛𝑛 =  −� ℏ22𝜇𝜇𝐴𝐴 ∇𝑅𝑅�⃗ 𝑖𝑖2𝑀𝑀𝐴𝐴 + �� 𝑍𝑍𝐴𝐴𝑍𝑍𝐵𝐵𝐹𝐹24𝜋𝜋𝜀𝜀0�𝑅𝑅�⃗𝐴𝐴 − 𝑅𝑅�⃗ 𝐵𝐵�𝑀𝑀𝐵𝐵𝑀𝑀𝐴𝐴  
Equation 4 - The electronic Hamiltonian (top) and nucleic Hamiltonian (bottom), the separation of which 
are possible as a result of the Born-Oppenheimer approximation 
Due to the approximation that the nuclei are stationary, this makes their kinetic energy (𝑇𝑇𝑛𝑛𝑛𝑛𝑛𝑛) 
zero.  The nuclear Hamiltonian therefore simply becomes the repulsive nuclear-nuclear 
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interaction (𝑉𝑉𝑛𝑛𝑛𝑛𝑛𝑛−𝑛𝑛𝑛𝑛𝑛𝑛), which when the nuclei are stationary is a constant, so is a 
computationally cheap and therefore short calculation. 
3.4 Hartree-Fock theory 
Once the Born-Oppenheimer approximation has been employed, the computational bottleneck 
is calculating the repulsive electron-electron interaction (𝑉𝑉𝑒𝑒𝑒𝑒−𝑒𝑒𝑒𝑒).  Simplifying this term can be 
achieved by employing Hartree-Fock theory.  Although largely superseded by density functional 
theory (DFT), Hartree-Fock theory forms the basis for DFT as well as almost all quantum 
chemistry methods. 
3.4.1 Hartree approximation 
The spatial molecular orbitals of a species can be roughly approximated as a linear expansion of 
its constituent spatial atomic orbitals, in what is known as the linear combination of atomic 
orbitals (LCAO) method.  As shown in Equation 5, the spatial molecular orbital of electron i (𝜑𝜑𝑖𝑖) 
can be defined in terms of a set of K basis functions (𝜙𝜙𝜇𝜇) and a set of expansion coefficients 
(𝐶𝐶𝜇𝜇𝑖𝑖). 
𝜑𝜑𝑖𝑖 =  �𝐶𝐶𝜇𝜇𝑖𝑖𝜙𝜙𝜇𝜇𝐾𝐾
𝜇𝜇=1
 
Equation 5 - LCAO approach to constructing molecular orbitals from basis functions 
The Hartree approximation uses this approach to simplify the electronic wavefunction in terms 
of one electron molecular orbitals.  The molecular wavefunction is the wavefunction of all 
electrons within a molecule, and can then be approximated as the product of all of its 
constituent one electron spatial wavefunctions as seen in Equation 6, where 𝜑𝜑𝑖𝑖(𝑟𝑟𝑖𝑖) is the one-
electron spatial wavefunction of the ith electron. 
𝛹𝛹𝑒𝑒𝑒𝑒 = 𝛹𝛹(𝑟𝑟1, 𝑟𝑟2, 𝑟𝑟3, … , 𝑟𝑟𝑁𝑁) ≈  𝜑𝜑1(𝑟𝑟1)𝜑𝜑2(𝑟𝑟2)𝜑𝜑3(𝑟𝑟3) …𝜑𝜑𝑁𝑁(𝑟𝑟𝑁𝑁) 
Equation 6 - LCAO method of constructing molecular orbitals, as described in terms of electronic 
wavefunctions 
As it stands, this wavefunction breaks the Pauli exclusion principle.  Pairs of electrons are 
described as occupying the quantum state due to the spin states of the electrons not being 
included in the spatial orbitals.  To amend this, spin orbitals must be used in place of spatial 
orbitals.  Spin orbitals are generated as the product of a spatial orbital and a spin state (either α 
or β), which can be either spin up (𝜔𝜔 = +½) or spin down (𝜔𝜔 = -½), as shown in Equation 7.  In a 
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closed shell molecule, there will be as many occupied spin up atomic orbitals as occupied spin 
down atomic orbitals.  In a ground state molecule, the lowest energy orbitals will be occupied 
and the higher energy orbitals (known as “virtual orbitals”) will be unoccupied. 
𝜒𝜒(?⃗?𝑥) =  𝜒𝜒(𝑟𝑟, 𝑠𝑠) = � 𝜑𝜑(𝑟𝑟)𝛼𝛼(𝜔𝜔)𝑜𝑜𝑟𝑟
𝜑𝜑(𝑟𝑟)𝛽𝛽(𝜔𝜔)�  
Equation 7 - Generation of spin orbitals from spatial orbitals 
The electronic wavefunction, 𝛹𝛹𝑒𝑒𝑒𝑒, can now be approximated as the product of all one electron 
spin orbitals, as shown in Equation 8. 
𝛹𝛹𝑒𝑒𝑒𝑒 = 𝛹𝛹(𝑟𝑟1, 𝑟𝑟2, 𝑟𝑟3, … , 𝑟𝑟𝑁𝑁) ≈  𝜒𝜒1(?⃗?𝑥1)𝜒𝜒2(?⃗?𝑥2)𝜒𝜒3(?⃗?𝑥3) …𝜒𝜒𝑁𝑁(?⃗?𝑥𝑁𝑁) 
Equation 8 - Approximating the electronic wavefunction as the product of all one electron spin orbitals 
3.4.2 Slater determinants 
Equation 8 still does not fully satisfy the Pauli exclusion principle, which also states that a many-
electron system must have the property of antisymmetry, requiring that if two electrons are 
interchanged, there must be a change of sign of the wavefunction.  For example, in a two 
electron system, an appropriate equation that satisfies the requirement for antisymmetry is 
shown in Equation 9. 
Ψ(?⃗?𝑥1, ?⃗?𝑥2) =  −Ψ(?⃗?𝑥2, ?⃗?𝑥1) 
Equation 9 - A two electron wavefunction that satisfies the requirement for antisymmetry 
With a two electron system, this equation is easy to construct, but with many electrons, the 
number of interchangeable electrons grows rapidly.  One way to assure that the rules of 
antisymmetry dictated by the Pauli exclusion principle are adhered to is to use a Slater 
determinant.  A Slater determinant utilises the mathematical properties of an antisymmetric 
matrix which ensures that any multielectronic wavefunction will have the property of 
antisymmetry, and the general form of the equation is shown in Equation 10 
(?⃗?𝑥1, ?⃗?𝑥2, … ?⃗?𝑥𝑁𝑁) =  Φ =  1
√𝑁𝑁!  ��
𝜒𝜒1(?⃗?𝑥1) 𝜒𝜒2(?⃗?𝑥1) ⋯ 𝜒𝜒𝑁𝑁(?⃗?𝑥1)
𝜒𝜒1(?⃗?𝑥2) 𝜒𝜒2(?⃗?𝑥2) ⋯ 𝜒𝜒𝑁𝑁(?⃗?𝑥2)
⋮ ⋮ ⋱ ⋮
𝜒𝜒1(?⃗?𝑥𝑁𝑁) 𝜒𝜒2(?⃗?𝑥𝑁𝑁) ⋯ 𝜒𝜒𝑁𝑁(?⃗?𝑥𝑁𝑁)�
�
 
Equation 10 - The Slater Determinant for a system of N electrons 
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Equation 10 describes the Slater determinant (Φ) as a matrix of 𝑁𝑁! terms, which is then 
normalised by the factor 1 √𝑁𝑁!⁄ .  Interchanging any two electrons can be described 
mathematically by exchanging two rows in the matrix.  The result of this will be a change in the 
sign of the wavefunction, therefore the Slater determinant (and by association the 
wavefunction) is antisymmetric. 
3.4.3 Variation principle 
The variation principle, on which Hartree-Fock theory is based, tells us that the calculated value 
of the Hamiltonian operator, 𝐻𝐻�, will always be higher in energy (i.e. is an upper bound) to the 
exact ground state energy, 𝐸𝐸𝑒𝑒𝑒𝑒𝑒𝑒𝑛𝑛𝑒𝑒.  Therefore, when calculating the energy of a series of trial 
wavefunctions for a molecule, the best wavefunction is that which has the lowest calculated 
energy. 
Looking back to Equation 5, trial wavefunctions are generated in part by selecting values for the 
expansion coefficients (𝐶𝐶𝜇𝜇𝑖𝑖).  Due to the variation principle, energy minimisation is therefore 
achieved by varying these values in order to lower the calculated energy. 
3.4.4 The Hartree-Fock equation 
Much of the Schrödinger equation has now been simplified, but as mentioned earlier, the 
computational bottleneck is calculating the repulsive electron-electron interaction (𝑉𝑉𝑒𝑒𝑒𝑒−𝑒𝑒𝑒𝑒), the 
only remaining many-body component of the equation. 
The 𝑉𝑉𝑒𝑒𝑒𝑒−𝑒𝑒𝑒𝑒 component is constructed from the sum of all two-electron repulsive interactions, 
and is shown again in full in Equation 11. 
𝑉𝑉𝑒𝑒𝑒𝑒−𝑒𝑒𝑒𝑒 =  �� 𝐹𝐹24𝜋𝜋𝜀𝜀0�𝑟𝑟𝑖𝑖 − 𝑟𝑟𝑗𝑗�𝑁𝑁𝑗𝑗𝑁𝑁𝑖𝑖  
Equation 11 - electron-electron interaction term of the Schrödinger equation 
As mentioned earlier, the Hartree-Fock approximation is a method for reducing this many body 
problem into a series of one-electron problems.  This is achieved by considering each electron 
not as interacting with every other electron separately, but as being in an average field caused 
by all other electrons.  This averaged field (i.e. averaged potential) is known as the Hartree-Fock 
potential, with the Hartree-Fock potential of the ith electron given the symbol 𝜐𝜐𝐻𝐻𝐻𝐻(𝑖𝑖).  The 
electronic Hamiltonian operator for the ith electron (𝐻𝐻�𝑒𝑒𝑒𝑒(𝑖𝑖)) is now simply the sum of the one-
electron components and the Hartree-Fock potential felt by the electron (Equation 12).  Within 
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Hartree-Fock theory, this approximation of the one-electron electronic Hamiltonian is called the 
Fock operator (𝑓𝑓𝑖𝑖), and is described in terms of the kinetic energy of the ith electron (𝑇𝑇(𝑖𝑖)), the 
interaction between the Ath nucleus and ith electron (𝑉𝑉𝐴𝐴𝑖𝑖) and the Hartree-Fock potential. 
𝐻𝐻�𝑒𝑒𝑒𝑒(𝑖𝑖) ≈ 𝑓𝑓𝑖𝑖 =  𝑇𝑇(𝑖𝑖) +  �𝑉𝑉𝐴𝐴𝑖𝑖𝑀𝑀
𝐴𝐴=1
+  𝜐𝜐𝐻𝐻𝐻𝐻(𝑖𝑖) 
Equation 12 - The form of the one electron Hamiltonian operator for electron i 
Therefore the full electronic Schrödinger equation can be approximated as Equation 13. 
�𝐻𝐻�𝑒𝑒𝑒𝑒(𝑖𝑖)𝑁𝑁
𝑖𝑖
Ψ(?⃗?𝑥1, ?⃗?𝑥2, ?⃗?𝑥3, … , ?⃗?𝑥𝑁𝑁) = 𝐸𝐸Ψ(?⃗?𝑥1, ?⃗?𝑥2, ?⃗?𝑥3, … , ?⃗?𝑥𝑁𝑁) 
Equation 13 - Approximation for the Schrödinger equation after applying the Hartree-Fock 
approximation 
This equation can then be broken down into separate equations for each electron (Equation 14) 
to yield the Hartree-Fock equations.  The eigenvalues (𝜀𝜀𝑖𝑖) in this equation are equivalent to the 
molecular orbital energies. 
𝑓𝑓𝑖𝑖𝜒𝜒𝑖𝑖(?⃗?𝑥𝑖𝑖) =  𝜀𝜀𝑖𝑖𝜒𝜒𝑖𝑖(?⃗?𝑥𝑖𝑖) 
Equation 14 - The Hartree-Fock equation 
3.4.5 Self-Consistent Field Method 
The Schrödinger equation would now be in a computationally solvable state if a calculation could 
begin.  However, in order to calculate the eigenvalue for the ith electron (𝜀𝜀𝑖𝑖), one must know 
the Hartree-Fock potential (𝜐𝜐𝐻𝐻𝐻𝐻(𝑖𝑖)), but in order to know the value of the Hartree-Fock 
potential, the form of the orbitals (𝜒𝜒𝑖𝑖(?⃗?𝑥𝑖𝑖)) must be known.  The orbitals can’t be known until the 
Hartree-Fock equation is solved, so the equation is therefore unsolvable analytically. 
A workaround for this problem is rather than attempt to analytically solve the Hartree-Fock 
equation, to instead take an initial guess of the orbitals (which includes some adjustable 
parameters), and use this to construct a Fock operator.  This Fock operator can then be used to 
make a better approximation of the orbitals, which can then be used to construct an improved 
Fock operator.  This iterative process continues until the improvement in the precision of the 
Fock operator falls to within predefined acceptable levels.  This method of iteratively improving 
the solution to such an equation is known as the self-consistent field (SCF) method, and when 
applying this method to the Hartree-Fock equation it is known as the Hartree-Fock self-
consistent field (HF-SCF) method. 
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3.5 Basis sets 
So far, as shown in Equation 5, molecular orbitals have been described in terms of their basis 
functions (𝜙𝜙, also known as atomic orbital functions) and sets of expansion coefficients (𝐶𝐶), but 
the nature of the basis functions has not yet been described. 
Within computational chemistry, a basis function is a mathematical descriptor of an atomic 
orbital, and each orbital of each element has its own basis function or functions.  Because 
molecular orbitals are considered as a linear combination of atomic orbitals (i.e. the LCAO 
method), they are calculated as a linear combination of basis functions. 
Series of basis functions for a series of elements are collated into basis sets, with almost all basis 
sets only describing a subset of the periodic table.  Basis sets however do not perfectly describe 
orbitals, and there are hundreds of basis sets to choose from, with different basis sets being 
more appropriate for certain tasks.  Selecting the right basis set is important in order to get data 
which more closely matches experiment. 
3.5.1 Minimal Basis Sets 
As the name suggests, minimal basis sets are the smallest and therefore computationally 
cheapest basis sets available.  They are defined by having only one basis function for each 
occupied atomic orbital, so hydrogen is described by only one basis function (for the 1s orbital) 
and carbon is described by five basis functions (for the 1s, 2s, 2px, 2py and 2pz orbitals). 
Although calculations that use minimal basis sets are computationally inexpensive, these basis 
sets typically describe orbitals poorly, so are rarely used when calculating the properties of small 
molecules. 
3.5.2 Split Valence Basis Sets 
Single basis functions struggle to correctly describe the electron density within an orbital over a 
wide range of radii.  The solution to this is to include multiple basis functions that are designed 
to describe the electron density of an orbital at different radii, i.e. different basis functions will 
describe orbitals of different sizes which, when overlapped, will more accurately describe 
realistic orbitals properties.  The downside is that more basis functions means an increase in 
computational cost. 
When including split valence orbitals in a basis set, priority is given to splitting the valence 
orbitals as these orbitals have the biggest impact on the properties of a molecule.  If more 
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computational time or power is available, core orbitals can also be split.  When all orbitals are 
split into two basis functions, this is known as a “double-zeta” (or double- ζ) basis set, and when 
all orbitals are split into three basis functions, this is known as a “triple-zeta” (or triple- ζ) basis 
set. 
3.5.3 Extended Basis Sets 
In order to further improve the accuracy of basis sets, there are two more additions that can be 
included: polarisation functions and diffuse basis functions. 
Polarisation functions allow previously inflexible basis functions to be distorted by nearby nuclei, 
much like how orbitals are polarised.   
 
Figure 19 - Impact of adding a d polarisation function to an s orbital (top) and of adding a p polarisation 
function to a d orbital (bottom)** 
Polarisation functions are typically added first to heavy atoms (i.e. all atoms except hydrogen), 
and basis sets which have these polarisation functions are denoted as such with an asterisk (or 
“star”) in their name, for example the 6-311G* basis set is the 6-311G basis set with such added 
polarisation functions.  If more computational time or power is available, polarisation functions 
are added to the hydrogens, and this is denoted by two asterisks, for example the 6-311G** 
basis set is the 6-311G basis set with added polarisation functions on all atoms. 
Diffuse basis functions are a further potential addition to basis sets.  Diffuse basis functions 
model the portions of an orbital that are far from the nucleus, which are necessary to more 
accurately model anions that typically have a spread out charge.  Diffuse basis functions on 
heavy atoms are denoted by the addition of a plus (or in some cases the term “aug”) within the 
                                                          
** Original graphic created solely for this thesis 
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name of the basis set, such as 6-311+G or aug-cc-pVDZ.  Additionally, having diffuse basis 
functions on hydrogen atoms is denoted by the addition of two plusses within the name of the 
basis set, such as 6-311++G. 
3.6 Density Functional Theory 
A major deficiency of Hartree-Fock theory is the treatment of electron-electron interactions in 
an averaged way via the use of the Hartree-Fock potential, 𝜐𝜐𝐻𝐻𝐻𝐻, which results in instantaneous 
electron-electron interactions (i.e. electron correlation) being ignored.  Although there are 
methods for accounting for electron correlation, they are typically either inaccurate or 
computationally very expensive.  A further limitation of Hartree-Fock theory is that it doesn’t 
scale well for use on large molecules.  The computational expense of Hartree-Fock calculations 
scales as N4, where N is the number of basis functions.  This computational cost can be reduced 
somewhat by ignoring the interaction of orbitals which are a considerable distance from one 
another, but the Hartree-Fock method is still impractical for use with large molecules or large 
basis sets. 
Due to the poor scaling of the Hartree-Fock method, an alternative method is required.  One 
option is to employ semi-empirical methods, whereby computational complexity is reduced by 
replacing some of the intensive calculations with experimentally derived values.  Although these 
methods are computationally cheaper, there is often a trade-off with accuracy.  Alternatively, 
improved ab initio methods can be employed.  Ab initio, which translates to “from the 
beginning”, describes techniques for determining properties using only methods derived from 
first principles, i.e. no experimental or empirical parameterisation is employed.  Although not a 
true ab initio method,†† density functional theory (DFT) is now widely considered as the 
predominant method for calculating structures, energies and properties of small molecules.  It 
is an expansion of HF theory, retaining many similarities, but DFT methods have been shown to 
additionally account very well for electron correlation 
Rather than considering the wavefunction as the fundamental unknown, DFT instead focuses on 
the electron probability density, which can be described as the probability of finding an electron 
                                                          
†† Some of the functionals used in this thesis (described later) are parameterised, therefore the methods 
employed are technically classed as semi-empirical.  However, the vast majority of the method is derived 
from first principals. 
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in a specific area.  The functionals in DFT therefore refer to functionals of electron density, 
whereas in the HF method the functionals describe orbitals. 
One of the models on which DFT is based is the Thomas-Fermi (TF) model, which actually 
predates the Hartree-Fock method.  The Thomas-Fermi model equates a value for energy (𝐸𝐸𝑇𝑇𝐻𝐻) 
as a summation of the electronic kinetic energy (𝑇𝑇𝑒𝑒𝑒𝑒), the electron-nucleus interactions (𝑈𝑈𝑒𝑒𝑒𝑒−𝑛𝑛𝑛𝑛𝑛𝑛) 
and the electron-electron interaction (𝑈𝑈𝑒𝑒𝑒𝑒−𝑒𝑒𝑒𝑒), as shown in Equation 15.  This yields an equation 
that is strikingly similar to the electronic Hamiltonian used in the Hartree-Fock method after 
application of the Born-Oppenheimer approximation (Equation 4). 
𝐸𝐸𝑇𝑇𝐻𝐻 =  𝑇𝑇𝑒𝑒𝑒𝑒 +  𝑈𝑈𝑒𝑒𝑒𝑒−𝑛𝑛𝑛𝑛𝑛𝑛 +  𝑈𝑈𝑒𝑒𝑒𝑒−𝑒𝑒𝑒𝑒 
Equation 15 - Thomas-Fermi method for calculating the energy of a system 
Although this was an important first step, values obtained for the kinetic energy of the electrons 
(𝑇𝑇𝑒𝑒𝑒𝑒) were a large source of error in the energetic calculation for a system.  Although reasonable 
values could be obtained for atomic systems, the method could not handle molecular systems. 
3.6.1 Hohenberg-Kohn Theory 
The basis of DFT first emerged over 30 years later in the form of the two Hohenberg-Kohn 
theorems, as developed by Hohenberg and Kohn. 
The first theorem states that the ground state electron density of a system, termed 𝜌𝜌(𝑟𝑟), 
uniquely determines the external potential (𝑉𝑉𝑒𝑒𝑒𝑒𝑒𝑒(𝑟𝑟), the term used in DFT to describe the 
interactions between electrons and nuclei and previously termed 𝑉𝑉𝑛𝑛𝑛𝑛𝑛𝑛−𝑒𝑒𝑒𝑒), which therefore 
determines the Hamiltonian operator, which therefore defines the entire system.  This was 
proven by showing that two different external potentials couldn’t possibly result in the same 
electron density. 
The second theorem states that the form of 𝜌𝜌(𝑟𝑟) that results in the lowest total energy of the 
system is the ground state density of the system, and that this total energy is the ground state 
energy of the system.  It also states that, as in the HF method, these value can be obtained 
variationally. 
Hohenberg and Kohn were therefore able to show that the exact electronic energy functional 
(𝐸𝐸𝑒𝑒𝑒𝑒[𝜌𝜌]) for the ground state of a molecule could be determined by the electron probability 
density (as stated by their first theorem), and that it was equal to the sum of the electronic 
kinetic energies, the electron-nucleus interactions and the classical electron-electron 
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interactions (collectively termed 𝐸𝐸𝑛𝑛𝑒𝑒𝑒𝑒𝑐𝑐𝑐𝑐𝑖𝑖𝑛𝑛𝑒𝑒𝑒𝑒[𝜌𝜌]), plus the exchange-correlation energy (𝐸𝐸𝑋𝑋𝑋𝑋[𝜌𝜌])  
as shown in Equation 16. 
𝐸𝐸𝑒𝑒𝑒𝑒[𝜌𝜌] =  𝐸𝐸𝑛𝑛𝑒𝑒𝑒𝑒𝑐𝑐𝑐𝑐𝑖𝑖𝑛𝑛𝑒𝑒𝑒𝑒[𝜌𝜌] + 𝐸𝐸𝑋𝑋𝑋𝑋[𝜌𝜌] 
𝐸𝐸𝑛𝑛𝑒𝑒𝑒𝑒𝑐𝑐𝑐𝑐𝑖𝑖𝑛𝑛𝑒𝑒𝑒𝑒[𝜌𝜌] = 𝑇𝑇𝑒𝑒𝑒𝑒(𝑟𝑟) + 𝑉𝑉𝑒𝑒𝑒𝑒−𝑒𝑒𝑒𝑒(𝑟𝑟) +  𝑉𝑉𝑒𝑒𝑒𝑒𝑒𝑒(𝑟𝑟) 
Equation 16 - One of the findings of Hohenberg and Kohn 
The equation for  𝐸𝐸𝑛𝑛𝑒𝑒𝑒𝑒𝑐𝑐𝑐𝑐𝑖𝑖𝑛𝑛𝑒𝑒𝑒𝑒[𝜌𝜌] is again very similar to those seen in the Hartree-Fock method 
(Equation 4) and the Thomas-Fermi method (Equation 15).  The 𝐸𝐸𝑋𝑋𝑋𝑋[𝜌𝜌] term includes a 
correction to  𝑇𝑇𝑒𝑒𝑒𝑒 to account for electron-electron interaction as well as accounting for the non-
classical electron-electron interaction energy 
Again, although Hohenberg-Kohn theory gives information on the form of these equations, it 
gives no way of determining its value.  It can, however, be tackled using the variational principle, 
as only the ground state electron density will yield the ground state electronic energy functional.  
In other words, the lower the calculated electronic energy of a system, the closer the electron 
density is to the real solution.  We can therefore calculate the electronic energy by finding the 
electron density that minimises 𝐸𝐸𝑒𝑒𝑒𝑒. 
3.6.2 Kohn-Sham Theory 
Although the Hohenberg-Kohn theorems are a very important proof of concept, they don’t help 
in determining solutions to these equations.  Kohn-Sham theory attempts to identify the 
Hohenberg-Kohn functional through the use of two approximations. 
The first approximation is that the electrons are considered to be non-interacting, and moving 
through a field of constant potential generated by the other electrons, yet with the same 
electron density as there would be with interacting particles.  This fictitious system is called a 
“Kohn-Sham system”.  This system is then computationally inexpensive to solve in a similar 
fashion to within Hartree-Fock theory, by linearly combining the one-electron orbitals to give 
the total density of the system.  The Kohn-Sham system can be described by Kohn-Sham 
equations, a common form of which is given in Equation 17, with 𝜈𝜈𝑒𝑒𝑒𝑒𝑒𝑒(𝑟𝑟) representing the 
external potential through which the electrons move (i.e. the “Kohn-Sham potential”), 𝜙𝜙𝑖𝑖(𝑟𝑟) is 
known as the Kohn-Sham orbital, and 𝜀𝜀𝑖𝑖  is the orbital energy of said Kohn-Sham orbital. 
�−
ℏ22𝑚𝑚∇2 + 𝜈𝜈𝑒𝑒𝑒𝑒𝑒𝑒(𝑟𝑟)�𝜙𝜙𝑖𝑖(𝑟𝑟) =  𝜀𝜀𝑖𝑖𝜙𝜙𝑖𝑖(𝑟𝑟) 
Equation 17 - A common representation of the Kohn-Sham equations 
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The Kohn-Sham potential, 𝜈𝜈𝑒𝑒𝑒𝑒𝑒𝑒(𝑟𝑟), is made up of the electron-electron interaction, the external 
potential acting on the system (𝜈𝜈𝑒𝑒𝑒𝑒𝑒𝑒) and the exchange-correlation potential (𝜈𝜈𝑋𝑋𝑋𝑋), as shown in 
Equation 18.  
𝜈𝜈𝑒𝑒𝑒𝑒𝑒𝑒(𝑟𝑟) =  �𝜌𝜌(𝑟𝑟)𝜌𝜌(𝑟𝑟′)|𝑟𝑟 − 𝑟𝑟′| 𝑑𝑑𝑟𝑟𝑑𝑑𝑟𝑟′ +  𝜈𝜈𝑒𝑒𝑒𝑒𝑒𝑒(𝑟𝑟) +  𝜈𝜈𝑋𝑋𝑋𝑋(𝑟𝑟) 
Equation 18 - Constituent factors in the Kohn-Sham potential 
The electron density of the system can be described in terms of Kohn-Sham orbitals (Equation 
19). 
𝜌𝜌(𝑟𝑟) =  �|𝜙𝜙𝑖𝑖(𝑟𝑟)|2𝑁𝑁
𝑖𝑖
 
Equation 19 - The electron density in terms of Kohn-Sham orbitals 
Because the Kohn-Sham potential depends on the electron density, a solution can be 
determined by using the self-consistent field (SCF) method. 
The second approximation is to construct the so-called Hohenberg-Kohn functional, 𝐹𝐹[𝜌𝜌], to 
group all unknown variables into a single component.  In a similar notation as given previously 
for Hartree-Fock theory, the functional can be broken into the sum of all single electron kinetic 
energies (𝑇𝑇𝑒𝑒𝑒𝑒[𝜌𝜌]), the coulombic electron-electron interaction energy (𝐽𝐽[𝜌𝜌], considered as an 
electron interacting with a mean field generated by the other electrons), and the exchange and 
correlation energy (𝐸𝐸𝑋𝑋𝑋𝑋[𝜌𝜌]), as shown in Equation 20.  𝐹𝐹[𝜌𝜌] =  𝑇𝑇𝑒𝑒𝑒𝑒[𝜌𝜌] +  𝐽𝐽[𝜌𝜌] + 𝐸𝐸𝑋𝑋𝑋𝑋[𝜌𝜌] 
Equation 20 - Rearranged form of the Hohenberg-Kohn functional 
The exchange-correlation energy component (𝐸𝐸𝑋𝑋𝑋𝑋[𝜌𝜌]) is therefore made up of a corrective 
kinetic energy term (𝑇𝑇𝑛𝑛) and a non-classical contribution to electron-electron interaction energy 
(𝐸𝐸𝑛𝑛𝑛𝑛𝑒𝑒).  The equation for 𝐸𝐸𝑋𝑋𝑋𝑋[𝜌𝜌] is shown in Equation 21. 
𝐸𝐸𝑋𝑋𝑋𝑋[𝜌𝜌] =  𝑇𝑇𝑛𝑛 +  𝐸𝐸𝑛𝑛𝑛𝑛𝑒𝑒 
Equation 21 - Equation for the exchange-correlation energy component of the Kohn-Sham equation 
3.6.3 The Exchange-Correlation Functional 
The exchange-correlation functional, 𝐸𝐸𝑋𝑋𝑋𝑋[𝜌𝜌], cannot be determined systematically, so it must 
be approximated.  There are a number of methods for doing this, but this section will only focus 
on those methods that are relevant to this project. 
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The most common method for determining 𝐸𝐸𝑋𝑋𝑋𝑋[𝜌𝜌] is called the local density approximation 
(LDA).  Within this method, electrons are treated as a uniform electron gas (UEG), whereby they 
are approximated as being averaged evenly over the space of the molecule.  The LDA form of 
𝐸𝐸𝑋𝑋𝑋𝑋  is given in Equation 22, which includes 𝜀𝜀𝑋𝑋𝑋𝑋(𝜌𝜌(𝑟𝑟)), the exchange-correlation potential per 
particle in a UEG of density 𝜌𝜌(𝑟𝑟). 
𝐸𝐸𝑋𝑋𝑋𝑋
𝐿𝐿𝐿𝐿𝐴𝐴[𝜌𝜌] =  �𝜌𝜌(𝑟𝑟)𝜀𝜀𝑋𝑋𝑋𝑋(𝜌𝜌(𝑟𝑟))𝑑𝑑𝑟𝑟 
Equation 22 - The local density approximation method for approximating the exchange-correlation 
potential 
The LDA approach relies on the species under investigation being “soft”, i.e. species which are 
relatively large, have low charge states and are highly polarisable, such as salts.  This typically 
doesn’t hold true for drug-like molecules, which are typically only weakly polarisable. 
An alternative to the LDA approach is the generalised gradient approximation (GGA).  The GGA 
approach includes both the local electron density and gradient of the electron density, as 
opposed to the UEG approximation employed within the LDA approach.  As a method of 
calculating exchange-correlation energy, there are many different exchange-correlation 
functionals for use with GGA.  Including the popular functionals B3P86 and B3LYP.  Both B3P86 
and B3LYP employ the B3 exchange functional, but have different correlation functionals (P86 
as opposed to LYP). 
B3 functionals such as B3P86 or B3LYP are also known as “hybrid functionals”, meaning that 
they include input on the exchange-correlation energy from multiple methods.  In the case of 
B3 functionals, input from the three methods (hence the “3” part of the functional name) LDA, 
GGA and Hartree-Fock are included. 
3.6.4 Summary of DFT 
In conclusion, modern molecular modelling software that utilises the DFT method will attempt 
to find an approximation to the Schrödinger equation using a variety of simplifications and 
approximations to calculate the electron probability density of a system.  The primary 
approximation is the Born-Oppenheimer approximation, which considers the nuclei and 
electrons of a system separately due to their large differences in mass and speed.  The 
Hohenberg-Kohn theorems next tell us firstly that a system can be uniquely described by the 
ground state electron density of said system and secondly that the lowest calculated energy of 
a system will be closest in energy to the true energy of the system, and that therefore the energy 
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of a system can be determined variationally.  The next approximation is included within Kohn-
Sham theory, and approximates all electrons as non-interacting particles moving through a field 
of constant potential generated by the other electrons, which drastically simplifies the 
computational complexity required.  The final significant approximation involves the use of a 
functional to approximate the exchange-correlation energy.  Bringing all of this together allows 
for software to calculate the energies of compounds, and therefore allows the medicinal chemist 
access to related energetic values such as bond dissociation enthalpies. 
DFT, when complimenting empirical evidence, is a powerful tool for giving insight into reaction 
mechanisms and molecular structures that would be difficult if not impossible to determine 
experimentally.  DFT is well suited to determining relative energies of species such as the relative 
energy of a radical to its neutral counterpart, and is therefore an ideal method for calculating 
values such as of BDE, PA, ETE, AIP and PDE.  The accuracy and precision of the values obtained 
will depend largely on the methodological choices made, such as using a relevant functional and 
basis set, as well as reasonable input geometries.  These choices can often be reduced down to 
a trade-off between computational cost and quality of data obtained, so a solid methodological 
foundation is essential. 
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4.1 Introduction 
As discussed in the introduction chapter, the traditional approach to drug development has 
typically been to simply synthesise various analogues of a known active compound based on 
chemical intuition and literature precedent.  This approach is undertaken in this chapter, 
whereby analogues of both lead compounds are produced with the intention of developing a 
structure-activity relationship (SAR). 
4.2 Design and Synthesis of Analogues of I3C and Compound 5 
As was shown earlier, the anticancer activity of indole-3-carbinol (I3C) is thought to be due to 
the formation of the metabolic active product 3,3’-diindolylmethane (DIM), which is formed via 
a 3-methyleneindolinium intermediate,[116] as shown in Scheme 39.  The activity of the 
analogous compound 5 is therefore thought to occur due to the formation of an analogous 
metabolic product, as shown in Scheme 40. 
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Scheme 39 - Generation of DIM from I3C via a 3-methyleneindolinium intermediate [116] 
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Scheme 40 - Hypothesised analogous mechanism of the degradation of compound 5 
I3C (and, by extension, compound 5) can therefore be considered as prodrugs.  This leads to two 
options when considering the design of analogues; analogues of both the prodrug and the active 
form can be produced and tested.  In this section, focus will initially be on analogues of the 
prodrug, and focus on analogues of the active form will follow on. 
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4.2.1 Analogues of the prodrug form 
With prodrugs, a significant quality that can often be controlled is the rate of conversion to the 
active drug.  In the common case of prodrugs that contain a carrier (with some well-known 
examples including aspirin,[212] progabide[213] and alprazolam[214]), this is often done by changing 
the carrier group to affect the rate of metabolism, thus the active form of the drug is structurally 
unaffected.  In the case of I3C and compound 5, the metabolism of the prodrug is more 
complicated, so designing superior prodrugs while leaving the active form unaffected is difficult. 
To more fully understand how structural changes to I3C may affect the metabolism, a more 
complete metabolic mechanism is required.  Such a mechanism, shown in Scheme 41, shows 
that the structurally most important features of I3C are the hydroxymethyl group at the 
3-position, conjugation to delocalise the resultant cation and the nitrogen at the 1-position.  The 
hydroxymethyl group is important as it goes on to produce two leaving groups (H2O and CH2O), 
the conjugation allows the cationic charge to be more delocalised, and the nitrogen is important 
as it gives the positive charge on an electronegative atom on which to sit, thus lowering the 
energy of the intermediate cation. 
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Scheme 41 - A more complete mechanism for the acid degradation of I3C to DIM 
The Role of Conjugation 
The conversion of I3C to DIM is only possible due to the relatively low energy of the intermediate 
cation.  A significant amount of this stability comes from the delocalisation of charge.  By adding 
more conjugated centres, such as the addition of the 2-phenyl group in compound 5, the charge 
can be more delocalised, and therefore will have a lower barrier to formation.  In the example 
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of I3C, the cation can be delocalised over two centres, whereas the cation of compound 5 can 
be delocalised over five centres (Figure 20) 
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Figure 20 - The two resonance forms of the I3C cation (left) and the five resonance forms of the cation for 
compound 5 (right) 
As previously discussed in the introduction, the EC50 values for I3C and compound 5 have been 
reported as 526 μM and 176 μM respectively, so there is a considerable improvement upon the 
addition of the 2-phenyl ring.  To try and elucidate if this is coincidental, an attempt was made 
to test analogues both with and without a 2-phenyl substituent. 
The Role of the Carbinol Group 
The carbinol group of I3C (more commonly referred to as a hydroxymethyl group within the 
wider field of chemistry) is mechanistically involved in the metabolism of I3C.  It would therefore 
be likely to have a significant effect on the metabolism of I3C.  Based on Scheme 41, it would 
appear that having the hydroxymethyl group conjugated with an electronegative atom on which 
the positive charge can rest is important to the ability of the molecule to form the intermediate 
cation.  By extending the carbon chain of the hydroxymethyl group to a hydroxyethyl group, the 
conjugation is disrupted, and this should prevent the formation of the active form of the drug.  
This disruption to conjugation is shown in Scheme 42. 
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Scheme 42 - The formation of the intermediate cation is possible with a 3-hydroxymethyl group (top) but 
is not possible with a 3-hydroxyethyl group (bottom) 
The hydroxyethyl analogue of I3C (compound 126) was therefore purchased for testing, and the 
hydroxyethyl analogue of compound 5 (compound 129) was synthesised for testing.  Their 
structures, with comparisons to their hydroxymethyl analogues, are shown in Figure 21.  The 
synthesis of compound and 129 is described in Section 8.2.4. 
N
H
OH
N
H
OH
N
H
OH
N
H
OH
II3C 126 5 129  
Figure 21 - From left to right, I3C, compound 126, compound 5 and compound 129 
An alternative and simpler way of determining the necessity of the 3-hydroxymethyl group is 
simply to remove it.  This approach of stripping a molecule back until it loses its activity is a 
common approach in determining the structurally vital components of a compound.  The 
dehydroxymethylated compounds indole and 2-phenylindole (shown in Figure 22) were 
therefore procured for testing. 
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Figure 22 - The structures of indole (left) and 2-phenylindole (right) 
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The effect of N-substituents 
Looking back to the 3-methyleneindolinium intermediate (6) shown in Scheme 41, the third 
important structural feature of I3C is the electronegative nitrogen atom on which a cationic 
charge can sit.  By adding substituents that transiently affect the electronics of this nitrogen, or 
by replacing the nitrogen with a different element, the ease with which their respective 
metabolites are formed may be affected. 
The first step was to synthesise some N-substituted analogues.  By adding a substituent at the 
N-position, this would affect not just the structure of the prodrug, but also the structure of the 
active form.  It was decided therefore that a hydrolysable substituent should be tested. 
One such example of a group that can be hydrolysed off an indole is an acetyl group. 
N-acetylindoles are known to be hydrolysed under both basic[215] and acidic[216] conditions at 
mild temperatures, so would be expected to be hydrolysed in the body, especially in the 
presence of numerous cellular proteases.  The rate of hydrolysis compared to the rate of 
dimerisation would determine in which order these two processes would be likely to occur.  For 
example, if the acetyl group is removed too easily, then I3C would be readily formed and the 
rate of dimerisation would likely be the same as the rate of dimerisation of I3C, so no change in 
activity might be expected.  However, if the acetyl group is stable enough, it might have an effect 
on the rate of formation of the dimer, which may result in a different activity.  These competing 
pathways are shown in Scheme 43. 
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Scheme 43 - The two potential pathways to DIM from compound 130 
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The N-acetyl analogue of I3C (compound 130) and the N-acetyl analogue of compound 5 
(compound 132) were synthesised as described in sections 8.2.5 and 8.2.6 respectively.  Their 
structures are shown in Figure 23. 
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Figure 23 - The two N-acetyl analogues, compound 130 (left) and compound 132 (right) 
 To test if the inclusion of a hydrolysable group is significant, an analogue containing a non-
hydrolysable N-substituent should be included.  This non-hydrolysable group should be as 
chemically similar as possible to the acetyl group in order to keep the analogue as otherwise 
similar as possible to the N-acetyl analogues.  Therefore, the group should have electron 
withdrawing mesomeric properties, be relatively small, and be a hydrogen bond acceptor.  A 
substituent that fulfils all of these criteria is the tosyl group (also known as the p-toluenesulfonyl 
group, commonly abbreviated as Ts).  The N-tosyl analogue of I3C (compound 133, shown in 
Figure 24) was synthesised (as described in Section 8.2.7) to be tested in direct comparison to 
I3C and its N-acetyl analogue. 
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Figure 24 - Compound 133 (left) alongside I3C (centre) and compound 130 (right) 
Alternative heteroatoms 
A second way of affecting the electronic environment at the 1-positon of I3C is to change the 
heteroatom completely.  Analogous heteroaromatic systems to indole include the benzofuran 
(an oxygen-containing heteroaromatic system) and benzothiophene (a sulfur-containing 
heteroaromatic system), the structures of which are shown in Figure 25. 
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Figure 25 - The structures of indole (left), benzofuran (centre) and benzothiophene (right) 
Another difference between indole and the two analogues in Figure 25 is the lack of a hydrogen 
at the 1-position.  This may be significant, as the potential of this hydrogen to be abstracted may 
lead to a significant stabilisation of the 3-methyleneindolinium intermediate during the 
metabolism of I3C to DIM.  Other than this effect, benzofuran contains an oxygen in place of a 
nitrogen, which is a more electronegative element and may therefore lead to a less readily-
formed cationic intermediate.  Conversely, sulfur is less electronegative than nitrogen, so the 
formation of a cationic intermediate from a benzothiophene analogue may be less difficult.  As 
a result of these potentially complex factors, the choice between testing a benzofuran or 
benzothiophene analogue became fairly arbitrary, and the decision to synthesise the 
benzothiophene analogue 134 for testing (Figure 26), the synthesis of which is described in 
Section 8.2.8, was ultimately down to commercial availability of the required starting material. 
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Figure 26 - I3C (left) and its benzothiophene analogue (right) 
4.2.2 Analogues of the active compound DIM 
The final comparison within this series of compounds is to investigate the necessity of using the 
prodrug at all.  It is known that the metabolism of I3C to DIM doesn’t occur with quantitative 
yields, so one might assume that by testing the isolated active compound, activity would 
increase along with the increase in quantity of active compound.  However, this may be an 
oversimplification.  As discussed in the introduction chapter, the work of Staub[129] and 
Bjeldanes[116] suggested that in the case of I3C, DIM is generated in the nucleus of the cells. By 
introducing DIM to cells, it is possible that the compound is unable to make it to the nucleus, 
where it appears to be acting. 
A further issue is solubility.  I3C is only sparingly soluble in aqueous media, and by losing the OH 
group, DIM becomes a highly hydrophobic molecule.  Of course, solubility can always be 
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addressed later in the drug development process through the addition of solubilising groups, so 
this hydrophobicity need not pose a significant problem at this stage. 
To investigate the necessity of using the prodrugs, the active forms of both I3C and compound 
5 (DIM and the compound 9) were purchased and synthesised respectively for testing.  Their 
structures are shown in Figure 27, and the synthesis for compound 9 is described in Section 
8.2.3. 
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Figure 27 - The prodrug I3C and its active form DIM (left) and the prodrug compound 5 alongside its 
active form compound 9 (right) 
4.3  Design and Synthesis of Analogues of Compound 4 
As yet, the mechanism of action for compound 4 is unknown (the structure of which is shown in 
Figure 28), making the design of analogues much more difficult.  Because the target is unknown, 
and it is unknown what form the compound is in when it is delivering its activity, the structural 
features that are important are unknown.  As a result, the only approach is to investigate as 
many structural features as resources will allow. 
N
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Figure 28 - The structure of compound 4 
The first striking structural feature is that the compound is simply an indole connected to a 
phenol.  This raises the question as to the necessity of either the indole fragment or the phenol 
fragment; is anticancer activity observed when either fragment is not present?  This is an easy 
question to address.  Indole and a series of eight phenols were purchased in order to determine 
if one fragment of the molecule was important or if there was a synergistic effect in play 
between the two fragments.  A representation of separating compound 4 into its constituent 
fragments is shown in Figure 29. 
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Figure 29 - A representation of separating compound 4 into its two constituent fragments in order to test 
the fragments separately, and the eight derivatised phenols that were included in this work 
The next structural feature of interest is that the indole and phenol fragments are conjugated.  
Current evidence suggests that reactive oxygen species (ROS) are involved in the mechanism of 
action for compound 4,[6] so it is possible that the ability of compound 4 to form a radical is 
relevant to its activity.  If phenol was to form the phenolic radical, that radical can be delocalised 
across four centres, whereas if compound 4 was to form a phenolic radical, it could be 
delocalised across eight centres.  This greater level of delocalisation will lead to a more stable 
and more readily formed radical, which may be relevant to the activity of this compound. 
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Figure 30 - The four resonance structures of the phenol radical and the eight resonance structures of the 
radical form of compound 4 
In order to determine if this conjugation is important, an analogous unconjugated compound 
would be necessary.  There are a number of possible structures for such an analogue, each with 
its own drawback.  The structures of three such possible compounds are shown in Figure 31. 
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Figure 31 - Compound 4 (far left) alongside three compounds with reduced conjugation: two indolines 
(centre left and centre right) and an indane (far right) 
Compound 149, shown in Figure 31, is an indoline that is simply the reduced form of compound 
4, but differs from compound 4 in two significant ways.  The first is that whereas the 3D structure 
of compound 4 is largely planar, the five membered ring of compound 149 would assume an 
envelope conformation.  The carbon at the 2-position is now also sp3 hybridised, significantly 
affecting the physical shape of the molecule.  The second significant difference is that the NH 
group in compound 149 now acts as an amine, significantly increasing the potential for acting as 
both a hydrogen bond acceptor and donor.  This may have an effect on intermolecular 
interactions with a potential binding site, as well as intramolecular interactions with the phenolic 
group. 
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The second analogue, compound 150 attempts to address some of the issues with planarity by 
trying to fix the 3-position more in plane with the fused aromatic ring.  This would however be 
a significant synthetic challenge due to the large strain that this would introduce to the 
molecule, as well as significantly affecting both the size, shape and hydrophobicity of the 
molecule.  There may also be steric clashes between the OH group and the new vinyl group, 
affecting relative position of the phenol ring. 
The third analogue, compound 151, attempts to address the addition of an amine in the first 
analogue.  This indane would obtain a broadly similar overall conformation to compound 149, 
yet would be incapable of acting as either a hydrogen bond donor or acceptor.  Indoles are 
known to participate in weak hydrogen bonding,[217–219] so by removing the nitrogen altogether, 
the potential for an important interaction may be removed. 
The choice comes down to either the simpler indoline (compound 149, which is likely to over-
represent the extent of hydrogen bonding) or the indane (compound 151, which will under-
represent the extent of hydrogen bonding).  The choice was made to synthesise compound 149, 
as described in Section 8.2.9, on account of it having a dipole that more accurately matched the 
dipole of compound 4. 
Another structural feature to investigate is the necessity of the phenolic OH group.  As 
mentioned earlier, the radical of 4 may be involved in the production of ROS, so a loss of activity 
would be expected if the OH group or the entire phenolic group was to be removed.  To 
investigate this, indole and 2-phenylindole (the structures of which are shown in Figure 32) were 
purchased in order to be tested alongside compound 4. 
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Figure 32 - The structures of compound 4 (left), indole (centre) and 2-phenylindole (right) 
Another way of investigating the necessity of the phenolic system is to investigate if a similar 
system has similar activity.  The most similar systems to phenolic systems are anilinic (with an 
NH2 in place of the OH) or thiophenolic (with an SH in place of the OH) systems.  The structures 
of the anilinic analogue (compound 152) and thiophenolic analogue (compound 153) of 
compound 4 are shown in Figure 33. 
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Figure 33 - Compound 4 alongside its anilinic and thiophenolic analogues 
Due largely to the wider abundance of anilines compared to thiophenols (and therefore a higher 
potential for ease of synthesis and purchase of future analogues), it was decided that aniline 
152 would be included in this work. 
An alternative approach to determining the role of the phenolic group of compound 4 is to add 
protecting groups.  If the phenolic OH group is essential for activity, masking this OH with a group 
that can’t be removed by hydrolysis should reduce the anticancer activity, whereas masking this 
OH with a group that can be removed by hydrolysis should maintain the same anticancer activity, 
albeit with a delay, while at the same time providing a prodrug approach. 
To investigate this hypothesis, six O-substituted analogues of compound 4 were synthesised, 
including a benzyl, tert-butyldimethylsilyl (also known as TBDMS, or simply TBS), benzoyl, 
heptanoyl, methanesulfonyl (also known as a mesyl) and acetyl analogue.  The structures of 
compound 4 and these six analogues are shown in Figure 34, and their syntheses are described 
in sections 8.2.10 to 8.2.15.. 
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Figure 34 – The structures of compound 4 alongside some O-substituted derivatives: the benzyl analogue 
154, the TBS analogue 155, the mesyl analogue 156, the benzoyl analogue 157, the acetyl analogue 158 
and the heptanoyl analogue 159 
Of the six analogues shown in Figure 34, the three esters (the heptanoyl 159, the acetyl 158 and 
the benzoyl 157) would be expected to undergo enzyme-catalysed hydrolysis, albeit at different 
rates.  Protecting alcohols (or phenols in this case) with acyl groups to form esters is the most 
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common strategy employed when designing prodrugs,[220] and is employed in drugs as diverse 
as the chemotherapeutic irinotecan to the anti-inflammatory aspirin (Scheme 44) 
 
Scheme 44 - The prodrug irinotecan being metabolised by carboxylesterase 1 (CES1) to its active form 
(top) and aspirin metabolysing to salicylic acid under acidic conditions (bottom) 
The other three derivatives shown in Figure 34 (i.e. the benzyl 154, the TBS 155 and the mesyl 
156) would not be expected to be removed easily, so might be expected to show no activity. It 
is however always possible that these groups could be cleaved by an enzyme (either hydrolysed 
or via redox mechanisms) to produce the active compound 4.  For example, enzymatic cleavage 
of Si-O bonds is known,[221,222] although typically these have only been reported for more 
hydrophilic residues. 
Up until now, all the focus has been on compounds that closely resemble the lead structure of 
compound 4 in shape.  Investigating an analogue that is electronically similar to compound 4 but 
has a different shape may yield information on any potential active site that the drug may be 
interacting with.  An isomer of compound 4 whereby the phenol group is simply at a different 
position on the indole ring would have a different shape but otherwise very similar electronics. 
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Figure 35 - The seven isomers of 2'-hydroxyphenylindole 
The seven isomers of the lead compound 4 are shown in Figure 35.  In the interest of keeping 
analogues as similar as possible, only isomers with the phenol ring as a substituent on the pyrrole 
ring should be considered.  A further constraint should be that the NH group is preserved in case 
it is involved in some weak hydrogen bonding.  This leaves only the 3-substituted isomer, 
compound 160, as shown in Figure 36.  This compound was therefore synthesised, as described 
in Section 8.2.16. 
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Figure 36 - Compound 4 (left) and compound 160 (right) 
The analogue shown in Figure 36 differs in a few subtle ways from the lead compound.  Primarily, 
and most importantly is that the basic shape of the molecule is slightly different.  Secondly, 
because the substituent is on an adjacent carbon, the resonance structures of the respective 
radicals are slightly different.  These resonance structures, depicted in Figure 37, show that the 
radical can be delocalised onto different carbons between the two isomers, however it is 
unknown what effect this would have on activity. 
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Figure 37 - The possible places that a phenolic radical could become delocalised to on compound 4 and 
compound 160 
The final structural feature of compound 4 that necessitates investigation is the indole core.  This 
is perhaps the most important structural change available, as the development that can be done 
on a compound further along the drug development process is severely limited by the choice of 
drug core.  A series of analogues (which were by no means exhaustive) were devised that could 
begin to explore whether the anticancer activity of compound 4 is dependent on the inclusion 
of an indole core, the structures of which are shown in Figure 38. 
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Figure 38 - Compound 4 alongside analogues that include a non-indole core: a benzoxazole (compound 
166), a benzothiazole (compound 167), a naphthyl (compound 168) and a phenyl (compound 169) 
The benzoxazole and benzothiazole analogues (compounds 166 and 167) were included due to 
having a very similar shape, being aromatic, and containing an aromatic nitrogen.  These cores 
differ from the lead compound in that they include two moderately strong hydrogen bond 
acceptors but no hydrogen bond donors, whereas the indole core contains a weak hydrogen 
bond donor and a weak hydrogen bond acceptor. 
The naphthalene analogue 168 has a slightly different shape to compound 4 and contains no 
hydrogen bond donor or acceptor, but is isoelectronic.  This compound may yield important 
information about the necessity of the NH group in compound 4, so was synthesised (as 
described in Section 8.2.17) for use later in the project. 
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The phenyl analogue 169 is a stripped back version of the naphthalene analogue, and will 
hopefully bridge the gap in chemical space between the highly conjugated analogues 
investigated thus far and the much simpler phenols described earlier. 
4.3.1 Conclusion on Analogues of Compound 4 
This section has described the design of analogues that can investigate the importance of the 
structural features of compound 4.  The choices of analogues discussed within this section, along 
with the structural features under investigation, are brought together in Figure 39. 
 
Figure 39 - A summation of the structural features and analogues of compound 4 
4.4 Miscellaneous Synthetic Challenges and Methods 
In the course of this work, a number of synthetic and analytical challenges presented themselves 
which in some cases limited the intended scope of the work being undertaken.  In some cases, 
existing synthetic methods were incapable of producing the required compounds, therefore 
certain structural features and derivatisations could not be realised despite much 
experimentation changing standard reaction parameters.  In other cases, an unexpected 
product was formed, resulting in the inclusion of an unplanned analogue in the work.  In one 
particular case, a rearrangement which had gone unreported for over 40 years was responsible 
for the formation of a compound that proved very difficult to characterise. 
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4.4.1 Structural features that were unable to be investigated 
For both the lead compounds 4 and 5, there were analogues and structural features which could 
not be investigated.  Some analogues could not be produced due to synthetic limitations, 
whereas some analogues could not be tested due to being too unstable. 
One such analogue of I3C that was intended to be investigated was an N-benzyl analogue 
(compound 170), which was intended to be tested alongside compound 133, the N-tosyl 
analogue (the structures of which are shown in Figure 40).  This compound was found to be too 
unstable for use as a drug, as it decomposed fully over a period of just a few days.  This 
compound would therefore give no useful information with regards to an SAR, as any potential 
pharmacological effects may be due to the effects of a degradation product and not the 
synthesised compound. 
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Figure 40 - The structures of I3C, its N-benzyl analogue (170) and its N-tosyl analogue (133) 
It can be confidently asserted that compound 170 itself was successfully synthesised from 
indole-3-carboxaldehyde (compound 171), as shown in Scheme 45.  The degradation product is, 
however, more difficult to assess, and due to time constraints was not fully investigated. 
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Scheme 45 - The synthesis of compound 170 
These N-substituted I3C analogues shown in Figure 40 might be expected to degrade in much 
the same way as I3C does into a series of metabolites, as discussed in the introduction, and there 
is some evidence that this occurs.  Whereas I3C degrades into a number of metabolites including 
3,3’-diindolylmethane (DIM), the N-benzyl analogue 170 might be expected to form the  
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analogous metabolite 174 (Scheme 46).  The characteristic peak of DIM, the bridging CH2 group, 
has a 1H NMR shift of 4.26 ppm (singlet) and a 13C NMR shift of 21.35 ppm.  Crude NMR spectra 
of the degradation products of compound 133 shows a 1H NMR shift at 4.29 ppm (singlet) and a 
13C NMR shift at 21.17 ppm, suggesting that the analogous degradation product 174 may have 
been formed. 
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N N
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Scheme 46 - Suspected degradation product of compound 170 into the DIM analogue 174 
It may seem unusual that compound 170 would be significantly less stable than compound 133 
or I3C.  However, it may be the case that the inductive effect of the benzyl group stabilises the 
cationic intermediate (shown in Scheme 46 as compound 173), making the degradation more 
favoured.  The N-tosyl group of compound 133 on the other hand would destabilise a nitrogen-
based cation, whilst also reducing the propensity for the nitrogen to donate its lone pair of 
electrons, which would result in a disfavoured degradation pathway. 
There were also structural features of compound 4 that could not be investigated due to 
synthetic limitations.  One such feature was to be the rotation around the indole-phenol bond.  
By rotating about this bond, as shown in Figure 41, the OH group can be located in a different 
area of space, potentially affecting any drug-protein interactions that may occur.  By adding a 
second OH group at the 6’-position, as in compound 175, it may be possible to improve this 
interaction. 
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Figure 41 - An illustration of the rotation around the indole-phenol bond in compound 4, and the hybrid 
structure of these two rotamers (compound 175) 
Many attempts to synthesise the dihydroxylated analogue 175 under a range of Fischer 
conditions were made.  The acid catalyst utilised ranged from polyphosphoric acid[223] (both 
without and with either ethanol or toluene as a diluant), p-toluenesulfonic acid,[224] Eaton’s 
reagent (formed in situ from phosphorus pentoxide and methanesulfonic acid)[225,226] and 
cyanuric chloride (also known as TCT).[227] 
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Scheme 47 - The two-step Fischer synthesis of compound 175 
Under Fischer conditions, the formation of an indole is a two-step reaction which goes via a 
hydrazone (Scheme 47).  However, because the second step occurs under similar conditions to 
the first step (albeit at higher temperatures), this synthesis is often carried out in one pot.  It 
was found that when mild conditions were employed, the intermediate hydrazone, compound 
178, could be isolated without issue.  However, when attempting to cyclise the hydrazone using 
a series of acid catalysts, the dihydoxyacetophenone starting material (compound 176) seemed 
to be reformed. 
The reversibility of the hydrazone formation is known.  The formation of the hydrazone results 
in the loss of water, and the reformation of the starting materials therefore requires water.  In 
order to prevent this, the cyclisation step was again retried using dried toluene, Dean-Stark 
apparatus (in order to remove any water), and molecular sieves on a larger scale, but only traces 
of product were ever detected. 
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The synthesis was also attempted using compound 179 as a starting material (Scheme 48), which 
is an O-methoxy protected form of compound 176.  These methoxy groups are routinely used 
to protect OH groups during syntheses, and can be removed relatively easily.  Upon failure to 
make this synthesis work, the Fischer synthesis was abandoned in favour of an alternative 
approach. 
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Scheme 48 - Failed Fischer synthesis using dimethoxyacetophenone and phenylhydrazine 
The Truce-Smiles rearrangement was attempted as an approach to synthesise compound 
175.[177]  The first step of this reaction, which couples the acetophenone 176 and 
fluoronitrobenzene (181) under basic conditions (Scheme 49), was repeatedly shown not to 
occur. 
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Scheme 49 - The attempted synthesis of compound 175 via the Truce-Smiles rearrangement 
Although the target product was not formed, mass spectroscopy and a 1H NMR spectrum 
suggest the formation of compound 183, as shown in Scheme 50.  This is also chemically 
reasonable when considering the pKa values of an o-hydroxyacetophenone and the conjugate 
acid of potassium carbonate, and potassium carbonate should be able do deprotonate these 
phenolic groups.  At this point it was decided in the interest of pursuing other targets, this target 
compound would no longer be pursued. 
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Scheme 50 - Suspected product formed from reaction between 2,6-dihydroxyacetophenone (176) and 
o-fluoronitrobenzene (181) 
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Another area of chemical space that was intended to be explored was the activity of a 
hydroquinone analogue of compound 4, such as compound 184 shown in Scheme 51.  
Hydroquinones were of interest because they are known to be commonly involved in redox 
cycling, whereby they can readily form reactive oxygen species (ROS).[228,229] 
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Scheme 51 - Compound 4 (left) and the conversion between compound 184 and its benzoquinone 185 
(right) 
After the challenges encountered with compound 175, less effort was put into compound 184.  
Synthesis of this analogue was attempted a number of times under Fischer conditions using 
polyphosphoric acid and Eaton’s reagent.  However, after these attempts were unsuccessful, it 
was decided not to pursue this target any longer in the interest of pursuing other analogues. 
As will be discussed in Chapter 6, in the course of the project the 3-methyl analogue of 
compound 4, referred to throughout this thesis as compound 186, became a compound of 
interest.  This compound was synthesised, as described in Section 8.2.18, but it was observed 
that on standing over a period of a few days, compound 186 (a thick yellow oil) had crystallised 
into a pale yellow solid, and on doing so had changed by 1H NMR. 
N
H HO
186  
Figure 42 - The structure of the desired compound 186 
The resultant product was purified by recrystallization (ethyl acetate and petroleum ether) to 
form large amber crystals.  A series of NMR experiments, including a 1H, 13C, DEPT135, 1H-13C 
HSQC and 1H-13C HMBC, as well as a low-resolution mass spectrometry experiment were carried 
out.  A summation of this data is shown in Table 2. 
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STRUCTURAL FEATURE EVIDENCE IMPLIED STRUCTURE 
8 AROMATIC CH PROTONS 1H NMR 
DEPT135 
 
5 AROMATIC QUATERNARY 
CARBONS 
13C NMR 
DEPT 135 
Fewer aromatic carbons, so some 
aromaticity has been lost 
TWO HYDROGEN-BONDING 
HYDROGENS 
(Δ = 13.59, 2.78) 
1H NMR Phenol has been retained? 
Due to loss of aromaticity, NH may be 
hydrogen bonding? 
New hydrogen bonding group? 
CH3 GROUP WITH NO ADJACENT 
HYDROGENS 
1H NMR 
(3H, singlet) 
3-Methyl group retained? 
 
AN M/Z OF 239 Mass spectrometry Unlikely to have dimerised – Nitrogen 
rule 
Gain of oxygen? 
VERY DESHIELDED PROTON 
(Δ = 13.59) 
1H NMR One of the hydrogen-bonding groups 
involved in strong intramolecular 
hydrogen bonding 
Table 2 - Spectroscopic evidence for structural features of the degradation product of compound 186 
Based on the evidence in Table 2, a number of possible structures (some of which are shown in 
Figure 43) were derived, but none of these structures satisfied all of the evidence.  Many of the 
compounds were still based on 2-phenylindoles, which don’t match the aromaticity suggested 
by NMR.  Finding a way for a proton with a 1H shift of 13.59 was also a challenge.  
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Figure 43 - Possible structures derived from evidence shown in Table 2 
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An alternative approach was to try and determine how compound 186 could degrade.  As 
discussed in Section 6.3.2, this analogue was designed in order to investigate the effect of 
stabilising the phenolic radical, as shown in Figure 44. 
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Figure 44 - The delocalisation of the phenolic radical of compound 186.  The resonance form stabilised by 
the 3-methyl group is identified with a box. 
Because the 3-methyl group would be expected to stabilise a radical that could be delocalised 
to the 3-position of the indole ring, it stands to reason that the radical would formally spend 
more time on this lower energy position.  It might therefore be expected that another radical 
might react at this positon.  A number of possible radicals were considered, and their respective 
radical termination products are shown in Scheme 52. 
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Scheme 52 - Potential products of a number of radical termination products 
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Of the radical termination products shown in Scheme 52, compound 198 fits all of the 
spectroscopic evidence shown in Table 2.  It has a mass of 239, has reduced aromaticity, has two 
exchangeable protons, and the phenolic proton which is hydrogen-bonded to the newly formed 
imine could have a very high 1H NMR shift. 
In order for this assignment to be plausible, formation of the product needs to be plausible.  
Aerial oxidations of 2,3-disubstituted indoles are also known,[230] and a proposed mechanism of 
formation is shown in Scheme 53. 
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Scheme 53 - Proposed mechanism for aerial oxidation of compound 186 to compound 198 
In order to confirm this assignment, the crystal structure of the product was obtained by the 
EPSRC UK National Crystallography Service at the University of Southampton.[231]  An image of 
the crystal structure is shown in Figure 45.  This assignment is in agreement with a previously 
reported formation of this product.[230] 
N
OH
OHMe
(±)
198  
Figure 45 - The skeletal structure of compound 198 (left) alongside its XRD structure (right) 
The most notable structural feature in this crystal structure is the bridging hydrogen (labelled 
“H2” in Figure 45).  The N1⋯H2 interaction length is 1.63 Å, hinting at a potential resonance 
form (Scheme 54).  This would lead to a highly deshielded proton, which would result in a very 
high 1H NMR shift, therefore explaining the unusually downfield peak at δ = 13.5. 
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Scheme 54 - Potential resonance form of compound 198 
Although compound 198 was an unexpected product, the anticancer activity of this compound 
was also established, and is discussed in Chapter 7.  Further information on its synthetic pathway 
is given in Section 8.2.18. 
4.4.2 A novel approach to 3,3’-diindolylmethanes 
As has been established in the main body of work, 3,3’-diindolylmethanes are promising 
anticancer compounds.  3,3’-Diindolylmethanes, such as the simplest example of DIM, shown in 
Scheme 55, are known to be formed from indole-3-carbinols both under laboratory[232] and 
physiological[116] conditions. 
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Scheme 55 - Degradation of I3C to DIM 
Although it is possible to synthesise DIM analogues from their respective indole-3-carbinols, the 
instability of these reagents makes this synthesis disfavoured.  The most common synthesis for 
DIM analogues is to synthesise them from their 3-unsubstituted indoles and formaldehyde, 
however this limits the products to symmetrical 3,3’-diindolylmethanes, and requires the use of 
carcinogenic formaldehyde.  A representative reaction for the formation of DIM from indole is 
shown in Scheme 56. 
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Scheme 56 - Synthesis of DIM from indole and formaldehyde 
In the course of this work, a novel synthesis of 3,3’-diindolylmethanes was discovered, which 
uses safer reagents, and should allow for unsymmetrical 3,3’-diindolylmethanes to be 
synthesised.  Although only compound 9 was produced using this method (Scheme 57), this 
proof of concept can be developed in the future. 
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Scheme 57 - Novel synthesis of a DIM analogue 
Briefly, 2-phenylindole was dissolved in ethanol and acetic acid.  Compound 5, dissolved in 
ethanol, was added to the reaction gradually, and the reaction was stirred for 1 minute until 
complete by TLC.  The solvent was then removed in vacuo, and the product was isolated and 
purified by preparative liquid chromatography to yield compound 9 (62 mg, 58% yield).   A full 
characterisation and synthetic method for this product is given in Section 8.2.3. 
The potential of this reaction as a method for synthesising unsymmetrical DIM analogues is 
clear; by employing an excess of the 3-unsubstituted indole and/or introducing the 3-substituted 
indole gradually, the 3-substituted indole should tend to react with the 3-unsubstituted indole. 
4.4.3 A microwave mediated Fischer indole synthesis 
In the process of finding efficient syntheses for indoles, a publication by Creencia et al., was 
found which allegedly reports on a one-pot, one-step microwave assisted Fischer indole 
synthesis.[233]  This paper however fails to report the temperatures at which the reactions were 
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carried out, and the results were therefore unrepeatable.  Efforts therefore began to develop 
generic conditions for a microwave assisted Fischer indole synthesis. 
As it was a compound of interest at the time, the methodological development of these 
conditions was carried out on the synthesis of compound 186, the reaction for which is shown 
in Scheme 58. 
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Scheme 58 - Microwave-mediated synthesis of compound 186 
During a preliminary reaction, tosic acid was trialled as the acid catalyst.  The reaction was 
carried out at 200 oC for 5 minutes, and product was detected by NMR.  Therefore, tosic acid, 
which was also the acid catalyst reported to have been used by Creencia et al., was utilised as 
the acid catalyst for this set of condition screening. 
 The yield of the reaction would be determined by GC-MS, relative to the external standard 
2-phenylindole.  The retention times of the two reagents, the product and the standard were 
determined, and their relative peak areas were calculated. 
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Compound 
Retention time 
(Rt / minutes) 
Relative intensity 
N
H
NH2
 
6.31 0.50 ±0.076 
OOH
 
6.85 0.80 ± 0.12 
N
H
HO
 
12.58 0.87 ± 0.13 
N
H  
11.71 1 
Table 3 - Determination of retention time (Rt / minutes) and peak intensity relative to 2-phenylindole.  
Values are an average of five runs 
As can be seen in Table 3, 2-phenylindole makes a suitable internal standard for determining the 
concentration (and therefore yield) of the product using GC-MS. 
The next step would be to determine an appropriate temperature and time for the reaction to 
run for.  Once the reaction had reached the specified temperature, reactions were run at both 
160 oC and 200 oC for 1, 2, 5, 10 and 20 minutes (with reactions run at 200 oC also being run for 
30, 40 and 50 minutes).  The experimental procedure for these reactions was as follows: 
Phenylhydrazine (compound 177, 108 mg, 1 mmol), 2-hydroxypropiophenone (compound 204, 
225 mg, 1.5 mmol) and tosic acid (19 mg, 0.1 mmol) were added to a microwave reaction vessel 
and were heated under microwave radiation at the specified temperature for the specified 
period of time.  At the end of the reaction time, the crude reaction was cooled to room 
temperature, and one equivalent of 2-phenylindole was added as a standard.  The reaction was 
dissolved in dichloromethane (6 mL) and the tosic acid was filtered off through cotton wool.  The 
reaction was then diluted in dichloromethane (54 mL), and the relative quantities of all 
components was determined via GC-MS. 
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T = 160 oC  T = 200 oC 
Reaction time 
(minutes) 
Yield (%)  
Reaction time 
(minutes) 
Yield (%) 
1 3  1 49 
2 5  2 65 
5 11  5 73 
10 17  10 78 
20 31  20 86 
   30 89 
   40 87 
   50 93 
Table 4 - Table of yields for the reaction shown in Scheme 58 at two temperatures and a range of 
reaction times 
 The yield values for this methodology work are shown in Table 4, with the graphs for this data 
shown in Graph 3.  Further information on this methodological development is given in 
Appendix 1.  This data shows that the higher temperature reaches a good yield at a significantly 
quicker rate than the lower temperature without any apparent degradation of the product, as 
shown by the plateau in yield.  As there appears to be very little benefit in heating beyond 20 
minutes at 200 oC, this reaction time and temperature was used for all subsequent microwave-
mediated Fischer indole syntheses. 
 
Graph 3 - Product yield against time for the formation of compound 186 (Scheme 58) at 160 oC (left) and 
200 oC (right) 
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This chapter has described the justification and methods for synthesising the compounds of 
interest mentioned thus far, which were all designed using chemical intuition.  The next chapter 
will look at ways of computationally exploring a broader area of chemical space, and how that 
can be utilised as part of this project.
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5.1 Introduction 
The previous chapter describes the process of intuitively designing compounds to investigate 
the significance of certain structural features, but this intuitive process will inherently be limited 
to areas of chemical space that the medicinal chemist carrying out the process is familiar with.  
By using this intuitive approach, the likelihood of finding truly novel active analogues is 
drastically reduced. 
Carrying out a computational similarity search against a database expands the area of chemical 
space being explored from what is familiar to the single medicinal chemist to that which is 
documented in a curated database.  Of course, the choice of database is an important one, and 
can strongly influence the results of a similarity search.  For example, similarity searches on 
databases focused on compounds with known biological activity are more likely to return active 
compounds but less likely to return novel compounds. 
This section details a similarity search that was carried out in order to find otherwise 
unconsidered structural analogues of compound 4.  A similarity search was not carried out for 
I3C or compound 5 due to the majority of the analogues of these compounds described in 
Chapter 4 being analogues of a prodrug, and structural analogues of these compounds would 
be unlikely to form the active form of the drug in the same way that I3C and compound 5 do. 
5.2 Methodological Choices 
In order to investigate a broader area of chemical space, it was decided that a similarity search 
would be carried out to find structurally similar analogues of the lead compound 4.  Therefore, 
decisions need to be made on what database of compounds to interrogate, and what software 
to use to do the interrogation.  As this project is a predominantly depth-first approach to 
discovering active analogues as opposed to a breadth first approach, any methodological choices 
should reflect this. 
5.2.1 Choice of database 
As described in the introduction, there are a number of available databases that can be used in 
a similarity search, and the most commonly used databases are summarised in Table 5. 
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Database 
(Number of Entries) 
Pros Cons 
DrugBank[193–195] 
(8206) 
All compounds have known biological 
activity. 
Many compounds are already 
FDA-approved. 
Very small, therefore less likely to 
generate any hits. 
BindingDB[196–200] 
(541 thousand) 
Most compounds are known to 
interact with a protein(s). 
Relatively small. 
ChEMBL[201,202] 
(1.5 million) 
Reasonable number of compounds. 
Many physiological properties listed. 
Large variety of molecular weights 
included, meaning relatively few 
compounds will have a good size 
match with the lead compound. 
ZINC[4,5] 
(22 million) 
Well curated, with a subsets of 
fragment-like drugs. 
Links to vendors where most 
compounds can be purchased. 
Lots of the vendor links are 
outdated. 
PubChem[204,205] 
(89 million) 
Large area of chemical space covered. 
Biological data is included in the 
database. 
No subdirectories, meaning 
database interrogation would be 
prohibitively arduous. 
CAS REGISTRY 
(114 million) 
Most extensive database of known 
chemicals. 
Impractically large. 
Contains many non-drug like 
compounds. 
Not free to use. 
GDB-17[136,211] 
(116 billion) 
Conclusive mapping of chemical space 
of compounds of 17 heavy atoms or 
fewer. 
Limited to compounds of 17 atoms 
or fewer. 
Impractically large. 
Most compounds are synthetically 
difficult. 
Table 5 - Comparison of the most commonly used available chemical databases 
On balance, the most suitable database for this project is the ZINC database.[4,5]  It is of particular 
interest due to how the data is curated into subsets, which increase computational efficiency by 
removing compounds that are very dissimilar before interrogation begins.  The full ZINC 
database can be downloaded as subsets such as shards (molecular weight < 190 g mol-1), 
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fragment-like (molecular weight ≤ 250, logP ≤ 3.5, number of rotatable bonds ≤ 5),[203] lead-like 
(molecular weight ≤ 350, logP ≤ 3.5, number of rotatable bonds ≤ 7)[234] and drug-like 
(molecular weight of 100-500, logP ≤ 5, number of rotatable bonds ≤ 7, polar surface area < 
150, hydrogen bond donors ≤ 5 and hydrogen bond acceptors ≤ 10).[235]  The database can be 
further cut down by filtering based on commercial availability.  In this work, the subset of data 
that has been opted for is the fragment-like subset of compounds which are advertised as 
currently in stock, a subset that includes 700,000 entries.  The fragment-like subset was chosen 
because the filtering criteria was most appropriate for the lead compounds being used.  The 
choice to only include commercially available compounds that were advertised as in stock was 
to hopefully increase throughput of compounds by being able to simply buy in any compound 
of interest and send it off for testing. 
5.2.2 Similarity searching software 
The aim of this subset of the project is to search an appropriate database of over 700,000 
compounds for structures that are similar to that of the lead compound 4.  This therefore 
requires a software that can generate a similarity index between a lead compound and a large 
database. 
There are many softwares available for similarity searching,[236] but one such software that fills 
these requirements and has been successfully utilised within the group in the past is ShaEP.[237] 
ShaEP, standing for Shape and Electrostatic Potential, is a software which calculates the shape 
and electrostatic potential similarity between two rigid bodies (i.e. between two 3D structures 
which can’t be conformationally adjusted).  ShaEP works by overlaying two molecules in such a 
way that the volume overlap of the two molecules are maximised, before generating a structural 
similarity score and an electrostatic similarity score and outputting an overall similarity score as 
an average of these two values.  It was designed and built with the purpose of handling large 
datasets, and each comparison is typically calculated on a subsecond timescale.  Because ShaEP 
employs rigid body molecules (i.e. the software does not manipulate the geometries of 
molecules in order to enhance similarities), multiple conformations of each compound are 
accepted, and the similarity score reported is the highest value achieved between each pair of 
conformations. 
5.2.3 Preliminary work 
Before undertaking such a large area of work, some preliminary work on smaller datasets was 
performed in order to gain an appreciation of the similarity values outputted by ShaEP.  The first 
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step to this preliminary work was to determine the similarity scores between three compounds 
that are clear to a chemist as highly similar. 
Using the freeware Balloon,[238] five conformers of the lead compound 4 and two of its very close 
analogues were produced, as shown in Figure 46.  These compounds are clear analogues in the 
eyes of a medicinal chemist, as phenols and anilines share similar chemistry,[239,240] and the 
indole and naphthalene scaffold are both isoelectronic.  ShaEP was then used to determine their 
similarity scores, and the values for their shape similarity and electrostatic potential similarity 
along with an average of the two values (i.e. the overall similarity score) is displayed in Figure 
46. 
N
H
N
H
OH
Shape
 = 0.745
Electrostatic
 = 0.972
Average
 = 0.858
Shape
 = 0.690
Electrostatic
 = 0.923
Average
 = 0.806
Shape
 = 0.657
Electrostatic
 = 0.946
Average
 = 0.802
HOH2N
4152
168  
Figure 46 - Similarity between three known analogues, as determined by ShaEP 
As might be expected, compound 4 and its aniline analogue compound 152 are considered to 
be the most similar with regards shape and electrostatic potential.  The naphthalene analogue 
168 is considered to have a closer shape similarity to compound 4, but a closer electronic 
similarity to compound 152.  Based on these results, what a medicinal chemist might call “very 
similar”, ShaEP would consider to have a similarity of around 0.8. 
The next step was to determine the necessity of generating conformers.  ShaEP, which only deals 
with rigid bodies, tolerates multiple input conformations for each compound to account for the 
inherent flexibility of many molecules.  However, by including structural conformers, this leads 
to more pairs of compounds to calculate similarity indices for, therefore increasing 
computational cost.  It would therefore be important to determine the effect of including 
structural conformers. 
Arbitrarily, the first 686 compounds from the “fragments now” subset of the ZINC database were 
extracted as a trial database, and up to three conformers of each compound in this trial database 
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were generated using Balloon.  Of the 686 compounds in this trial database, 1210 conformers 
were generated (at an average of 1.76 conformers per compound).  These two databases (one 
including 686 compounds and one including the 686 compounds its 524 conformers) were 
interrogated using the five conformers of compound 4 generated previously.  The results of 
these searches are shown in Table 6. 
  Similarity score 
Database  0.6 0.7 0.8 
686 compounds 
(no conformers) 
Interrogation time 90 s 98 s 97 s 
Hits 50 0 0 
686 compounds 
plus conformers 
Interrogation time 187 s 187 s 188 s 
Hits 117 3 0 
Table 6 - Comparison of interrogating a database without and with generated conformers 
Perhaps unsurprisingly, by almost doubling the number of conformers to calculate similarity 
scores for, the computational time almost doubles too.  There is, however, a large increase in 
the number of hits found.  Because compounds with a similarity score of over 0.8 will be of 
particular interest (as discussed above), and because time is not a limiting factor during this 
section of work, the increase in chances of finding hits of a higher similarity score outweighs the 
inconsequential increase in computational time.   
5.2.4 Method 
Based on the findings from the preliminary work, the work proper could begin.  As was decided 
based on the preliminary work, the whole 700,000 compounds of the “fragments now” subset 
of the ZINC database was used, and had up to three conformations per compound generated 
using Balloon, taking around a month of computational time on a standard desktop computer.  
This conformer-containing database was then interrogated using the five previously generated 
conformers of 4, which again took around a month of computational time.  A table of the most 
similar hits found through this method is given in Appendix 2. 
5.3 Results 
Following the similarity screening of the ZINC “fragments now” database, the 105 compounds 
with the highest overall similarity value were taken forward as being considered “similar” by 
ShaEP, with the lowest similarity score being carried forward being 0.77.  105 compounds of 
Chapter 5 – Similarity Searching 
130 
 
interest is within the realms of what can be analysed by eye, and upon inspection it became 
apparent that these compounds could be grouped based on their similarity to the lead 
compound and its presumed mechanism of activity being via a phenolic radical. 
The first and largest group comprised of compounds that had no way of generating a phenolic 
(or analogous) radical, for example, compounds that had no phenol or aniline ring.  Some 
examples of these compounds are shown in Figure 47, and includes compounds with no group 
that can lose a hydrogen radical (such as compounds 205 and 208), unconjugated alcohols (such 
as compound 5) and protected alcohols and alcohol analogues (such as compounds 206 and 
207), as well as some other non-phenolic compounds.  This class of compounds contains 59 
entries, and as these compound don’t fit with the current evidence on how the lead compound 
acts, they were not included in the work beyond this point.  By excluding this class of 
compounds, this leaves 46 compound of interest. 
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Figure 47 - Examples of compounds considered to have no functional groups capable of forming a 
phenolic (or analogous) radical 
The next class of compounds, of which there are 15 examples, are isomers or pseudoisomers of 
compound 4.  This class of compounds, some examples of which are shown in Figure 48, include 
an aromatic alcohol or amine located on a 2-phenylindole core (such as compounds 152, 209 
and 210), as well as some compounds which might be expected to hydrolyse to produce these 
compounds.  Unsurprisingly, compounds in this class typically had the highest similarity score, 
with the potential prodrugs such as the amide analogue shown in Figure 48 having a slightly 
lower similarity score. 
Chapter 5 – Similarity Searching 
131 
 
N
H
HO
N
H
N
H OH NH
NH
O Hyd
rolysable
H2N
152 209 210 211  
Figure 48 - Examples of isomers of the lead compound 4 and its aniline analogue 
This class of compounds are the most similar to the lead compound 4, and as a result had largely 
already been considered as potential analogues prior to beginning this section of work.  Because 
the purpose of this section of work was to encounter analogues which would otherwise not have 
been considered, focus was given to those compounds that appear to be more dissimilar.  As a 
result, compounds in this class will also not be considered further. 
The third class of compounds are compounds which may be able to form a conjugated radical, 
but have a core other than 2-phenylindole.  A total of 26 compounds were assigned to this class, 
with some examples shown in Figure 49.  This class of compounds also includes compounds such 
as the pyridone-containing compound 213, which has the resonance form of compound 216 
whereby a proton lies on the oxygen, therefore allowing for a phenolic-like radical to be formed.  
As previously mentioned, this area of work was intended to suggest analogues that would have 
otherwise not have been considered, so this class of compounds are of particular interest due 
to their potential for scaffold-hopping.[190,241] 
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Figure 49 - Examples of analogues of compound 4 that have a different core 
Within this class, a total of 14 different cores (not including the 2-phenylindole core) were 
identified.  Of the 14 different cores found, all of which are displayed in Figure 50, there is one 
core that occurs far more often than any other. 
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Figure 50 - The 14 different cores identified during the similarity search 
The benzimidazole core appears 11 times in the best 105 hits, accounting for over a third of the 
examples in this class of compounds.  Based on this data, it is difficult to say whether this 
apparent abundance of benzimidazoles is because they are particularly similar to the 
2-phenylindole lead structure, or if this scaffold is particularly highly represented within the ZINC 
database (or a combination of both factors).  What is known is that the benzimidazole scaffold 
has previously been described as a privileged structure,[242,243] suggesting that it would probably 
be well represented within databases of known compounds.  Regardless, it seems only sensible 
that a benzimidazole analogue of compound 4 should be included in future work.  Discussion as 
to which benzimidazole compound to include will be discussed later. 
The final class of compounds are those that don’t seem to be close analogues of the lead 
compound at all in the eye of the medicinal chemist, and appear to be considerably different.  
Perhaps unsurprisingly, this class of compounds was the smallest class with only five entries, 
three of which are shown in Figure 51.  These compounds are all simply ortho-substituted 
phenols, but it is difficult as a medicinal chemist to otherwise see the structural similarity. 
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Figure 51 - Examples of those compounds considered to be considerably different to the lead compound, 
yet may still be capable of forming a phenolic radical 
The reason for carrying out this similarity search is, as mentioned earlier, to probe otherwise 
unconsidered areas of chemical space.  Due to constraints both on time and resources, the 46 
compounds that make up the “isomers and pseudoisomers”, “different core” and “considerably 
different” classes is still more compounds than can be tested, so the question now turns to 
choosing the most appropriate compounds to put forward to biological testing.  As this area of 
work is attempting to probe novel areas of chemical space, perhaps the first compounds that 
should be disregarded are those that are particularly obvious to the medicinal chemists, i.e. the 
15 isomers and pseudoisomers of compound 4.  These 15 compounds represent a narrow 
breadth of chemical space, and to spend the limited time and resources available exploring such 
a small area would be inefficient.  By disregarding these compounds, 31 compounds of interest 
in the “different core” and “considerably different” classes remain. 
When building up a structure-activity relationship, comparisons are made between two or more 
compounds to see the difference that structural changes have on activity.  It is therefore ideal if 
there is only one difference in structure when comparing two compounds, so that the change in 
activity can be confidently attributed to a specific structural change.  For example, one could not 
compare an ortho-phenol with a meta-aniline, as one would not be able to tell if any subsequent 
change in activity was due to changing the functional group or due to changing the position of 
the group.  With this in mind, and considering the previously discussed justifications for wanting 
to include a benzimidazole compound in the future work, the benzimidazole that is as otherwise 
identical to the lead compound should be chosen. 
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Figure 52 - The 10 benzimidazoles found during the similarity search 
Of the 10 benzimidazoles that appeared within the 105 best hits (shown in Figure 52), only 
compound 214 differs to compound 4 in only one way, the structure of which is shown in Figure 
53 alongside the lead compound 4.  All other options can be disregarded based on having NH2 
groups in place of the OH group (such as with compound 228), moving the position of the OH 
group about the scaffold (such as with compound 226), the addition of methyl groups about the 
scaffold (such as compound 222), or a combination of these reasons. 
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Figure 53 - The lead compound 4 (left) with its most closely resembling benzimidazole compound 214 
(right) 
Aside from compound 214, there are a number of other compounds found during this similarity 
search that differed from the lead compound in only the structure of the scaffold, which are 
shown in Figure 54.  Of these are three pyridones (compounds 230, 231 and 213, which have a 
phenolic-like resonance form), a 3-hydroxypyridine (compound 232) and a phthalimide 
(compound 217).  Of these five compounds, the compound that is different in only one aspect 
from the lead compound is compound 217, so this compound was purchased and would be 
included in future work. 
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Figure 54 - Direct analogues of compound 4: three pyridones (top), a 2-hydroxypyridine (bottom left) and 
a phthalimide (bottom right) 
As well as testing some different scaffolds, the five “considerably different” compounds shown 
in Figure 55 may also be of interest.  If the largely inflexible lead compound 4 is interacting with 
an active site, then compounds which can be orientated into a similar shape and have a similar 
electrostatic potential, may also be able to interact with the same active site in the same way. 
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Figure 55 - Compounds considered similar by ShaEP, but have a considerably different structure to the 
lead compound 4 
The commercial availability of the five “considerably different” compounds, shown in Figure 55, 
was investigated.  Although all of the compounds in the ZINC “fragments now” database are 
technically in stock, many of the vendors are based in the USA or China, so lead times in excess 
of weeks is not uncommon.  Along with the extra costs of importing chemicals, this makes many 
of the compounds in the ZINC database prohibitively expensive.  Of the five compounds shown 
in Figure 55, only compound 218 was available in the UK at a reasonable price.  Fortunately, this 
compound was the simplest example of this class of compounds, so is likely to have been the 
compound of choice regardless of availability. 
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5.4 Conclusion 
This section of work described the similarity search carried out by the ShaEP software on the 
ZINC “fragments now” subset of commercially available fragment-like compounds, which had 
up to three conformations for each entry generated by Balloon.  All software used was freeware, 
and the hardware on which it was all carried out was a standard desktop computer.  The 
methodology described in this section could easily be carried out by any research group with 
the inclination to carry out their own structural similarity search. 
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Figure 56 - The three compounds taken forward to the next section of work, with the lead compound 4 
shown on the far right 
The search yielded three compound of interest, shown in Figure 56, which were taken forward 
to the proceeding sections of work.  The first compound, compound 214, was chosen as a 
chemically appropriate representative of the many benzimidazoles that ShaEP considered as 
similar to the lead compound.  The second compound, compound 217, was chosen as another 
chemically appropriate analogue that contains a previously unconsidered scaffold at its core.  
The third compound, compound 218, was chosen to investigate the possibility of a much less 
rigid molecule being able to interact with an active site in the same way as the structurally 
dissimilar lead compound (despite being identified as similar by ShaEP). 
One constraint of this method was in generating conformers of the ZINC database.  Although 
the time taken to generate said conformations could be reduced with the use of more 
specialised or advanced hardware, this significant amount of time would be a one-off, and 
subsequent similarity searches could use the same database of conformations.  Even as the ZINC 
database updates, as it often does, only the newest entries to the database would need to have 
their conformations generated, meaning that the database of conformations could be routinely 
kept up to date at a negligible computational cost. 
Aside from the one-time cost of generating conformations for the interrogatable database, the 
major computational cost is interrogating the database.  In this work, that computational cost 
took around a month, which would be too long for many research or industrial groups.  This time 
could be significantly reduced to perhaps a week or less using a number of methods. 
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One way in which the time taken to interrogate a database could be decreased would be to use 
fewer conformations of the lead structure.  In this work, five conformations of the lead structure 
were used, which may seem excessive for a structure with only two rotatable bonds, but a 
decrease in this number of conformations would likely result in lower similarity scores for some 
compounds.  Investigating the connection between conformations of input structures and 
magnitude of similarity scores may lead to either a more efficient or more thorough method. 
Another way of potentially decreasing the time taken to interrogate the database would be to 
reduce the size of the database through the use of molecular fingerprints.  Molecular 
fingerprints are used in databases where interrogation needs to be done in seconds or less, such 
as catalogues of chemicals from chemical retailers.  By reducing a compound down to a binary 
file of features that the compound contains, searching a database of millions of molecular 
fingerprints can occur on a timescale of seconds.  Compounds in this work were only considered 
if they contained a phenolic or anilinic system, so by removing all compounds that don’t contain 
these moieties, the size of the database would decrease considerably.  Because molecular 
fingerprints are stored as very small binary files, generating a database of appropriate 
compounds could be done rapidly at little computational cost, and could reduce the overall 
computational time by a large factor. 
The choice of database also has a large impact on the interrogation time.  The “fragments now” 
subset of the ZINC database, which includes fragment-like compounds which are advertised as 
currently in stock, was used in this work.  This subset of the ZINC database is ideal if one plans 
on simply buying chemicals off the shelf for testing regardless of cost of lead time.  If one wishes 
to simply explore chemical space and is willing to synthesise compounds, the larger subset of 
“clean fragments” would likely be more appropriate.  It is over twice the size, and excludes 
compounds such as thiols and aldehydes, which are notorious for often giving false positives in 
many assays. 
On the other hand, if one does not plan on simply buying compounds off the shelf, then the 
novelty of the ZINC database is irrelevant.  Looking back to Table 5, the PubChem database may 
be useful for such a project, assuming that the entries in the database could be molecularly 
fingerprinted, thus reducing interrogation times.  The PubChem database is much larger, is also 
free to use and download, and could be cut down to include compounds of a similar size to those 
found in the ZINC “fragments now” subset. 
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6.1 Introduction 
Current evidence suggests that the anticancer activity of compound 4 is related to an increase 
in levels of reactive oxygen species (ROS).  As it is known that under certain conditions phenols 
can generate ROS non-enzymatically,[244] it is therefore worth investigating if there is a 
connection between the ability of compound 4 to form a radical and its anticancer activity. 
As discussed in the introduction, there are a number of mechanisms by which a phenolic radical 
can be formed from a phenol: hydrogen atom transfer (HAT), sequential proton loss-electron 
transfer (SPLET), single electron transfer (SET) or sequential electron transfer-proton transfer 
(SET-PT), as shown in Scheme 59. 
OH O
O
OH
HAT
PL ET
PTSET
- H+
- e-
H
-
- H+
- e-
 
Scheme 59 - Possible ways in which a phenolic compound could form its respective radical species.  HAT = 
Hydrogen Atom Transfer.  PL = Proton Loss.  ET = Electron Transfer.  SET = Single Electron Transfer.  PT = 
Proton Transfer 
The propensity of a compound to undergo any of the mechanistic steps shown in Scheme 59 can 
be determined by measurable values associated with said mechanistic steps; bond dissociation 
enthalpy (BDE) for HAT, proton affinity (PA) for PL, electron transfer enthalpy (ETE) for ET, 
adiabatic ionisation potential (AIP) for SET and proton dissociation enthalpy (PDE) for PT.  The 
smaller the enthalpic value for a specific step, the more favoured that pathway becomes. 
It is unknown which of the mechanistic pathways mentioned above, if indeed any, are 
undergone by compound 4 and its analogues.  It is therefore essential to determine the enthalpic 
values for all of the mechanistic steps in order to be able to conclusively detect any correlations. 
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6.2 Computational Details 
6.2.1 Software 
In this section of work, all calculations were carried out by software included in the Schrödinger 
software suite.[245]  The Schrödinger software suite was used because it is widely used and 
trusted, is easy to learn due to its good documentation, and was available to use in-house.  A 
full description of the theoretical basis of the quantum chemical calculations is given in Chapter 
3.  A simplified process flowchart demonstrating the molecular modelling calculations 
performed, descriptions of which are given in further detail below, is shown in Figure 57. 
 
Figure 57 - A process flowchart for the molecular modelling section of this work 
6.2.2 Ligand Preparation 
Using 2D input structures, 3D structures and plausible ionisation states and tautomers at pH 7.0 
(physiological conditions) were generated with LigPrep v3.6.  The OPLS3 force field,[246] which 
has been parameterised for use with drug-like small molecules, is also now well parameterised 
for halogen bonding and halogen interactions.  The Epik program, which does the bulk of the 
calculations within LigPrep, was used due to its ability to calculate energetic penalties for the 
states it predicts. 
Once the favourable ionisation states and tautomers were determined, MacroModel v11.0[245] 
conformation searches were used to generate potential conformers.  The Monte Carlo Multiple 
Minima (MCMM) torsional sampling method[245] was performed using the OPLS3 force field.[246]  
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A Monte Carlo approach is a stochastic method that generates a large number of potential 
conformers by the random adjustment of select dihedral angles.  Energy minimisation of the 
generated conformations was carried out using up to 500 iterations of the truncated-Newton 
conjugate-gradient (TNCG) method, set to converge on a gradient threshold of 0.05 units.  
Duplicate conformations were removed by route mean squared distance (RMSD) comparisons.  
Conformations within 10 kcal mol-1 of the lowest energy conformation were taken forward. 
6.2.3 DFT Calculations 
Optimisation of the Monte Carlo geometries was carried out using Jaguar v9.0[245,247], a software 
which can use DFT to precisely determine a more accurate structure and therefore energy of a 
system.  As this is the vital step in the process of our molecular modelling protocol, significant 
effort went into designing the methodology used through Jaguar, which is documented in the 
coming section.  A maximum of 200 optimisation steps was allowed, symmetry was turned off, 
the medium density SCF grid was used and self-consistent field spin was restricted.  True minima 
were determined by no imaginary frequencies.  Zero-point energies were calculated at 298.15 K. 
6.3 Results and Discussion 
6.3.1 Benchmarking Studies – Method and Basis Set Selection 
When using DFT, the major methodological factor is to determine the most appropriate level of 
theory to use, i.e. what basis set and functional to employ.  The ideal way of doing this would be 
to compare relevant calculated properties of chemically relevant trial structures calculated with 
all combinations of basis sets and functionals against empirical data, and then to choose the 
level of theory that gives the best result.  Obviously, there are far too many basis sets and 
functionals for this to be practical, so a more intuitive approach needs to be considered. 
What is typically done in these situations is to look into what levels of theory are common in the 
literature for calculating similar properties for similar chemical classes.  Because the activity of 
compound 4 is believed to stem from its phenolic ring, and we are particularly interested in how 
readily compound 4 forms a radical, methods for determining BDE values of phenolics were 
searched for in the literature.  A representative sample is shown in Table 7. 
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Compounds investigated Functional Basis Set Reference 
Sesamol derivatives B3LYP 6-31G(d,p) – Optimisation 
6-311++G(2d,2p) – SPE 
[248] 
Catechol derivatives B3LYP 6-31G(d,p) [249] 
Magnolol derivatives B3LYP 6-31G(d,p) – Optimisation 
6-311++G(2d,2p) – SPE 
[250] 
Chroman-6-ol derivatives B3LYP 6-31G(d,p) – Optimisation 
6-311++G(2d,2p) – SPE 
[251] 
p- and m-substituted phenols B3LYP 6-311++G** [252] 
Natural polyphenols B3P86 6-31+G(d,p) [253]  
Table 7 - Levels of DFT theory used in a representative sample of the literature for calculating BDE values 
of phenols and phenolic derivatives 
As can be seen in Table 7, the B3LYP functional[254–256] is by far the most popular functional for 
this type of work, so shall be considered.[248–252]  The B3P86 functional[256,257] has also been shown 
to give good data,[253] so shall also be included.  With regards to basis sets, split-valence Pople-
type basis sets seem popular, in particular the double-zeta basis set 6-31G[258–267] and the slightly 
larger triple-zeta basis set 6-311G,[265,266,268–273] with varying diffuse and polarisable functions.  
The smaller basis sets are typically used for the optimisation step due to their computational 
efficiency, but due to improvements in desktop computing power, computational expense is 
now less of an issue.  Therefore, the larger 6-311G basis set was tested here with varying diffuse 
and polarisable functions. 
The selection of trial compounds was also important.  Trial compounds should be chemically 
similar to those that are being investigated, while also having empirical data that the calculated 
values can be compared against.  In this work, the trial compounds must be chemically similar 
to compound 4, and must have published experimental values for radical formation. 
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Figure 58 - Compound 4 (left) with the three trial compounds phenol, catechol and 4-phenylphenol 
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The trial compounds used in this work, shown in Figure 58, are phenol (due to being the simplest 
phenolic), catechol (due to being a well characterised ortho-substituted phenol) and 
4-phenylphenol (due to the hydroxyl group being conjugated with a second aromatic system, 
such as in compound 4).  The accepted mechanism of formation of their radicals is hydrogen 
atom transfer (HAT), for which there are experimental BDE values available for comparisons with 
our calculated equivalents.[274–276] 
Compound 
Literature BDE 
Value / kcal mol-1 
B3LYP/ 
6-311G*+ 
B3LYP/ 
6-311G** 
B3LYP/ 
6-311G**+ 
B3LYP/ 
6-311G**++ 
Phenol 88.7[274] 79.2 83.6 83.7 83.6 
Catechol 79.3[275] 69.8 73.0 74.1 74.0 
4-Phenylphenol 84.8[276] 76.6 81.1 81.0 80.9 
 
Compound 
Literature BDE 
Value / kcal mol-1 
B3P86/ 
6-311G*+ 
B3P86/ 
6-311G** 
B3P86/ 
6-311G**+ 
B3P86/ 
6-311G**++ 
Phenol 88.7[274] 83.1 87.7 87.7 87.7 
Catechol 79.3[275] 73.0 76.4 77.4 77.3 
4-Phenylphenol 84.8[276] 80.5 85.2 85.1 85.0 
Table 8 - Comparison of empirical BDE values against those calculated at eight different levels of theory 
for the three trial compounds shown in Figure 58, with B3LYP results shown on top and B3P86 results 
shown underneath.  BDE values are given in kcal mol-1 
The data for the calculated BDE values for the three trial compounds at eight levels of theory is 
shown in Table 8.  Surprisingly, using the more popular B3LYP functional significantly 
underestimates BDE values.  All methods tested reproduced the relative trends in BDE values, 
with catechol having the lowest BDE value and phenol having the highest BDE value.  However, 
the B3P86 functional gives much more accurate absolute values, especially when using more 
polarisable and diffuse functions.  The best levels of theory tested are the B3P86/6-311G**+ 
and B3P86/6-311G**++ levels of theory, which gave largely equal values.  Due to the slight 
computational benefit of using fewer diffuse functions, the B3P86/6-311G**+ level of theory, 
this level of theory was chosen to be used in the rest of this work. 
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6.3.2 Preliminary Work – Singly Substituted Analogues of Compound 4 
In order to get familiarised with the method and to get an appreciation for the magnitudes of 
BDE value differences when considering compound 4 and its analogues, a series of compounds  
as similar to one another as possible but with differing BDEs would be required.  Since activity 
via a phenolic radical was suspected, a way to affect the BDE value would be to affect the 
stability of the radical species formed. 
N
H
O
N
H
O
N
H
O
N
H
O
N
H
O
N
H
O
N
H
O
N
H
O
1
34
5
6
7
3'
4'
5'6'
141 142 143
144145146
147 148  
Scheme 60 - The resonance forms of the radical of compound 4 
Typically, tertiary radicals are more stable than secondary radicals, which are more stable than 
primary radicals, and in the radical form of compound 4 the radical can become delocalised 
across many centres of the molecule (Scheme 60).  By adding a sterically small, non-hydrogen 
bonding electron-donating group (e.g. a methyl group) to a position where the radical can be 
formally localised, this should lower the relative energy of the radical, therefore reducing the 
BDE.  Conversely, a small, relatively non-hydrogen bonding[277] electron-withdrawing group (e.g. 
a fluorine) might be expected to have the opposite effect, and therefore increase the BDE.  
Therefore, BDE values for a series of singly- substituted methylated and fluorinated analogues 
of compound 4 were calculated, and are shown in Table 9. 
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Me-substituted  F-substituted 
Substituent Compound BDE Difference  Substituent Compound BDE Difference 
1-Me 236 86.3 9.1  1-F 245 84.5 7.4 
6'-Me 237 79.4 2.3  3'-F 246 78.7 1.6 
3-Me 186 77.8 0.7  7-F 247 78.3 1.2 
- 4 77.1 0.0  6'-F 248 77.8 0.7 
5-Me 238 77 -0.1  5-F 249 77.6 0.4 
7-Me 239 76.9 -0.2  4-F 250 77.4 0.3 
4-Me 240 76.8 -0.3  - 4 77.1 0.0 
6-Me 241 76.5 -0.7  6-F 251 76.7 -0.4 
4'-Me 242 76.3 -0.8  4'-F 252 76.6 -0.5 
3'-Me 243 75.9 -1.2  3-F 253 76.2 -0.9 
5'-Me 244 75.6 -1.5  5'-F 254 75.8 -1.3 
Table 9 - Calculated BDE values in kcal mol-1 for a series of methyl-substituted and fluoro-substituted 
derivatives of compound 4, ordered from highest to lowest BDE value 
The most dramatic changes in the calculated BDE values are found in compounds 236 and 245, 
which are derivatised at the 1-position (i.e. N-substituents).  Substituents at this position have a 
much higher relative BDE, which can be explained by comparing the structure of the 
1-substituted radical species with that of the radical of the parent compound 4.  Although the 
neutral species for this class of compounds are far from planar (compound 4 has an N-C2-C1’-C2’ 
dihedral angle of -137.8O), its radical form is planar (N-C2-C1’-C2’ dihedral angle for compound 4 
= 0.2o, shown in Figure 59), and there appears to be an interaction between the proton of the 
NH and the oxygen.  This interaction considerably lowers the energy of the radical, reducing the 
size of the BDE.  However, in the 1-methyl analogue 236 (shown in Figure 59) and 1-fluoro 
analogue 245 (not pictured), this interaction is not possible, planarity is lost (1-Me N-C2-C1’-C2’ 
dihedral angle = 39.4o, 1-F N-C2-C1’-C2’ dihedral angle = 171.2o), the relative energy of the radical 
is raised, and therefore the BDE increases. 
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Figure 59 - The radical forms of compound 4 (left) and its 1-methyl analogue 236 (right), shown from 
face on (top) and from underneath (bottom), showing how planarity is affected when there are 
substitutions on the N-position 
Steric effects for the 3- and 6'-substituted compounds might be expected to reduce the planarity 
of their radicals in a similar manner, thus weakening the NH⋯O interaction.  However, on 
examination of their energetically minimised structures, it would appear that planarity is indeed 
not lost, with all 3- and 6’-substituted analogues having N-C2-C1’-C2’ dihedral angles < 1o.  This 
suggests that the stabilising NH⋯O interaction should therefore still be present, strengthening 
the hypothesis that such an interaction is important.  However, as can be seen in Table 9, the 
3- and 6'-substituted compounds give uncharacteristically high BDE values, indicating a 
unfavourable interaction.  This unfavourable interaction is more apparent when measuring the 
N-C2-C1’ and C2-C1’-C2’ angles, which shows that in the 3- and 6'-substituted compounds, the 
linearity of the molecules is affected and that these angles become strained.  A comparison of 
these differences is shown between compound 4 and its 6’-methyl derivative, compound 237, 
in Figure 60. 
 
Figure 60 - The difference in N-C2-C1’ and C2-C1’-C2’ angles between compound 4 and its 6’-Me derivative 
compound 237 
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Excluding the 1-, 3- and 6’-substituted derivatives for the steric reasons mentioned above, Figure 
61 shows data for relative difference in BDE from compound 4 (Table 9) against the position of 
the substituent, with data for the methylated derivatives on the left and the fluorinated 
derivatives on the right, as well as a structure in the centre which shows the positions that the 
radical can be formally placed via resonance (as demonstrated fully in Scheme 60).  Clear from 
the figure is that substituents at the positions where the radical will be delocalised leads to 
greater stabilisation of the species, which is reflected in a lower BDE. 
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Figure 61 - BDE values (relative to the BDE of compound 4) of singly-substituted methyl (left) and fluorine 
(right) derivatives of compound 4 at the specified positions.  The centre structure shows which carbons 
the radical can formally be located on (shown with an asterisk), as depicted in Scheme 60 
In Table 10 we see that the methylated derivatives tend to decrease BDE values more, by around 
0.5 kcal mol-1, when located on positions where the radical can be delocalised to.  This was as 
expected, and is likely to be due to tertiary radicals being more stable than secondary radicals. 
Substituents Radical BDE Non-radical BDE 
Methylated -0.9 -0.4 
Fluorinated -0.5 0.4 
Table 10 - Average calculated BDE values for derivatives located on a potential radical site ("Radical 
BDE") and not on a potential radical site ("Non-radical BDE") 
As can be seen in Figure 61, the trend for the fluorinated derivatives is considerably skewed by 
the 3’-substituent of compound 246.  This is due to a particularly low energy neutral species due 
to the hydrogen bonding between the OH group and the 3’-F group, which is shown in Figure 
62.  This stabilisation makes the loss of the hydrogen radical considerably disfavoured, therefore 
increasing the BDE value by 1.6 kcal mol-1 relative to compound 4. 
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Figure 62 - The structure of the neutral species of compound 246, which shows the hydrogen bonding 
between the OH group and the 3'-F group 
By also excluding the 3’- position from the analysis of fluorine-substituted derivatives (along with 
the sterically hindering substituents at the 1-, 3- and 6’-positions), a trend emerges whereby the 
fluorinated derivatives tend to decrease BDE values by an average of 0.5 kcal mol-1 when located 
on a position where the radical can be delocalised to, and increase the BDE values by an average 
of 0.4 kcal mol-1 when located on a position where the radical can’t be delocalised to (Table 10).  
This is explained by the fact that fluorine can act as an electron withdrawing group due to its 
electronegativity, as well as an electron donating group by its mesomeric effect due to its lone 
pair(s).  The data in Table 10 therefore suggests that when the fluorine substituent is located on 
a position where the radical can be delocalised to, such as the 5’-position, the fluorine 
substituent stabilises the radical via mesomeric effects, whereas when located on a position 
where the radical can’t be delocalised to, such as the 4’-position, the fluorine substituent 
destabilises the radical by drawing electron density out due to its electronegativity.  These 
examples are depicted in Figure 63. 
N
H O
N
H O
F
N
H O
F
F
254 252  
Figure 63 - The stabilising effects of fluorine via its mesomeric effect (left) and the destabilising effect of 
fluorine via its inductive effect (right) 
6.3.3 Calculated BDE Values 
A worked example of how the enthalpic values were determined can be found in Appendix 3, 
and a full table of calculated BDE, AIP, PDE, PA and ETE data is included in Appendix 4.  Appendix 
4 includes absolute values for all compounds, but as relative values are often of more use than 
absolute values, the values are also given relative to compound 4. 
The enthalpic values calculated, a selection of which are shown in Table 11, will be compared 
against anticancer activity in Chapter 7. 
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Structure Compound 
Enthalpic values / kcal mol-1 
BDE AIP PDE PA ETE 
N
H HO  
4 77.1 173.4 231.3 327.0 77.7 
N
H HO  
149 90.2 177.4 240.4 345.4 72.4 
N
H
N
HO  
214 87.1 187.3 227.5 330.6 84.2 
HO
OH  
Hydroquinone 82.1 193.1 216.6 350.1 59.6 
OH
 
168 86.6 184.9 229.3 339.7 74.5 
N
H H2N  
152 84.8 172.8 239.6 344.4 67.9 
O
N
HO  
166 98.0 193.6 232.1 345.1 80.5 
OH
NO2
 
2-Nitrophenol 101.1 223.1 205.5 337.4 91.3 
OH
 
Phenol 87.7 209.1 206.3 349.3 66.0 
OH
 
169 87.0 193.9 220.7 342.4 72.3 
Table 11 - A selection of compounds included in this work, with their calculated BDE, AIP, PDE, PA and 
ETE values shown.  Full data is included in Appendix 4 
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These enthalpic values that have been calculated are gas phase values, and any solvation or 
enzymatic effects on radical formation are not considered.  However, in lieu of not knowing what 
solvation or enzymatic effects are occurring in a complex cellular environment, these gas phase 
values are the only data from which we can attempt to draw conclusions.  From a search of the 
literature, it would appear that relative trends for the enthalpic values within a chemical class 
and mechanistic pathway are unaffected by solvation, although the favoured mechanistic 
pathway may be solvent dependant.[248,250,251,278–280] 
As discussed in the introduction to this chapter, there are four possible mechanistic pathways in 
which a phenolic radical can be formed from a phenol.  These pathways are hydrogen atom 
transfer (HAT), sequential proton loss-electron transfer (SPLET), single electron transfer (SET) or 
sequential electron transfer-proton transfer (SET-PT).  Each mechanistic step has an enthalpic 
value associated with it; bond dissociation enthalpy (BDE) for HAT, proton affinity (PA) for PL, 
electron transfer enthalpy (ETE) for ET, adiabatic ionisation potential (AIP) for SET and proton 
dissociation enthalpy (PDE) for PT.  A smaller enthalpic value indicates a more favoured 
mechanistic step.  In the case of sequential mechanistic steps, the highest enthalpic value of the 
multiple steps is likely to act as the rate determining step. 
As can be seen by the representative data in Table 11, in the gas phase the most probable radical 
forming mechanism is HAT, due to the relatively low BDE values.  This appears to be in 
agreement with the considerable number of publications in the literature which appear to focus 
much more on BDE than any other enthalpic value.[248,250,251,253,281] 
As predicted relative BDE values hold far greater accuracy when comparisons are made within 
structurally similar series of compounds, we follow suit in our analysis herein. 
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Figure 64 - The BDE values of compound 4 and all simple phenols 
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The first class of compounds are simple phenols (Figure 64), most of which are ortho-substituted 
phenols.  The trend in BDE values amongst this class of compounds can be well described by 
Hammett constants,[282] which is understandable considering that Hammett describe the extent 
to which substituents donate or withdraw electron density from a conjugated system, which is 
a major way in which phenolic radicals can be stabilised.  Although the majority of the 
compounds in this class are ortho-substituted phenols, Hammett constants are only available 
for para-substituents in order to focus exclusively on the electronic effects and therefore 
exclude steric effects.  Due to the ortho- and para- positions being conjugated and that Hammett 
constants exclusively describe electronic effects, using para- constants is considered valid. 
 
Graph 4 - The effect of Hammett constants on BDE values for the series of nine simple phenols shown in 
Figure 64 
Graph 4 shows a good correlation between BDE values plotted against Hammett constants 
(R2 = 0.866).  There are three obvious outliers that break a close to perfect linear trend.  The two 
outliers above the trendline (the o-CONH2 of salicylamide and o-OH of catechol) have lower BDE 
values than would be expected by their Hammett values due to hydrogen bonding between the 
substituent and the radical, therefore lowering the energy of the radical.  The outlier below the 
line is the o-OMe derivative, guaiacol, which has a higher BDE value than expected due to the 
hydrogen bonding present in the neutral species, resulting in a lowering of energy of the neutral 
species and therefore a higher BDE value. 
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Figure 65 - Compound 4 and some of its 2-phenylindole isomers 
The next class of compounds are isomers of compound 4 that are based around the 
2-phenylindole scaffold, the structures of which are shown in Figure 65.  Of this class, compound 
4 has the lowest BDE value (77.1 kcal mol-1), largely down to the stabilising intramolecular 
interaction between the NH group and the phenolic radical, as discussed in Section 6.3.2.  As 
would be expected due to their conjugated positions, the 5-OH isomer (compound 210) and 
4’-OH isomer (compound 255) have very similar BDE values (82.8 kcal mol-1 and 82.1 kcal mol-1 
respectively), differing by only 0.7 kcal mol-1. Trying to determine why the 3’-OH isomer 
(compound 209) has a considerably higher BDE value (87.9 kcal mol-1) than compounds 210 and 
255 is more difficult.  They all have the same number of canonical radical forms (Figure 66), and 
there is no intramolecular interactions in any of the compounds.  It does, however, seem that 
the spin density of compound 209 is less delocalised, with 95% of the unpaired electron being 
localised to the phenolic ring in compound 209, compared to 72% for compound 255.  With less 
delocalisation for the radical of compound 209, the radical is relatively less stable and has a 
higher BDE value. 
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Figure 66 - Canonical radical forms of compounds 210, 255 and 209, with BDE values for each structure 
shown underneath 
The next class of compounds, shown in Figure 67, are compounds which contain a pyridone as 
part of their structure. 
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Figure 67 - Compound 4 alongside the compounds which contain a pyridone or hydroxypyridine as part 
of their structure.  BDE values are shown below each structure 
 The BDE values shown in Figure 67 show that the pyridone compounds 213, 258, 259 and 260 
have consistently higher BDE values.  These compounds are, however, considerably different to 
compound 4 due to the BDE value being based on the loss of a hydrogen from an NH group 
rather than a phenolic group. 
The 3-hydroxypyridine analogues shown in Figure 67 (compound 256, for which the BDE of the 
OH group was determined, and compound 257, for which the BDE of the NH group was 
determined) were both considered plausible under physiological conditions by LigPrep.  They 
do, however, have vastly different BDE values.  It would be probable that these two compounds 
can easily tautomerise, meaning that the lower BDE value of compound 257 would be the more 
appropriate value to focus on.  However, compound 257 is not a phenol analogue, so a direct 
comparison to compound 4 is difficult to make.  Nonetheless, compound 257 is one of the few 
compounds analysed that has a lower BDE value than compound 4, presumably because of the 
weak H-N+ interaction. 
The next class of compounds, shown in Figure 68, is made up of analogues of compound 4 which 
have different scaffolds (i.e. scaffold-hopping analogues).  The effect of hydrogen-bonding in the 
neutral species is immediately apparently, with all the compounds that have been found to 
participate in intramolecular hydrogen bonding via molecular modelling having consistently 
higher BDE values than compound 4.  The OH group compound 217 is seen to hydrogen bond to 
an oxygen, whereas the OH groups in compounds 166, 167 and 214 are seen to hydrogen bond 
to the lone pair of the nitrogen.  The loss of the stabilising NH⋯O interaction in the radical form 
of compounds 160, 169 and 168 is also met with an increase in BDE values.  Most noticeably, by 
moving the phenol from the 2-position of the indole (as in compound 4, BDE = 77.1 kcal mol-1) 
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to the 3-position (as in compound 160, BDE = 82.9 kcal mol-1) results in a BDE increase of 
5.8 kcal mol-1. 
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Figure 68 - Scaffold-hopping analogues of compound 4.  BDE values are shown below the structures 
Comparing the isomers of compound 4 (compound 4, compound 160 and compound 261), an 
unexpected trend emerges.  Compound 261, which still has the stabilising NH⋯O interaction in 
its radical form (albeit to a lesser extent) has a higher BDE value than even compound 160, which 
has no stabilising interaction at all.  This is despite all three compounds having the same number 
of canonical radical structures.  This unexpectedly high BDE for compound 261 may, however, 
just be due to the considerable strain that the radical form of the compound is under, as shown 
in Figure 69; the radical species is both out of plain and has both the C-O and N-H groups forced 
away from their natural position 
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Figure 69 - Bond angles of the radical form of compound 261 (left) and a view that shows the extent of 
planarity in this species (right) 
The next class of compounds is much smaller, and includes anilinic analogues of compound 4, 
the structures of which are shown in Figure 70.  The phenolic compound 4 being 7.7 kcal mol-1 
lower than the anilinic compound 152 is as expected, as the BDE values of phenols are known 
to be lower than those of anilines.[74,283]  The comparison of compound 152 to compound 228 is 
equivalent to the comparison of compound 4 with compound 214 in the previous series, and the 
anilinic analogues do indeed maintain the same trend, with the reasonably strong 
intramolecular hydrogen bond making the abstraction of a hydrogen atom less favoured, 
resulting in the BDE of compound 228 being 12.5 kcal mol-1 higher than that of compound 152. 
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Figure 70 - Compound 4 alongside two anilinic analogues.  BDE values are shown below the structures 
The final compounds to be discussed are compounds which don’t fit in any other class, and are 
shown in Figure 71. 
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Figure 71 - Compound 4 alongside a number of analogues which don't belong to any other class 
discussed thus far.  BDE values are shown below structures 
So far, the majority of compounds have had a higher BDE value than compound 4, so the stand-
out compounds in Figure 71 are those that have a lower BDE value than that of compound 4 
(BDE = 77.1 kcal mol-1), which are compound 212 (BDE = 73.0 kcal mol-1) and the tautomeric 
compounds 262 (BDE = 71.5 kcal mol-1) and 227 (BDE = 72.7 kcal mol-1). 
Compound 212, which has a BDE value 4.1 kcal mol-1 lower than that of compound 4, is the only 
compound within this work that has the 2-(2-pyridyl)indole scaffold.  This indicates that this 
scaffold may be of interest if a compound with lower BDE value was sought.  An obvious 
compound of interest would therefore be an analogue which would have the radical-stabilising 
NH⋯O interaction that compound 4 has, such as compound 264 shown in Figure 72. 
N
H
N
HO
264  
Figure 72 - Possible compound of interest if a compound with a lower BDE value was sought 
The tautomers 262 and 227 also have particularly low BDE values of 71.5 kcal mol-1 and 
72.7 kcal mol-1, compared to a value of 77.1 kcal mol-1 for compound 4.  These compounds also 
have considerably lower BDE values than the isomeric compound 214 (Figure 68), which has a 
Chapter 6 – Molecular Modelling Results 
157 
 
BDE value of 83.2 kcal mol-1 due to the hydrogen bonding in the neutral species making the 
hydrogen atom more difficult to abstract.  An analogue of this compound which allows for the 
stabilising radical NH⋯O interaction that compound 4 has is shown as compound 265 in Figure 
73. 
N
H
N
OH
265  
Figure 73 - Possible analogue of compounds 214 and 227 which allows for a stabilising NH⋯O radical 
interaction 
6.4 Concluding statements 
This chapter has shown the method used to determine the enthalpic values for the possible 
mechanisms involved in forming a phenolic radical from a phenol.  It has been shown that in the 
gas phase, the most probable mechanism for this formation hydrogen atom transfer (HAT), the 
enthalpic value for which is bond dissociation enthalpy (BDE). 
Section 6.3.3 discussed the effects on BDE brought on by structural changes, and found that the 
lead compound 4 has a reasonably low BDE of 77.1 kcal mol-1, with only a small number of 
analogues being shown to have a BDE value lower than this (Figure 74). 
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Figure 74 - The compounds with a lower BDE value than compound 4, with BDE values shown below each 
structure 
In the next chapter, the anticancer activity of the compounds described in Chapter 4 and Chapter 
5 is established, and the hypothesis that the anticancer activity of compound 4 and its analogues 
is related to the ease with which they can form their phenolic or anilinic radicals is investigated.
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7.1 Introduction 
Throughout this project, the analogues of compound 4 and of I3C and compound 5 have been 
considered as entirely separate series.  There are a total of 12 compounds in the I3C and 
compound 5 series and 30 compounds in the compound 4 series.  This chapter describes how 
the anticancer activity of these compounds were determined, as well as building up a basic 
structure-activity relationship (SAR) based on these activities. 
7.1.1 Anticancer Assays 
As it would be unethical and impractical to test prospective anticancer compounds on animals 
or humans at such an early stage in the drug development process, the efficacies of compounds 
in this work are established on cultured mammalian cells.  The more active compounds will 
obviously kill a larger number of cultured cancerous cells, but cell death is difficult to directly 
measure.  The workaround for this is to measure the remaining healthy cells using an established 
assay, and deduce the efficacy from that. 
By far the most well-known, established and accepted assay is the MTT assay.  This colourimetric 
assay determines cellular metabolism by detecting NADH and NADPH, sometimes collectively 
referred to NAD(P)H.  NAD(P)H reduces the straw-yellow MTT into a ring-opened formazan, 
which has a bright purple colour.  Conversion of MTT to its formazan is therefore correlated to 
the number of viable cells.  
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Scheme 61 - Single-electron reduction of MTT to a formazan by NAD(P)H 
There are many variants on the MTT assay, such as the MTS assay, which has a simpler protocol 
and a slightly different tetrazolium salt.  The MTS assay, like the MTT assay, is a colourimetric 
assay whereby MTS undergoes single-electron reduction.  Unlike in the MTT assay, MTS cannot 
permeate the cell, so requires an intermediate electron carrier such as phenazine methosulfate 
(PMS).  A representative reaction cycle is shown in Scheme 62. 
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Scheme 62 - Single-electron reduction of MTS to a formazan by NAD(P)H, utilising the intermediate 
electron carrier PMS, as occurs in the MTS assay 
There are, however, a number of downsides to these methods.  Primarily, the formazan products 
are often toxic, resulting in a possible harm to researchers, as well as killing the cells, meaning 
that only one measurement may be made at a time.  The protocol is also highly time-
constrained; once the protocol has been begun, there is no point at which it can be paused, 
somewhat limiting its use. 
An alternative to NAD(P)H assays such as the MTT and MTS assays is the Sulforhodamine B (SRB) 
assay, which, although being less common, has been commonly used since its original 
publication in 1990.[284]  The process involves first fixing the cells with trichloroacetic acid (TCA), 
then applying the SRB dye to cells.  The assay works by the SRB dye binding to basic amino acids 
on the surface of the fixed cells.  Unbound dye is then washed off, and the quantity of the bright 
pink dye is determined colourimetrically.  The assay therefore measures cellular protein content, 
which is proportional to the number of healthy cells.  Because the cells are fixed, the end-point 
measurement is not time critical, which can make for a preferred procedure.  However, as with 
the MTT/MTS assay, the cells are killed in the process, meaning that only one measurement may 
be made at a time. 
A relatively modern assay that is rapidly becoming very popular is the PrestoBlue assay.  The 
active agent in PrestoBlue is resazurin, which is reduced to resorufin by NAD(P)H (Scheme 63).  
Much like the MTT and MTS assays, the PrestoBlue assay therefore detects metabolically healthy 
cells. 
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Scheme 63 - Single-electron reduction of resazurin to resorufin by NAD(P)H, as occurs in the PrestoBlue 
cell viability assay 
Although the PrestoBlue assay is more expensive than the MTT, MTS or SRB assay, it is gaining 
widespread usage due to being non-toxic, allowing for the dye to be removed after 
measurements are carried out, thus allowing the cells to continue growing.  This significantly 
reduces the workload associated with time course experiments, as well as being safer for those 
carrying out the experiments. 
7.2 Replicating Past Work 
This work is a continuation of the work done previously within the Snape group,[6] in which a 
small number of analogues were tested on the two cell lines 1321N1, an astrocytic cell line, and 
U87, a glioblastoma cell line.  These IC50 values, which were determined using the MTS assay, 
are displayed in Table 12. 
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Structure Compound 
MTS assay IC50 value / μM 
132N1 U87 
N
H
OH
 
I3C 309 ± 2 526 ± 2 
N
H
OH
 
5 111 ± 1 176 ± 1 
N
H  
2-phenylindole --- --- 
N
H
O
 
266 --- --- 
N
H
HO
4  
4 445 ± 4 379 ± 4 
N
H
O
 
267 --- --- 
Table 12 - IC50 values for some analogues of I3C and compound 4, as determined by Prabhu.[6]  Dashes 
indicate that IC50 values were not reached 
To confirm that the trends shown by Prabhu are repeatable, it would be necessary to retest the 
active compounds previously tested using a different assay (Figure 75).  Whereas Prabhu et al. 
had used the MTS assay, the retesting was done here using the PrestoBlue assay (the procedure 
for which can be found in Appendix 5).  The PrestoBlue assay was chosen due to evidence 
suggesting that the MTS assay is unreliable when working with antioxidant molecules such as 
phenols, a limitation that the PrestoBlue assay does not have.  These three active compounds 
were also retested by Dr Farzana Rowther and Dr Ibrahim Tolaymat at the University of 
Wolverhampton using the sulforhodamine B (SRB) assay (the procedure for which can be found 
in Appendix 6). 
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Figure 75 - The active compounds found by Prabhu et al., I3C (left), compound 5 (centre) and compound 
4 (right) 
The results for the retested compounds can be seen in Table 14 and Table 14, where “high” 
indicates that at the highest concentration tested a maximal inhibition had still not been 
attained and “n/a” indicates that the compound was not tested on that cell line.  In both 
instances the compounds were tested against the glioblastoma cell line U87, but Prabhu et al. 
used the less aggressive astrocytoma cell line 1321N1 as a control cell line,[6] whereas this work 
used the non-cancerous astroglial cell line SVG p12 as a control cell line.  Rowther and Tolaymat 
used no control cell line, but instead included a second glioblastoma cell line U251, along with 
testing the two more active compounds on three short-term glioblastoma cell cultures.  
Although the values differ significantly between the assays and methodologies, compound 5 is 
shown in each case to be the most active, and I3C is shown to be the least active, so the relative 
trends are the same throughout.  From these data, it can be confidently confirmed that these 
classes of compounds respond well to a wide variety of assay conditions, and that the activities 
reported are representative of the true activities of the compounds and are not skewed by 
inappropriate assay conditions. 
Compound 
MTS PrestoBlue 
U87 1321N1 U87 SVG p12 
I3C 526 309 374 348 
5 176 111 113 88.5 
4 379 445 207 86.1 
Table 13 - EC50 values (µM) for compounds tested by Prabhu et al. using the MTS assay and this work 
using the PrestoBlue assay 
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Compound 
SRB 
U87 U251 IN1472 IN1528 IN1760 
I3C High High n/a n/a n/a 
5 134 279 300 411 552 
4 233 338 332 497 466 
 
Table 14 - EC50 values (µM) for compounds tested by Rowther and Tolaymat using the SRB assay 
7.3 Methodology 
Aside from the work done in replicating prior results, all anticancer testing was done by Dr 
Farzana Rowther and Dr Ibrahim Tolaymat at the University of Wolverhampton.  Their 
methodology, which is described in more detail in Appendix 6, includes the use of the SRB 
assay[284] to determine EC50 values of all trial compounds. 
Rowther and Tolaymat initially tested all compounds against two cell lines and three short-term 
cultures: U87, U251, IN1472, IN1528 and IN1760.  U87 and U251 are both established cell lines 
derived from glioblastomas, and are both commonly used as glioblastoma models.  IN1472, 
IN1528 and IN1760 are all short term cultures.  In the interest of improving throughput, it was 
decided that compounds tested in the later series would be tested against fewer cultures.  For 
these tests, the U251 cell line was chosen over the U87 cell line due to evidence that it acts and 
reacts more similarly to a true glioblastoma.[285]  With respect to the short term cultures, there 
is much less empirical evidence as to which ones act as an appropriate model, so choices had to 
be made based on personal experience.  The IN1760 cell line was included due to its observed 
chemoresistance, and may therefore be able to identify chemotherapies that may be active 
against chemoresistant tumours.  Between the IN1472 and IN1528 cultures, IN1472 had been 
shown to give less reproducible data than IN1528, so IN1472 was dropped from the panel of 
cultures against which the later series of compounds were tested.  This panel of cell cultures was 
therefore made up of U251, IN1528 and IN1760. 
7.4 Results and Discussion 
In this section, the significance and effects of the structural features investigated will be 
discussed in terms of their effects on anticancer activity, thus building up a structure-activity 
relationship (SAR).  As has been the case throughout this work, the I3C and compound 4 series 
of compounds will be discussed independently of one another. 
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7.4.1 The Structure-Activity Relationship of the I3C and Compound 5 Series 
As discussed in Chapter 1, there are a number of structural features of compound 5 that were 
to be investigated.  These features included the role of the 2-phenyl group, the carbinol group, 
N-substituents, the role of the heteroatom and comparing the prodrug to the active form.  These 
structural features and the analogues designed to probe them are summarised in Figure 76. 
 
Figure 76 - The structural features of compound 5, and the analogues tested to investigate these 
structural features 
7.4.1.1 The role of the 3-carbinol group 
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Figure 77 - Analogues designed to probe the significance of the 3-carbinol group 
I3C is considered a prodrug to the active form of the drug 3,3-‘diindolylmethane (DIM).  The 
3-carbinol group is considered important due to its role in the metabolism of I3C to DIM, as 
shown in Scheme 64.  The mechanism involves the loss of the OH group (which is lost as water), 
which relies on the resultant carbocation being stabilised via conjugation.  By extending the 
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length of the carbon chain from a carbinol (i.e. a CH2OH, as in I3C and compound 5) to 
hydroxyethane (i.e. a CH2CH2OH as in compounds 129 and 126), the carbocation formed via loss 
of the OH can’t become delocalised, and the diindolylmethane cannot be formed.  Likewise, by 
having no 3-substituent at all (as with indole and 2-phenylindole), a diindolylmethane metabolic 
product cannot be formed. 
N
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H N
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Scheme 64 - The degradation of I3C to DIM is reliant upon a conjugated 3-carbinol group 
Initially, the anticancer activities of I3C and compound 5 were compared against those of indole 
and 2-phenylindole respectively (Table 15).  Against the five varieties of cultured cells against 
which the compounds were tested, both I3C and indole had EC50 values that were too high to 
calculate based on the concentration ranges used, so no conclusions can be drawn from this.  
However, compound 5 was shown to have EC50 values in the range of 133 – 552 μM, whereas 
2-phenylindole was shown to have EC50 values that were too high to calculate, showing a large 
reduction in activity on removal of the 3-carbinol group. 
Compound U87 U251 IN1472 IN1528 IN1760 
I3C - - - - - 
5 133.4 279.2 299.9 410.5 551.8 
indole - - - - - 
2-phenylindole - - - - - 
Table 15 - Comparison of EC50 values (𝜇𝜇M) upon removal of the 3-carbinol group 
Exchanging the 3-carbinol group of I3C and compound 5 with a 3-ethan-2-ol group in compounds 
126 and 129 yields less conclusive results (Table 16).  Comparing I3C with its 3-ethan-2-ol 
analogue 126 shows that I3C has consistently higher activity across all five cultures on which 
they were tested.  However, the 2-phenyl analogues show much less consistency, with 
compound 5 having the higher activity against the two established cell lines U87 and U251, 
whereas its 3-ethan-2-ol analogue, compound 129, has the higher activity against the three 
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short-term cultures IN1472, IN1528 and IN1760.  These trends were confirmed upon retesting 
at a later date on the cultures U251, IN1528 and IN1760. 
Compound U87 U251 IN1472 IN1528 IN1760 
I3C 290 390 950 119 1580 
5 30 130 480 10 1430 
126 580 1220 1950 1740 4570 
129 110 250 350 4 330 
 
Compound U251 IN1528 IN1760 
I3C 1040 2740 35940 
5 390 2220 - 
126 5440 44810 - 
129 600 1080 8690 
Table 16 - Comparison of EC50 values (𝜇𝜇M) upon changing the 3-carbinol group to a 3-ethan-2-ol group 
7.4.1.2 The effect of N-substituents 
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Figure 78 - Analogues designed to probe the effect of adding N-substituents 
As shown in Scheme 64, a cationic intermediate is involved in the conversion of the prodrug I3C 
to the active form of DIM, and it is thought that the stability of this intermediate impacts the 
quantity of the diindolylmethane product produced.  By increasing the stability of the 
intermediate, yield of the diindolylmethane should increase, and the observed anticancer 
activity should therefore improve.  Conversely, destabilising the cation should result in lower 
anticancer activity. 
Figure 78 shows the three analogues that were produced in order to probe this hypothesis.  The 
two N-substituents chosen are both electron withdrawing groups of different strengths (the 
acetyl group is much less electron withdrawing than the tosyl group). 
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When tested against three glioblastoma cell cultures, the effect of the acetyl shows a clear 
negative effect on anticancer activity, with both I3C and compound 5 having better activity than 
their N-acetyl analogues 130 and 132 (Table 17).  This implies that the N-acetyl group is not 
effectively removed either by hydrolysis or by enzymatic activity. 
Compound U251 IN1528 IN1760 
I3C 1040 2740 35940 
5 390 2220 - 
130 1760 5820 31720 
132 600 19800 76050 
Table 17 - Comparison of EC50 values (𝜇𝜇M) between I3C and compound 5 and their N-acetyl analogues 
Conversely, an improvement in activity is noticed between I3C and its N-tosyl analogue 133 
(Table 18).  This was unexpected, as an electron withdrawing group at the N-position would be 
expected to destabilise the intermediate cation, therefore reduce the quantity of the resultant 
diindolylmethane.  It was also unexpected since the N-acetyl group (which is also electron-
withdrawing) shows a decrease in activity.  These findings do however agree with a literature 
precedent, that shows that N-sulfonyl analogues of I3C have a significant improvement in 
activity compared to I3C itself when studied against cancerous cell cultures.[286] 
Compound U251 IN1528 IN1760 
I3C 380 700 3370 
133 140 440 650 
Table 18 - Comparison of EC50 values (𝜇𝜇M) between I3C and its N-tosyl analogue 
After testing two different electron-withdrawing N-substituents, it seems apparent that 
N-substitution is not simply an electronic change, and that the specific substituent may have a 
more complicated effect.  This effect may be related to the ability of the prodrug to form the 
active compound, the interaction of the N-substituted active compound with a protein, or the 
solubility or uptake of either the prodrug or active compound.  The fact that the range of 
activities for the two N-substituents is so large suggests that the N-position would be a viable 
position to investigate derivatising. 
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7.4.1.3 The effect of a different heteroatom in the heteroaromatic system 
N
H
OH
S
OH
I3C 134  
Figure 79 - The benzothiophene analogue designed to probe the effect of changing the heteroatom 
As with the N-substituted analogues, the benzothiophene analogue 134 differs from I3C in that 
the intermediate cation will have a different stability.  This is due to two reasons: the changing 
of the most electronegative atom and the reduced aromaticity in the five-membered ring 
compared to indole.[287] 
Compound U251 IN1528 IN1760 
I3C 380 700 3370 
134 1240 3990 1080 
Table 19 - Comparison of EC50 values (𝜇𝜇M) between I3C and its benzothiophene analogue 
Comparing the EC50 values of I3C and compound 134, there is no clear superior compound, with 
I3C having better activity against the U251 and IN1528 cell lines and compound 134 having 
better activity against the IN1760 culture.  If one was searching for a new primary 
chemotherapy, this data would obviously be inconclusive as to which is the superior 
chemotherapy.  However, as IN1760 is considered by groups that work with such short-term 
cultures to be a particularly chemoresistant cell line, the benzothiophene analogue may turn out 
to be a useful fragment against chemoresistant tumours after further optimisation. 
7.4.1.4 The effect of administering the isolated diindolylmethane 
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Figure 80 - The diindolylmethane metabolites of compound 5 and I3C 
As the in vitro conversion of I3C to DIM is thought to be far below 100%,[128] by testing the 
isolated active form, it can be ensured that there is a much higher bioavailability of the active 
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compound.  Assuming the active compound can be taken up by the cells, this should result in a 
higher observed anticancer activity. 
Compound U251 IN1528 IN1760 
I3C 380 700 3370 
9 50 270 50 
DIM 280 440 230 
Table 20 - Comparison of EC50 values (𝜇𝜇M) between I3C and some diindolylmethane analogues 
The EC50 values for I3C, DIM and compound 9 in Table 20 show some convincing trends.  Despite 
the significantly reduced solubility of DIM compared to I3C and the suspected mechanism of 
uptake of I3C discussed in the introduction, the isolated active compound has significantly higher 
anticancer activity than its prodrug.  It is worth noting that at the highest concentrations tested, 
solubility issues were encountered, however solubility issues can be rectified later on in the drug 
development process. 
What is particularly interesting is that compound 9 has higher activity than even DIM.  It was 
initially assumed that the role of the 2-phenyl group in compound 5 was to aid in the formation 
of the diindolylmethane metabolic product.  However, because compound 9 has higher activity 
than DIM itself, this shows that the 2-phenyl group has a beneficial effect on the active form of 
the drug as well. 
What is also noteworthy is the considerable improvement of both diindolylmethanes (but 
especially compound 9) against the chemoresistant IN1760 cell line.  This is of particular interest 
as it suggests that this class of compounds not only have reasonable activity against the 
established cell line U251, they may also have a broad spectrum of activity against otherwise 
chemoresistant cells. 
It is apparent that due to the higher activity and improved stability of diindolylmethanes 
compared to their prodrug forms, future work in this area should focus exclusively on the active 
diindolylmethane form of the drug, and that further work into the prodrug form would be 
redundant. 
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7.4.1.5 Concluding statements on the SAR of the I3C and compound 5 series 
 
Figure 81 - The structural features of compound 5 that were investigated as part of this work 
A total of five structural features were investigated as part of this work, which are summarised 
in Figure 81.  Unsurprisingly, the most vital structural feature of the prodrug form was the 
3-carbinol group, without which the active form of the drug could not form.  The nitrogen of the 
indolic scaffold also appears to be important, as replacing the indole scaffold with a 
benzothiophene scaffold, as in compound 134, drastically reduced the activity of the compound 
against certain cell cultures.  N-substituted analogues of the prodrug appear to be a viable way 
of affecting a significant change in activity, with the N-tosyl substituent (compound 133) 
appearing to improve activity, as has also been shown by Weng et al.[286] 
Comparing the activity of prodrug 5 with that of the active form 9 shows no obvious benefit to 
using a prodrug in future, and indeed showed significantly higher activity when administering 
the isolated metabolite.  The prodrugs are also difficult to store and difficult to synthesise due 
to their inherent instability. 
The 2-phenyl group consistently showed an improvement in activity both in the prodrug and 
active form of the drug.  This structural feature should be included as standard in any future 
work. 
Overall, the most promising compound of this series is compound 9.  If further work is to go into 
this series of compounds, this compound should be used as a lead compound.  As N-substituents 
have been shown to have a significant effect on the activity of I3C and compound 5, 
N-substituted analogues of this diindolylmethane should be investigated, and a potential 
unsymmetric synthesis of such compounds is outlined in Section 4.4.2. 
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7.4.2 The Structure-Activity Relationship of the Compound 4 Series 
Structural analogues for compound 4, which are summarised in Figure 82 alongside the major 
structural features of compound 4, were considered partially due to chemical intuition and 
partially from the findings of the similarity search carried out in Chapter 5.  The structural 
features under investigation include structural isomers, the necessity of conjugation, the role of 
the phenolic ring, the role of the indole and the necessity of the 2-phenylindole core.  Many of 
the structural features addressed in this work are of interest because of the suspected role of 
the phenolic radical in the activity of compound 4. 
 
Figure 82 - The structural features and analogues of compound 4 
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7.4.2.1 Comparing the anticancer activity of compound 4 to that of a range of phenols 
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Figure 83 - The series of phenols tested in order to establish the importance of the indole group 
Compound 4 can be considered as an ortho-substituted phenol, with an indole group at the 
o-position.  To investigate the necessity of such a large substituent, the anticancer activities of 
a series of phenols (Figure 83) were determined. 
Compound U87 U251 IN1472 IN1528 IN1760 
phenol 930 2420 1990 1000 7350 
salicylamide 850 2420 1430 1190 8660 
2-nitrophenol 950 2270 190 1500 6560 
2-methylphenol 740 1960 1530 1040 3800 
guaiacol 570 4230 1520 1170 1660 
aspirin 780 3240 1640 1320 2910 
Table 21 - Comparison of EC50 values (𝜇𝜇M) between a series of simple o-substituted phenols 
Initially, the anticancer activities of a series of simple ortho-substituted phenols was determined, 
and this data is shown in Table 21.  Comparing the activities of individual compounds against 
individual cell cultures generally shows that there isn’t much variation in EC50 values (with the 
exception of 2-nitrophenol against the IN1472 cell line), however 2-methylphenol and guaiacol 
tend to have the generally higher activities. 
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Compound U251 IN1528 IN1760 
4 300 760 100 
phenol 5110 5170 1170 
2-methylphenol 3110 1550 4500 
aspirin 1110 5970 1200 
hydroquinone 220 67540 1310 
136 - - - 
Table 22 - Comparison of EC50 values (𝜇𝜇M) between compound 4, some simple o-substituted phenols and 
two hydroquinones 
A subset of those compounds tested in Table 21 were then retested, as well as two 
hydroquinones (although compound 136 was found to be insoluble under testing conditions).  
This data is shown in Table 22 alongside data for compound 4. 
Comparing the phenols with hydroquinone, we see that hydroquinone has far higher activity 
against the U251 cell line, comparable activity against the IN1760 cell line, and almost no activity 
against the IN1528 cell line.  This inconclusive data, coupled with the inconclusive data for the 
insoluble compound 136, means that no conclusion can be drawn for the relative activities of 
phenols and hydroquinones.  As mentioned in Chapter 4, however, hydroquinones are known 
to be involved in redox cycling,[228,229] so should still be considered in future work. 
Comparing the activity of the phenols with that of compound 4, it is obvious that against all 
three cell cultures, compound 4 has significantly higher anticancer activity.  The magnitude of 
the improvement in activity suggests that either the ortho-indole group is an excellent 
substituent to the phenol group, or that there is a unique and perhaps synergistic effect between 
the indole and phenol moieties. 
Literature precedents for simple phenols with anticancer activity are difficult to come by.  While 
there are many examples of more complex phenols, polyphenols and hydroquinones having 
reasonable anticancer activity,[288–292] the anticancer activities of simple phenols seem 
underreported, suggesting that they have generally been found to have poor activity, and the 
data has therefore gone unpublished.  As is in agreement with what has been found in this 
project, there is some evidence that simple phenols can have some anticancer activity, although 
increasing the complexity of the phenols seems to significantly improve activity.[293,294] 
Chapter 7 – Anticancer Assay Results and Discussion 
175 
 
7.4.2.2 Determining the importance of the phenolic group in compound 4 
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Figure 84 - The analogues used to probe the importance of the phenolic group 
In order to determine the significance of the phenolic group of compound 4, a series of close 
analogues were developed.  These analogues included an analogue without the phenol group 
(indole), an analogue without the phenolic OH group (2-phenylindole) and an aniline analogue 
(compound 152). 
Compound U87 U251 IN1472 IN1528 IN1760 
4 233.1 337.7 332.4 497.1 465.6 
152 354.6 537.5 527.1 690.9 4791.1 
indole - - - - - 
2-phenylindole - - - - - 
Table 23 - Comparison of EC50 values (𝜇𝜇M) between compound 4 and some analogues probing the 
significance of the phenolic group. 
Upon removal of either the phenolic OH group or the whole phenolic substituent, the EC50 value 
rises to above what can be determined under the assay conditions employed.  Although the 
extent of activity loss cannot be determined, it can be confidently asserted that the phenolic 
system is essential for anticancer activity. 
Comparing compound 4 with its aniline analogue 152 across all five cell cultures that they were 
tested on shows compound 4 having consistently higher activity, although both compounds 
have reasonable activity.  Normally, this would result in other similar analogues such as 
thiophenols or phenylphosphines (Figure 85) becoming compounds of interest, however, such 
compounds are uncommon pharmaceutical agents. 
N
H
HS
N
H
H2P
268 269  
Figure 85 - Two possible future compounds of interest, based on the activity of compound 4 and 
compound 152 
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7.4.2.3 Determining the importance of a specific scaffold via scaffold hopping 
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Figure 86 - The analogues of compound 4 with different scaffolds 
The five analogues of compound 4 developed by scaffold-hopping, shown in Figure 86, were 
included in this work in order to potentially discover new novel drug fragments for future study 
within the Snape group. 
Compound U87 U251 IN1472 IN1528 IN1760 
4 110 180 1360 650 680 
166 140 1670 - - 1670 
167 860 4210 640 3880 1110 
168 20 70 2390 20 340 
 
Compound U251 IN1528 IN1760 
4 60 270 60 
169 350 210 370 
160 40 300 90 
217 680 530 1110 
214 50 20 20 
Table 24 - Comparison of EC50 values (𝜇𝜇M) between compound 4 and a series of analogues with different 
scaffolds 
Compound 4 was tested against a naphthalene analogue (compound 168), a benzoxazole 
analogue (compound 166) and a benzothiazole analogue (compound 167) as one series, and 
against a phenyl analogue (compound 169) a 3-phenylindole analogue (compound 160), a 
2-phenylbenzimidazole analogue (compound 214) and a 1-phenylphthalimide analogue 
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(compound 217) in a separate series (Figure 86).  The EC50 values for all of these comparisons 
are shown in Table 24. 
Compared against the benzoxazole analogue 166, compound 4 has higher activity across all five 
cell cultures.  Compared against the benzothiazole analogue 167, compound 4 has higher activity 
against four of the five cell cultures, with the benzothiazole having a lower EC50 against IN1472 
than compound 4.  This seems to indicate that the 2-phenylindole core is better than the highly 
similar benzoxazole and benzothiazole cores in this class of antiglioblastoma compounds. 
Comparing compound 4 against its naphthalene analogue (compound 168) shows the 
naphthalene analogue having higher activity against four of the five cell cultures, with 
compound 4 having higher activity against only IN1472, indicating that the naphthalene 
analogue appears to be the more active compound.  This is very telling, as it indicates that the 
weakly hydrogen bonding NH group of compound 4 is not essential for anticancer activity, and 
that the role of the scaffold may be limited to such effects as sterics and/or π-stacking. 
Compound 4 was compared against compounds 169 and 160 on three cell cultures.  Comparing 
compound 4 with compound 169, compound 4 was found to have superior activity against the 
U251 and IN1760 cell cultures, whereas compound 169 was found to have superior (albeit close) 
activity against the IN1528 cell line. 
Compound 4 and compound 160 were compared as these isomers may give information about 
the importance of shape.  Their electronics are expected to be fairly similar, as they have the 
same number of canonical radical forms, as shown in Figure 87.  These isomers were found to 
have very similar activities against all three cell cultures on which they were tested, with 
compound 4 being slightly more active against the U251 and IN1760 lines, and compound 160 
being more active against the IN1528 line. 
N
H
OHN
H HO
*
*
***
* *
*
*
*
*
*
*
**
*
4
160
 
Figure 87 - The possible places that a phenolic radical could become delocalised to, identified by an 
asterisk (*) on compounds 4 and 160 
Compounds 217 and 214 were both found through the similarity search in Chapter 5, however, 
they show drastically different activities.  Compound 217 has drastically reduced activity against 
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all three cell cultures, whereas compound 214 has the highest activity of all compounds it was 
tested alongside.  This may indicate that specific scaffolds can have activity against cultured 
glioblastoma cells.  Even if activity is not occurring via the same mechanism, the process of 
scaffold hopping, if it yields compounds of higher activity than the lead compound, will still have 
been worthwhile. 
Considering all of this data together, it would seem that the activity of compound 4 is not highly 
sensitive to 3D shape, as shown by the significantly different shapes of compounds 4 and 160.  
This conclusion is derived from the chemically dissimilar compounds such as compound 214 and 
compound 168 which have higher activity than compound 4. 
7.4.2.4 Reducing the conjugation of compound 4 
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Figure 88 - The analogue of compound 4 with reduced conjugation 
In order to investigate the necessity of conjugation between the proposed phenol radical and 
the indole moiety, an analogue without the conjugation between the two ring systems, 
compound 149 (shown in Figure 88), was tested.  As discussed in Chapter 4, a suspected issue 
with this analogue is that its 3D shape is somewhat different to that of compound 4 due to the 
loss of planarity inherent in reducing the conjugation of this lead compound.  However, as has 
been shown by the analogues in Figure 86, anticancer activity within this class of compounds is 
not highly sensitive to 3D shape, so this issue may be alleviated. 
Compound U251 IN1528 IN1760 
4 60 270 60 
149 7 420 150 
Table 25 - Comparison of EC50 values (𝜇𝜇M) between compound 4 and its reduced analogue 149 
The EC50 values in Table 25 shows that compound 4 has the higher activity against both short-
term cultures, whereas compound 149 has higher activity against the established U251 cell line.  
Therefore, determining the superior antiglioblastoma agent is difficult based solely on the data 
in Table 25.  What can be stated is that the high level of conjugation in compound 4, which was 
originally considered to be essential for its activity, is perhaps not the only factor involved in 
promoting anticancer activity.  This lack of conjugation in compound 149 is also reflected in its 
Chapter 7 – Anticancer Assay Results and Discussion 
179 
 
BDE value, which is higher than that of phenol (BDE of compound 4 is 77.1 kcal mol-1, of phenol 
is 87.7 kcal mol-1, and of compound 149 is 90.2 kcal mol-1).  Again, this suggests that activity is 
not directly related to the stability of the radical or the ease with which the radical is formed 
(i.e. the BDE value). 
7.4.2.5 The effect of O-protected analogues 
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Figure 89 - O-protected analogues of compound 4 
As discussed in the introduction, compound 4 is known to act rapidly.  Compound 4 is also 
thought to act via a phenolic radical.  The series of compounds shown in Figure 89 are intended 
to investigate these two factors. 
Figure 89 includes three compounds that would not be expected to be easily hydrolysed under 
physiological conditions (the TBS analogue 155, the mesyl analogue 156 and the benzyl analogue 
154), which will probe the activity of analogues that cannot readily form a phenolic radical, and 
three analogues which would be expected to be hydrolysed under physiological conditions (the 
benzoyl analogue 157, the acetyl analogue 158 and heptanoyl analogue 159), which are 
intended to modulate the activity of compound 4. 
Chapter 7 – Anticancer Assay Results and Discussion 
180 
 
Compound U251 IN1528 IN1760 
4 60 70 30 
154 670 250 6670 
155 40 60 10470 
157 50 40 440 
159 40 100 310 
156 60 80 30 
158 30 120 10 
Table 26 - Comparison of EC50 values (𝜇𝜇M) between compound 4 and a series of O-substituted derivatives 
The activity data for the compounds shown in Figure 89 is shown in Table 26.  This data shows 
that the three analogues that were expected to have a loss of activity due to suspected 
irremovable substituents, compounds 154, 155, and 156, do not have appear to act as expected.  
While the O-benzyl analogue 154 has significantly lower activity against all three cultures on 
which these compounds were tested, the O-TBS analogue 155 shows similar activity to 
compound 4 on the U251 and IN1528 cultures, however it shows a loss of activity against the 
IN1760 culture, and the O-mesyl analogue 156 shows comparable activity to compound 4 
against all three cell cultures. 
As discussed in Section 4.3, enzymatic cleavage of Si-O bonds is uncommon but known,[221,222] so 
the enzymatic removal of TBS group of compound 155 is possible.  An alternative possibility is 
that compound 155 is an active agent in its own right.  Silicon-based derivatives of existing drugs 
have been shown to retain and in some instances improve activity,[295] potentially due to the 
high lipophilicity (and therefore improved membrane permittivity) of silicon residues.[296,297]  
Of the three O-substituted analogues that were expected to be hydrolysable, compounds 157, 
158 and 159, all three have comparable activity to compound 4 against the U251 and IN1528 
cultures.  The O-acetyl analogue 158 also has comparable activity against IN1760, with the 
O-benzoyl analogue 157 and the O-heptanoyl analogue 159 having lower activity against IN1760. 
The comparable activity of the O-acyl analogues 157, 158 and 159  to compound 4 was expected 
due to deacylation being a common drug biotransformation.[298]  What is more difficult to justify 
is the activities of the other three analogues.  There are known enzymes that cleave benzyl 
groups,[299] and it stands to reason that there are potential metabolic pathways that involve the 
cleaving of TBS or mesyl groups.  The alternative explanations are either that compounds 154, 
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155, and 156 are acting via a different mechanism, or that by derivatising at the O-position does 
not necessarily form an inactive compound.  The latter of these potential explanations would 
considerably alter the basic assumptions on the mechanistic process of compound 4.  A further 
possibility is that these O-substituted compounds, which may be expected to act as prodrugs, 
are simply being metabolised differently in different cell cultures.  Genetic mutations in tumours 
are now known to significantly affect cell signalling, resulting in drastically different metabolic 
potential between tumours,[300] so these unexpected trends may simply be a result of different 
cell cultures being able to metabolise these potential prodrugs differently. 
The comparative activity of compound 4 against its O-methyl derivative (Figure 90) has been 
previously carried out by Prabhu et al.,[6] who found that the O-methyl derivative was inactive 
against the U87 cell line. 
N
H
HO
N
H
O
4 267  
Figure 90 - Compound 4 (left) and its O-methyl derivative 267 (right), as tested by Prabhu et al.[6] 
To investigate the possibility of O-protected analogues of compound 4 being used as prodrugs 
for compound 4, time course assays for both compound 4 and its O-heptanoyl analogue 159 
were carried out within the research group by Saurabh Prabhu using the MTS assay.  The results 
from these assays, which were carried out on the primary glioblastoma culture BTNW911 and 
the short-term human glioma cell culture IN859, are shown in Graph 5.  These data shows that 
compound 4 has rapid initial activity against both cultures, whereas compound 159 reduced cell 
viability much more gradually.  Importantly, both compounds tend towards the same activity 
over time.  This would agree with the hypothesis that the heptanoyl group can be cleaved off to 
produce compound 4, as the activity of compound 159 is equal to that of compound 4, yet it 
takes time for the enzymatic cleavage to occur. 
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Graph 5 - Time course graphs comparing the activity of compound 4 (blue) against compound 159 
(brown) against BTNW911 (left) and IN859 (right) 
7.4.2.6 Miscellaneous analogues 
N
H
N
HO
HO OH
O
HO
4 198 218  
Figure 91 - Miscellaneous analogues of compound 4 
Finally, comparisons between compound 4 and its two miscellaneous analogues can be drawn.  
Compound 198 was produced as a degradation product of a compound of interest, as described 
in Chapter 4, and is chemically dissimilar to compound 4 despite being structurally similar.  
Compound 218 was found during the similarity search in Chapter 5, and is both chemically and 
structurally dissimilar, yet was considered by the ShaEP software to be highly similar in terms of 
both shape and electronics of the system. 
Compound U251 IN1528 IN1760 
4 60 270 60 
198 110 120 50 
218 6 70 340 
Table 27 - Comparison of EC50 values (𝜇𝜇M) between compound 4 and two miscellaneous analogues 
Interestingly, both of these analogues show some reasonable activity against at least one of the 
cultures on which they were tested, although clear trends are difficult to elucidate.  Compound 
198 has higher activity than compound 4 against the IN1528 short-term cultures, comparable 
activity against the IN1760 short-term culture and worse activity against the U251 cell line.  
Compound 218 has drastically higher activity against both the U251 and IN1528 cultures, yet 
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drastically lower activity against the IN1760 culture.  Based solely on this data, it is difficult to 
rank these three compounds due to their ambiguous trends.   
Both of these analogues are, to the eye of a chemist, considerably different to the lead 
compound 4.  Compound 198, despite being fairly similar in terms of shape, is chemically far 
removed from the lead compound, whereas compound 218 is little more than a substituted 
simple phenol.  Regardless, both of these compounds showed reasonable activity against at least 
one culture on which they were tested.  This suggests one of two things; either these active 
compounds have comparable activity due to their ability to assume a comparable 3D shape, thus 
being able interact with a protein or enzyme in the same way in which compound 4 does, or that 
these active compounds are not functional analogues of one another and that their activities is 
due to different mechanisms of action. 
7.4.2.7 Concluding statements on the SAR of compound 4 
 
Figure 92 - The structural features of compound 4 that were investigated as part of this work 
There were five structural features of compound 4 that were investigated as part of this work, 
which are summarised in Figure 92.  It was found that a phenolic (or analogous) group was 
required for activity, as removal of this group resulted in a loss of activity.  It was also shown 
that simple ortho-substituted phenols had much lower activity than compound 4, suggesting 
that the indole moiety has significant importance, as suggested in Section 2.1 where indole was 
described as a privileged structure. 
Investigating different scaffolds yielded some interesting findings.  It was found that the 
2-phenylnaphthalene scaffold of compound 168 improved activity, indicating that the NH group 
of the indole is not necessary for activity.  Other scaffolds were also shown to have activity, 
although the majority of the scaffolds tested had little activity. 
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The effect of O-substituted analogues showed lower activity for some compounds and 
comparable activity for others (with the possible exception of the O-acetyl derivative 158).  The 
meaning of these findings are inconclusive, as it may indicate that the substituents are being 
cleaved in vitro or that the OH group of compound 4 is not as essential for activity as once 
thought. 
This work has shown through scaffold hopping that compounds 168 and 214 (shown in Figure 
93) are the superior fragments on which to base the design of new drugs around, and future 
work should therefore utilise these compounds as lead compounds.  A significant breadth of 
chemical space has been explored so far within this work, however, the local chemical space of 
any of the active functional analogues of compound 4 has not been probed to any appreciable 
depth.  Future work should therefore focus on refining and developing the structures of 
compounds 168 and 214 in order to further improve their activities. 
N
H
N
HO HO
214 168  
Figure 93 - The structures of compounds 214 and 168 
Initially, it should be confirmed that compounds 168 and 214 act in the same way as compound 
4, in that they induce an increase in ROS levels in a cell, followed by apoptosis.  If their mode of 
activity is found to be the same as compound 4, the next step should be to investigate induceing 
elevated ROS levels, such as interacting with proteins or enzymes that can upregulate ROS 
production or downregulate antioxidant production. 
7.5 Comparing anticancer activity to BDE 
As was discussed in Chapter 6, the BDE values (as well as AIP, PDE, PA and ETE values) were 
calculated for a number of analogues of compound 4.  Because compound 4 is known to induce 
the rapid generation of ROS followed by cellular death,[6] the intention behind calculating these 
enthalpic values was to determine if there might be a connection between the ease of formation 
of these phenolic (and analogous) radicals and their anticancer activities.  As phenols are known 
to be oxidised by molecular oxygen, thus generating ROS,[301,302] it was suspected that this 
reaction may be responsible for the increase in ROS observed upon addition of compound 4 to 
cultured cells. 
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In order to compare EC50 values to BDE values across a number of batches of anticancer tests, 
EC50 values were compared against BDE values within each batch of testing, and the trend lines 
within each batch were compared for similarity.  These comparisons are given in Appendix 7, 
and information on which batches contain which compounds can be found within this appendix.  
A comparison between EC50 values and BDE values against the U251 cell line is given as a 
representative example in Graph 6.  As can be seen from this graph, there is very poor 
agreement between the trend lines for each batch of compounds, and even the extent to which 
each batch of compounds conforms to its trendline is poor.  This lack of agreement is also true 
for the other cell cultures on which the compounds were tested. 
 
Graph 6 - Combined data for all six batches of compounds, comparing EC50 values for the U251 cell line 
(𝜇𝜇M) against BDE values (kcal mol-1) 
In the interest of completeness, comparisons were also made between EC50 values and the other 
four enthalpic values calculated in Chapter 6 (AIP, PDE, PA and ETE), but no significant 
correlation was found in any of these cases.  A final attempt was made to find a correlation 
between anticancer activity and one of the calculated enthalpic values by normalising all EC50 
values to that of compound 4, then plotting this data as one series against each enthalpic value.  
The strongest correlation was found between anticancer activity and BDE against the IN1528 
culture (Graph 7), although with an R2 value of just 0.45, even this is not a strong enough 
correlation to be considered significant. 
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Graph 7 - Normalised dosage data for the IN1528 short-term culture plotted against calculated BDE 
values (in kcal mol-1) 
These data shows that this is a poor overall correlation between the observed anticancer activity 
and the calculated enthalpic values for the entire data set, but there are some other revealing 
trends.  On examination of the normalised data, it is apparent that particularly low BDE, AIP and 
PA values against the U251 and IN1528 cultures are consistently correlated with a higher 
activity, although no such trends are observed for the chemoresistant IN1760 culture.  These 
observations are for both compounds with a BDE below 80 kcal mol-1 (compounds 4 and 244), 
the five compounds with an AIP below 180 kcal mol-1 (compounds 4, 152, 244, 160 and 149) and 
both compounds with a PA of below 80 kcal mol-1 (compounds 4 and 244), the structures of 
which are shown in Figure 94.  It may, therefore, be possible that with a larger data set, a similar 
trend may emerge whereby particularly low enthalpic values can be used as a predictor of 
reasonable anticancer activity, although this approach would inherently miss a large number of 
active compounds with higher enthalpic values such as compound 168 (although false positives 
or negatives are inherent with every in silico drug design approach).  At the moment, this trend 
is too weak to be considered significant, and the compounds in Figure 94 may simply have been 
identified due to being part of a highly similar chemical class.  
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Figure 94 - The structures of compounds which appeared below the “threshold level” of at least one 
calculated enthalpic value, as described in the text 
Therefore, within this project, a strong and clear correlation between the propensity of this class 
of compounds to form radicals and anticancer activity has not been identified.  As with all 
inconclusive data, this can indicate one of two things.  The first thing that this could indicate is 
that the hypothesis was simply incorrect.  This would therefore indicate that the phenolic 
radicals formed by the class of compounds investigated are unlikely to form ROS by direct means 
(such as by directly reducing molecular oxygen to superoxide).  An alternative hypothesis would 
therefore be that compounds such as compound 4 either upregulate the production of ROS or 
downregulate the production of antioxidants. 
The second thing that this inconclusive data could indicate is that the hypothesis was not suitably 
investigated due to insufficient data.  If it is a case of insufficient data, then more experimental 
data is required in order to establish whether a calculated enthalpic value such as BDE is truly 
useful predictor of anticancer activity, however, the possibility of a more restricted hypothesis 
(e.g. particularly low values of BDE, AIP and/or PA indicate reasonable activity within a class of 
compounds) may still be plausible.  On the other hand, a limit of this investigation could be that 
the analogues investigated are too structurally dissimilar to have their activities directly 
compared, and therefore a series of more structurally similar compounds based around the 
same scaffold (for example the 2-phenylindole or 2-phenylnaphthalene scaffold) would be 
better suited to investigating this hypothesis. 
Considering this, the data was then revisited with the intention of analysing a “single chemical 
class”, and investigating if any trends between activity and enthalpic values was present.  The 
largest chemical class that was investigated as part of this work were the six simple ortho-
substituted phenols, so their activities (i.e. their -log10(EC50) values) were compared against the 
five calculated enthalpic values (BDE, AIP, PDE, PA and ETE), with the trendline equations and R2 
correlation value for each comparison shown in Table 28.  Excluding the U251 cell line 
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(R2 = 0.394), reasonable to good correlations were obtained between certain enthalpic values 
and anticancer activity.  This data shows that the PDE values correlate best with –log10(EC50) 
values against the U87 cell line (R2 = 0.677), the BDE values correlate best with –log10(EC50) values 
against the IN1472 (R2 = 0.700) and IN1528 (R2 = 0.844) culture, and the PA values correlate best 
with –log10(EC50) values against the IN1760 culture (R2 = 0.548).  This is in agreement with the 
findings from Chapter 6, which suggested that PDE values are more likely to be larger (and 
therefore the rate-limiting factor) than AIP values in the SET-PT radical formation pathway, and 
that PA values are more likely to be higher (and therefore the rate-limiting factor) than ETE 
values in the SPLET radical formation pathway, as shown in Scheme 8 in Section 1.2.2. 
  U87 U251 IN1472 IN1528 IN1760 
BDE 
Trendline 
y = -40.0x -
24.8 
y = 6.10x 
+112.0 
y = 12.7x 
+123.0 
y = -81.8x -
160.6 
y = -7.34x 
+64.3 
R2 0.315 0.016 0.700 0.844 0.121 
AIP 
Trendline 
y = -100.0x -
83.4 
y = 37.0x + 
333.1 
y = 19.8x 
+266.9 
y = -94.9x - 
85.3 
y = -19.3x 
+136.1 
R2 0.659 0.198 0.564 0.379 0.281 
PDE 
Trendline 
y = 60.1x 
+386.3 
y = -30.8x 
+106.5 
y = -7.04x 
+190.7 
y = 13.0x 
+252.3 
y = 12.0x 
+255.9 
R2 0.677 0.394 0.204 0.020 0.308 
PA 
Trendline 
y = 56.2x + 
507.9 
y = -30.6x 
+240.3 
y = -10.5x 
+312.8 
y = 57.1x 
+520.5 
y = 19.2x 
+414.9 
R2 0.412 0.269 0.317 0.271 0.548 
ETE 
Trendline 
y = -96.2x - 
205.1 
y = 36.7x 
+199.5 
y = 23.3x 
+144.8 
y = -138.9x - 
353.5 
y = -26.5x -
22.9 
R2 0.438 0.141 0.561 0.583 0.380 
Table 28 - Trendlines and R2 correlation values for the comparisons of –log10(EC50) values against 
calculated enthalpic values.  The data in red bold text indicates the highest R2 value for that particular 
cell culture 
The gradient values shown in Table 28, may also be of significance.  Considering again the data 
shown in bold in Table 28 (U251 data excepted), against the U87, IN1472 and IN1760 cultures, 
the gradients are positive, indicating that as the phenolic radicals become easier to form, their 
activity increases, and vice versa for the IN1528 short-term culture, which has a negative 
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gradient.  This may be indicative of the previously mentioned “threshold theory”, whereby the 
U87, IN1472 and IN1760 cultures may have mutated to have elevated ROS levels, and are 
therefore easier to kill by inducing even higher levels of ROS.  Conversely, the U251 and IN1528 
cultures may be more resilient to ROS if these cells have mutated to have lowered ROS levels. 
In conclusion, this data suggests that a correlation between radical formation and activity may 
still in fact be present, but only within a more specific chemical class.  In order to improve on 
the activity observed in this series of simple ortho-substituted phenols, future work could 
include a similar series of close analogues, and attempt to replicate the observed potential 
correlations shown in Table 28, but based on Compounds 168 or 214 (Figure 95), which would 
be ideal lead compounds for such a series. 
N
H
N
OH HO
168 214  
Figure 95 - The structures of compound 168 and 214 
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8.1 Overview of Materials and Methods 
Reactions were followed by analytical thin layer chromatography (TLC) using plastic-backed TLC 
plates coated in silica G/UV254, run in a variety of solvent systems and visualised with a UV light 
at 254 nm, p-anisaldehyde stain and/or potassium permanganate stain.  Commercially available 
solvents and reagents were purchased from Fisher, Sigma Aldrich, TCI and Fluorochem and were 
used without further purification unless specified in the syntheses.  Flash column 
chromatography was carried out on Davisil silica 60 Å (40 – 63 µm) under bellows pressure.  High 
resolution mass spectra were obtained at the EPSRC UK National Mass Spectrometry Facility in 
Swansea University’s College of Medicine using a LTQ Orbitrap XL™ Hybrid Ion Trap-Orbitrap 
Mass Spectrometer coupled to a TriVersa NanoMate® ESI source.  Low resolution mass spectra 
were obtained on a Thermo Finnigan LCQ Advantage MAX using electrospray ionisation (ESI) or 
atmospheric pressure chemical ionisation (APCI).  Crystal structures were obtained at the EPSRC 
National Crystallography Service at the University of Southampton using a Rigaku AFC12 
goniometer equipped with an enhanced sensitivity (HG) Saturn724+ detector mounted at the 
window of an FR-E+ SuperBright molybdenum rotating anode generator with VHF Varimax 
optics (70µm focus).  1H and 13C NMR were carried out on a Bruker Fourier 300 (300 MHz) or a 
Bruker Advance III 400 (400 MHz) with broad band decoupling, and all chemical shifts (δ) quoted 
in parts per million (ppm) relative to the residual solvent peaks of CHCl3 (δH 7.26, δc 77.16) or 
d5-DMSO (δH 2.50, δC 39.52).  J values are given in Hertz (Hz).  Infrared spectra were recorded on 
a solid sample using a Thermo Nicolet IR-200 FT-IR.  Melting points are uncorrected, and were 
recorded using a Stuart SMP10.  Preparative liquid chromatography was carried out on a 
Teledyne Isco CombiFlash® Rf 200.  Elemental analysis was carried out using a Thermo 
Scientific™ FLASH 2000 CHNS/O Analyser.  Petroleum ether refers to the fraction that boils 
between 40-60 oC.  Assignments of NMR spectra was aided with the use of DEPT-135, and in 
some cases HSQC and HMBC. 
8.2 Syntheses 
8.2.1 Procedure for the synthesis of 2-(1H-indol-2-yl)phenol (4)[6] 
OH O F
NO2
OOH
NO2
r.t.,
 
24
 
h
DMSO
K2CO3
 
To a solution of 2’-hydroxyacetophenone (5 g, 36.7 mmol) and 1-fluoro-2-nitrobenzene (3.9 mL, 
36.7 mmol) in DMSO (37 mL) was added potassium carbonate (12.7 g, 91.8 mmol).  The reaction 
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was stirred at room temperature for 24 hours.  Upon completion as indicated by TLC analysis, 
the reaction mixture was diluted with water (300 mL) and acidified to pH ca. 3 using 1 M HCl.  
The crude reaction was extracted with ethyl acetate (2 × 300 mL), and the organic layers were 
washed with water (2 × 300 mL) and brine (1 × 300 mL), dried (MgSO4), and the solvent removed 
in vacuo.  The crude product was purified by recrystallisation (ethyl acetate) to give 1-(2-
hydroxyphenyl)-2-(2-nitrophenyl) as a dark green solid (3.60 g, 47% yield).  Rf = 0.35 (5:3 
petroleum ether: ethyl acetate);  1H NMR (300 MHz, CDCl3): δH = 11.83 (1 H, br s, OH), 8.20 (1 H, 
dd, J = 8.0, 1.0 Hz, Ar), 7.91 (1 H, dd, J = 8.0, 1.5 Hz, Ar), 7.65 (1 H, td, J = 7.5, 1.5 Hz, Ar), 7.58-
7.49 (2 H, m, Ar), 7.36 (1 H, dd, J = 7.5, 1.0 Hz, Ar), 7.04 – 6.94 (2 H, m, Ar), 4.80 (2 H, s, CH2). 
N
H
HOOOH
NO2
Pd/C
r.t.,
 
3.5
 
h
MeOH
4  
Methanol (50 mL) was charged into a flask containing Pd/C (232 mg, 18 wt%), followed by the 
addition of 1-(2-hydroxyphenyl)-2-(2-nitrophenyl)ethanone (1.26 g, 6.02 mmol).  The flask was 
evacuated and backfilled with hydrogen, and the reaction was stirred at room temperature for 
3.5 hours.  Upon consumption of the starting material by TLC, the reaction was filtered through 
Celite® and washed with methanol (20 mL).  The filtrate was concentrated in vacuo, and was 
purified via flash column chromatography on silica gel (10:3 petroleum ether: ethyl acetate) to 
afford the title compound as a pale yellow solid (0.70 g, 55% yield). Rf = 0.18 (10:3 petroleum 
ether: ethyl acetate); 1H NMR (300 MHz, d6-DMSO): δH = 11.13 (1 H, br s, NH), 10.15 (1 H, br s, 
OH), 7.75 (1 H, dd, J = 7.5, 1.0 Hz, Ar), 7.51 (1 H, d, J = 7.5 Hz, Ar), 7.45 (1 H, d, J = 8.0 Hz, Ar), 
7.14 (1 H, td, J = 7.5, 1.0 Hz, Ar),  7.05 (1 H, t, J = 7.5 Hz, Ar) 7.02 – 6.86 (4 H, m, Ar); MS (ESI): 
m/z 210 ([M+H]+). 
8.2.2 Procedure for the synthesis of 2(phenyl-1H-indol-3-yl)methanol (5)[6] 
N
H
N
H
O OH
Reflux
 
1
 min,
 
then
 r.t.
 
2
 
h
NaBH4
EtOH
5  
2-Phenylindole-3-carboxaldehyde (1.00 g, 4.52 mmol) and NaBH4 (0.34 g, 9.04 mmol) were 
added to ethanol (34 mL) and heated at reflux for 1 minutes followed by stirring at room 
temperature for 2 hours.  NaOH (1%, 35 mL) was added, and the solvent was removed in vacuo.  
The reaction was extracted with Et2O (3 × 30 mL), dried (MgSO4), filtered and the solvent 
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removed in vacuo.  Due to the title compound being degraded on silica, the reaction was purified 
by recrystallization (EtOAc, few drops of PE) to yield the product as a colourless solid (187 mg, 
19% yield). Rf = 0.21 (5:2 petroleum ether: ethyl acetate); 1H NMR (300 MHz, DMSO): δH = 11.35 
(1 H, s, NH), 7.79 (2H, m, Ar), 7.66 (1 H, d, J = 7.5 Hz, Ar), 7.52 (2 H, t, J = 7.5 Hz, Ar), 7.35-7.44 (2 
H, m, Ar), 7.12 (1 H, td, J = 7.5 Hz, 1.0 Hz, Ar), 7.03 (1 H, td, J = 7.5, 1.0 Hz, Ar), 4.96 (1 H, t, J = 5.0 
Hz, OH), 4.67 (2 H, d, J = 5.0 Hz, CH2); 13C NMR (75 MHz, DMSO): δC = 135.94 (Ar, Cq), 135.82 (Ar, 
Cq), 132.41 (Ar, Cq), 128.74 (Ar, Cq), 128.71 (Ar, CH), 127.97 (Ar, CH), 127.57 (Ar, CH), 121.62 (Ar, 
CH), 118.94 (Ar, CH), 112.35 (Ar, Cq), 111.13 (Ar, CH), 53.86 (CH2); MS (ESI): m/z 206 ([M-OH]+). 
8.2.3 Procedure for the synthesis of bis(2-phenyl-1H-indol-3-yl)methane (9)[303] 
N
H
H
N
N
H
H2C
O
90
 oC,
 
90
 
h
H2O
AcOH
9  
Under a nitrogen atmosphere and in the dark, 2-phenylindole (338 mg, 1.75 mmol), acetic acid 
(50.1 µL, 0.88 mmol) and formaldehyde solution (37 wt%, 70.1 µL) were stirred in water (40 mL) 
at 90 oC for 6 days.  The crude reaction was extracted with ethyl acetate (2 × 15 mL), and the 
combined organic phases were dried (MgSO4), filtered and concentrated in vacuo.  The crude 
product was purified by preparative liquid chromatography (19:1 to 9:1 petroleum ether: ethyl 
acetate) to yield the title compound as a pale red solid (195 mg, 56%).  Rf = 0.37 (9:1 petroleum 
ether: ethyl acetate);  1H NMR (300 MHz, CDCl3): δH = 8.01 (2H, br s, NH), 7.60 – 7.52 (4H, m, Ar), 
7.45 – 7.18 (10H, m, Ar), 7.08 (2H, td, J = 7.5 Hz, 1.0 Hz, Ar) 6.86 (2H, td, J = 7.5, 1.0 Hz, Ar), 4.57 
(2H, s, CH2);  13C NMR (75 MHz, CDCl3): δC = 135.99 (Ar, Cq), 134.60 (Ar, Cq), 133.41 (Ar, Cq), 129.46 
(Ar, Cq), 128.79 (Ar, CH), 128.44 (Ar, CH), 127.61 (Ar, CH), 122.06 (Ar, CH), 120.12 (Ar, CH), 119.53 
(Ar, CH), 112.14 (Ar, Cq), 110.63 (Ar, CH), 21.42 (CH2); MS (APCI): m/z 397 ([M-H2+H]+);  HRMS 
found: [M+H]+ 399.1859, C29H22N2+H+ requires 399.1856. 
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8.2.4 Procedure for the synthesis of 2-(2-phenyl-1H-indol-3-yl)ethanol (129)[304] 
N
H
N
H
N
H
OH
O
O
O
Oxalyl
 chloride LiAlH4
THF
Reflux
Et2O
30
 oC,
 
17
 
h
129  
Oxalyl chloride (2.7 mL, 31.5 mmol) in dry Et2O (10 mL) was added to 2-phenylindole (1.93 g, 10 
mmol) in dry Et2O (40 mL) dropwise at 0 oC under an atmosphere of nitrogen.  The reaction was 
stirred at 30 oC for 17 h before being cooled to 0 oC and quenched with MeOH (2 mL).  The 
reaction was concentrated in vacuo to yield methyl 2-oxo-2-(2-phenyl-1H-indol-3-yl)acetate, 
which was used in the next step of the reaction without further purification.  To this crude 
product was added dry THF (15 mL) along with 4 Å molecular sieves (1 g).  The supernatant was 
added dropwise to a suspension of LiAlH4 (1.57 g, 41.4 mmol) in dry THF (40 mL) at 0 oC.  The 
reaction was heated at reflux for 6 h before being quenched at 0 oC first by water (1.5 mL), then 
NaOH (10%, 3 mL) and finally water (4.5 mL).  The reaction was filtered through Celite® and the 
solids were washed with MeOH.  The filtrates were dried (MgSO4), filtered and concentrated in 
vacuo.  The product was purified via flash column chromatography on silica gel (5:3  1:1 
petroleum ether: ethyl acetate) to afford a white solid (1.76 g, 74% yield).  M.p. 89 – 91 oC; Rf = 
0.52 (5:3 petroleum ether: ethyl acetate); 1H NMR (300 MHz, CDCl3): δH = 8.15 (1 H, br s, NH), 
7.70-7.60 (3 H, m, Ar), 7.48 (2 H, t, J = 7.5 Hz, Ar), 7.43-7.34 (2 H, m, Ar), 7.28-7.12 (2 H, m, Ar), 
3.98 (2 H, t, J = 6.5 Hz, CH2), 3.19 (2 H, t, J = 6.5 Hz, CH2), 1.56 (1 H, br s, OH); 13C NMR (75 MHz, 
CDCl3): δC = 135.92 (Ar), 135.88 (Ar), 132.84 (Ar), 129.16 (Ar), 128.95 (Ar), 128.17 (Ar), 127.91 
(Ar), 122.50 (Ar), 119.86 (Ar), 119.16 (Ar), 110.93 (Ar), 108.87 (Ar), 63.02 (CH2), 28.06 (CH2); IR 
(neat, cm-1) ν = 3396 (N-H stretch), 1450 (aromatic C-C stretch), 1037 (C-O stretch); MS (ESI): m/z 
238 ([M+H]+); HRMS found: [M+H]+ 238.1227, C16H15NO+H+ requires 238.1226. 
8.2.5 Procedure for the synthesis of 1-(3-(hydroxymethyl)-1H-indol-1-yl)ethanone 
(130)[305] ………… 
N
O
O
N
OH
O
NaBH4
r.t.,
 
70
 mins
THF
130  
1-Acetyl-1H-indole-3-carbaldehyde (0.5 g, 1.9 mmol) and NaBH4 (0.14 g, 3.7 mmol) were added 
to dry THF (20 mL), and the reaction was stirred at room temperature under a nitrogen 
atmosphere for 70 mins.  Upon completion by TLC, the reaction was quenched with saturated 
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NH4Cl (5 mL), and the solvent was removed in vacuo.  The reaction was extracted with ethyl 
acetate (2 × 5 mL), and the combined organic layers were washed with water (10 mL).  The 
organic layer was then dried (MgSO4), filtered, and the solvent was removed in vacuo.  The 
product was purified by flash column chromatography on silica gel (1:5 petroleum ether: ethyl 
acetate) to yield the title compound as a light orange-brown powder (0.18 g, 36% yield).  M.p. 
134 – 135 oC; Rf = 0.50 (1:5 petroleum ether: ethyl acetate);  1H NMR (300 MHz, d6-DMSO): δH = 
8.31 (1 H, d, J = 8.0 Hz, Ar), 7.71 (1 H, s, Ar), 7.69 - 7.62 (1 H, m, Ar), 7.36-7.22 (2 H, m, Ar), 5.16 
(1 H, t, J = 5.5 Hz, OH), 4.65 (2 H, dd, J = 5.5, 1.0 Hz, CH2), 2.62 (3 H, s, CH3); 13C NMR (75 MHz, 
d6-DMSO): δC = 169.37 (C=O), 135.42 (Ar, Cq), 129.40 (Ar, Cq), 124.77 (Ar, CH), 123.93 (Ar, CH), 
123.17 (Ar, CH), 122.64 (Ar, Cq), 119.70 (Ar, CH), 115.92 (Ar, CH), 55.20 (CH2), 23.86 (CH3);  IR 
(neat, cm-1) ν = 3501 (free O-H stretch, sharp), 1684 (C=O stretch), 1007 (C-O stretch);  MS (EI): 
m/z 130 ([M-OH-Ac]-, 100%), 147 ([M-Ac]-, 43%); HRMS found: [M+H]+ 190.0862, C11H11NO2+H+ 
requires 190.0863.  
8.2.6 Procedure for the synthesis of 1-(3-(hydroxymethyl)-2-phenyl-1H-indol-1-
yl)ethanone (132) 
N
O
N
OH
O O
N
H
O
1.
 
NaH
r.t.,
 
30
 mins
THF
2.
 
Ac2O
r.t.,
 
3
 
h
THF
STAB
Reflux,
 
40
 
h
THF
132  
A solution of 2-phenylindole-3-carboxyaldehyde (1 g, 4.52 mmol) with sodium hydride (60% in 
oil, 0.36 g, 9 mmol) in dry THF (20 mL) was stirred at room temperature for 30 mins.  Acetic 
anhydride (1.27 mL, 13.5 mmol) was added and stirred for a further 3 hours until the reaction 
was complete by TLC.  The crude reaction was quenched with the addition of water (1 mL) 
dropwise.  The reaction was diluted with water (30 mL), and was extracted with ethyl acetate (2 
× 15 mL).  The organic phase was dried (MgSO4), filtered and concentrated in vacuo, and purified 
by flash column chromatography on silica gel (10:1 petroleum ether: ethyl acetate) to yield 
1-acetyl-2-phenyl-1H-indole-3-carbaldehyde (1.07 g, 90% yield).  Rf = 0.57 (2:1 petroleum ether: 
ethyl acetate);  1H NMR (300 MHz, CDCl3): δH = 9.76 (1H, s, CHO), 8.44 - 8.37 (1H, m, Ar), 8.33 – 
8.25 (1H, m, Ar), 7.63 – 7.52 (5H, m, Ar), 7.50 – 7.38 (2H, m, Ar), 2.03 (3H, s, CH3). 
A solution of 1-acetyl-2-phenyl-1H-indole-3-carbaldehyde (388 mg, 1.47 mmol) and sodium 
triacetoxyborohydride (STAB, 375 mg, 1.77 mmol) in dry THF (35 mL) was heated at reflux for 
40 hours.  The solvent was then removed in vacuo, the crude reaction was redissolved in CH2Cl2, 
washed with saturated sodium carbonate, dried (MgSO4), filtered and concentrated in vacuo.  
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The reaction was purified by flash column chromatography on silica gel (9:1 petroleum ether: 
ethyl acetate with 1% TEA  2:1 petroleum ether: ethyl acetate with 1% TEA) to yield a mixture 
of the title product and 2-phenylindole-3-carboxyaldehyde.  This mixture was then dissolved in 
a small quantity of CH2Cl2 and filtered to yield the title product as a yellow gum (203 mg, 52% 
yield).  Rf = 0.37 (2:1 petroleum ether: ethyl acetate);  1H NMR (400 MHz, d6-DMSO): δH = 8.26 
(1H, d, J = 8.0 Hz, Ar), 7.78 (1H, m, J = 7.5 Hz, Ar), 7.56 – 7.49 (5H, m, Ar), 7.39 – 7.28 (2H, m, Ar), 
4.98 (1H, br s, OH), 4.39 (2H, s, CH2), 1.94 (3H, s, CH3);  13C NMR (100 MHz, d6-DMSO): δC = 170.85 
(C=O), 136.15 (Ar, Cq), 136.04 (Ar, Cq), 132.15 (Ar, Cq), 130.24 (Ar, CH), 128.86 (Ar, Cq), 128.78 
(Ar, CH), 128.54 (Ar, CH), 124.92 (Ar, CH), 123.23 (Ar, CH), 121.45 (Ar, Cq), 119.86 (Ar, CH), 115.49 
(Ar, CH), 53.97 (CH2), 27.34 (CH3);  IR (neat, cm-1) ν = 3397 (O-H stretch, broad), 1701 (C=O 
stretch), 1016 (C-O stretch);  MS (EI): m/z 265 (M);  HRMS found: [M+H]+ 266.1180, C17H15NO2+H+ 
requires 266.1176. 
8.2.7 Procedure for the synthesis of (1-tosyl-1H-indol-3-yl)methanol (133) 
N
H
O
N
O
SO
O
1.
 
NaH
r.t.,
 
45
 mins
THF
2.
 
p-TsCl
r.t.,
 
45
 mins
 
Sodium hydride (60% in oil, 328 mg, 8.20 mmol) in dry THF (15 mL) was added slowly to indole-
3-carboxaldehyde (596 mg, 4.10 mmol) in dry THF (20 mL) at 0 oC.  The reaction was then stirred 
at room temperature for 45 minutes.  p-Toluenesulfonyl chloride (938 mg, 4.92 mmol) in dry 
THF (15 mL) was added dropwise to the reaction, and it was stirred at room temperature for 45 
minutes until completion by TLC.  The solvent was removed in vacuo, and the crude product was 
used in the next step of the reaction without further purification.  1H NMR (300 MHz, CDCl3): δH 
= 10.09 (1H, s, CHO), 7.28 – 7.22 (2H, m, Ar), 7.95 (1H, d, J = 7.5 Hz, Ar), 7.85 (2H, d, J = 8.5 Hz, 
Ar), 7.39 (2H, pd, J = 7.5, 1.5 Hz, Ar), 7.29 (2H, d, J = 8.0 Hz, Ar), 2.38 (3H, s, CH3); 13C NMR (75 
MHz, CDCl3) δC = 185.51 (CHO), 146.30 (Ar), 136.38 (Ar), 135.52 (Ar), 134.42 (Ar), 130.46 (Ar), 
127.37 (Ar), 126.44 (Ar), 126.39 (Ar), 125.18 (Ar), 122.73 (Ar), 122.46 (Ar), 113.37 (Ar), 21.83 
(CH3). 
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N
OH
SO
O
N
O
SO
O
NaBH4
r.t.,
 
20
 mins
EtOH
133  
Dry ethanol (30 mL) and sodium borohydride (310 mg, 8.20 mmol) was added to the crude 
reaction from the previous step, and the reaction was stirred at room temperature for 20 
minutes.  Upon completion by TLC, the solvent was removed in vacuo, the excess sodium 
borohydride was quenched with sodium hydroxide solution (1%, 40 mL), and the reaction was 
extracted with ethyl acetate (3 × 20 mL) before being dried (MgSO4), filtered and purified by 
preparative liquid chromatography (19:1  2:1 petroleum ether: ethyl acetate) to yield the title 
product as a yellow gummy solid (600 mg, 49% yield over two steps).  Rf = 0.28 (9:1 petroleum 
ether: ethyl acetate); 1H NMR (300 MHz, CDCl3): δH = 7.99 (1H, d, J = 8.5 Hz, Ar), 7.77 (2H, d, J = 
8.5 Hz, Ar), 7.61 (1H, d, J = 7.5 Hz, Ar), 7.55 (1H, s, Ar), 7.34 (1H, t, J = 7.5 Hz, Ar), 7.29 – 7.18 (3H, 
m, Ar), 4.82 (2H, d, J = 4.5 Hz, CH2), 2.24 (3H, s, CH3), 1.62 (1H, t, J = 5 Hz, OH); 13C NMR (75 MHz, 
CDCl3) δC = 145.15 (Ar, Cq), 135.53 (Ar, Cq), 135.31 (Ar, Cq), 130.05 (Ar, CH), 129.54 (Ar, Cq), 126.99 
(Ar, CH), 125.13 (Ar, CH), 123.92 (Ar, CH), 123.43 (Ar, CH), 122.34 (Ar, Cq), 120.00 (Ar, CH), 113.83 
(Ar, CH), 57.32 (CH2), 21.72 (CH3). 
8.2.8 Procedure for the synthesis of benzo[b]thiophen-3-ylmethanol (134) 
S
O
S
OHNaBH4
r.t.,
 
90
 mins
EtOH
134  
To dry ethanol (20 mL) was added benzo[b]thiophene-3-carbaldehyde (246 mg, 1.52 mmol) and 
sodium borohydride (115 mg, 3.03 mmol), and the reaction was stirred at room temperature for 
90 mins.  When the reaction was complete by TLC, excess sodium borohydride was quenched 
with sodium hydroxide solution (1%, 20 mL), and the reaction was extracted with ethyl acetate 
(3 × 20 mL) before being dried (MgSO4), filtered and concentrated in vacuo to yield the title 
product in quantitative yield (249 mg).  Rf = 0.40 (5:2 petroleum ether: ethyl acetate); 1H NMR 
(300 MHz, CDCl3): δH = 7.90 – 7.83 (2H, m, Ar), 7.44 – 7.34 (3H, m, Ar), 4.92 (2H, s, CH2), 1.95 (1H, 
br s, OH); 13C NMR (75 MHz, CDCl3) δC = 140.87 (Ar), 137.75 (Ar), 136.04 (Ar), 124.69 (Ar), 124.32 
(Ar), 123.95 (Ar), 122.99 (Ar), 122.05 (Ar), 59.88 (CH2); MS (EI): m/z 164 (M). 
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8.2.9 Procedure for the synthesis of 2-(indolin-2-yl)phenol (149) 
N
H
HO
N
H
HO
NaBH3CN
r.t.,
 
26
 
h
AcOH4 149  
To a flask containing glacial acetic acid (10 mL) was added compound 4(1.0 mmol, 209 mg) and 
sodium cyanoborohydride (12.0 mmol, 754 mg), and the reaction was stirred at room 
temperature for 26 hours.  The crude reaction was then quenched by careful addition of water 
(100 mL), before adding solid sodium hydroxide to pH ~12.  The crude reaction was extracted 
with ethyl acetate (3 × 20 mL), dried over MgSO4 and filtered.  The product was purified via flash 
column chromatography on silica gel (19:1 petroleum ether: ethyl acetate) to afford the title 
compound as a pale orange solid (92 mg, 43% yield).  Rf =0.60 (3:1 petroleum ether: ethyl 
acetate), 0.16 (19:1 petroleum ether: ethyl acetate); 1H NMR (300 MHz, CDCl3): δH = 9.75 (1H, br 
s, OH), 7.28 – 7.10 (3H, m, Ar), 7.06 (1H, d, J = 7.5 Hz, Ar), 6.98 – 6.80 (4H, m, Ar), 4.92 (1H, dd, J 
= 12.5, 8.5 Hz, CH), 4.34 (1H, br s, NH), 3.38 – 3.04 (2H, m, CH2); 13C NMR (75 MHz, CDCl3); δC = 
156.88 (Cq, Ar), 148.70 (Cq, Ar), 130.80 (Cq, Ar), 129.12 (CH, Ar), 128.46 (CH, Ar), 127.67 (CH, Ar), 
124.93 (Cq, Ar), 124.80 (CH, Ar), 121.46 (CH, Ar), 119.54 (CH, Ar), 117.64 (CH, Ar), 111.95 (CH, 
Ar), 65.59 (CH), 38.42 (CH2); MS (ESI): m/z  212 ([M+H]+). 
8.2.10 Procedure for the synthesis of 2-(2-(benzyloxy)phenyl)-1H-indole (154) 
N
H
HO
N
H
O
BnBr
K2CO3
50
 oC,
 
18
 
h
DMF4
154  
To a flask containing DMF (15 mL), compound 4 (0.62 mmol, 130 mg) and potassium carbonate 
(172 mg, 1.24 mmol) was added benzyl bromide (88 µL, 0.74 mmol), and the reaction was stirred 
at 50oC overnight.  Upon completion by TLC, the crude reaction was diluted with water (90 mL), 
and was extracted with ethyl acetate (3 × 20 mL).  The organic layer was washed with water (10 
mL) and brine (10 mL), and was purified by preparative liquid chromatography (19:1 petroleum 
ether: ethyl acetate) to afford the title compound as a pale yellow solid (160 mg, 86% yield).  Rf 
= 0.47 (9:1 petroleum ether: ethyl acetate), 0.28 (19:1 petroleum ether: ethyl acetate);  1H NMR 
(300 MHz, CDCl3): δH =9.78 (1H, br s, NH), 7.91 (1H, d, J = 7.5 Hz, Ar), 7.65 (1H, d, J = 7.0 Hz, Ar), 
7.58 – 7.41 (5H, m, Ar), 7.34 – 7.05 (6H, m, Ar), 6.95 (1H, s, Ar), 5.24 (2H, s, CH2);  13C NMR (75 
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MHz, CDCl3): δC = 155.02 (Ar, Cq), 136.47 (Ar, Cq), 136.14 (Ar, Cq), 135.92 (Ar, Cq), 129.07 (Ar, CH), 
128.70 (Ar, CH), 128.61 (Ar, CH), 128.38 (Ar, CH), 128.03 (Ar, Cq), 127.88 (Ar, CH), 122.07 (Ar, 
CH), 121.88 (Ar, CH), 121.06 (Ar, Cq), 120.33 (Ar, CH), 119.87 (Ar, CH), 113.61 (Ar, CH), 110.94 
(Ar, CH), 99.85 (Ar, CH), 71.38 (CH2);  IR (neat, cm-1) ν = 3045.2 (Aromatic C-H stretch), 1226.7 
(C-O stretch), 1007.5 (C-O stretch), 737.5 (Aromatic C-H out-of-plane bend);  MS (APCI): m/z 300 
([M+H]+). 
8.2.11 Procedure for the synthesis of 2-(2-((tert-butyldimethylsilyl)oxy)phenyl)-1H-indole 
(155) 
N
H
HO
N
H
O
TBS
25
 oC,
 
18
 
h
DMF
TBS-Cl
Imidazole
4 155  
To a flask containing compound 4 (0.65 mmol, 135 mg) and imidazole (3.9 mmol, 266 mg) in 
DMF (25 mL) was added tert-butyldimethylsilyl chloride (3.2 mmol, 482 mg), and the reaction 
was stirred at 25 oC for 18 hours.  The reaction was quenched with water (75 mL), extracted with 
ethyl acetate (3 × 25 mL) and purified via preparative liquid chromatography (petroleum ether) 
to yield the title compound as a white solid (179 mg, 85% yield).  M.p. 92 - 94 oC;  Rf = 0.25 
(petroleum ether);  1H NMR (300 MHz, CDCl3): δH = 9.54 (1H, br s, NH), 7.78 (1H, dd, J = 8.0, 1.5 
Hz, Ar), 7.65 (1H, d, J = 7.5, Ar), 7.35 (1H, d, J = 7.5 Hz, Ar), 7.25 – 7.03 (4H, m, Ar), 6.96 (1H, dd, 
J = 8.0, 1.0 Hz, Ar), 6.82 (1H, s, Ar), 1.05 (9H, s, tBu), 0.22 (6H, s, 2 × Me);  13C NMR (75 MHz, 
CDCl3): δC = 152.02 (Ar, Cq), 136.37 (Ar, Cq), 135.99 (Ar, Cq) , 129.12 (Ar, CH), 128.46 (Ar, CH) , 
128.32 (Ar, Cq), 123.31 (Ar, Cq), 122.35 (Ar, CH), 121.90 (Ar, CH), 120.74 (Ar, CH), 120.43 (Ar, CH), 
119.88 (Ar, CH), 110.70 (Ar, CH), 99.81 (Ar, CH), 26.07 (C(CH3)3), 18.49 (3 × C(CH3)3), -4.11 (2 × 
Me);  IR (liquid film, cm-1) ν = 1242 (SiO-C);  MS (EI): m/z 266 (M-tBu, 100%), 323 (M, 22%);  HRMS 
found: [M+H]+ 324.1779, C20H25NOSi+H+ requires 324.1778. 
8.2.12 Procedure for the synthesis of 2-(1H-indol-2-yl)phenyl methanesulfonate (156) 
N
H
O
S
O
N
H
HO Et3N
DMAP
Me
O
Cl
S
O M
e
O r.t.,
 
18
 
h
CH2Cl24
156  
Compound 4 (0.97 mmol, 204 mg), methanesulfonyl chloride (1.16 mmol, 90 µL), triethylamine 
(1.46 mmol, 205 µL) and DMAP (0.1 mmol, 12 mg) was stirred in CH2Cl2 (10 mL) at room 
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temperature for 18 hours.  Upon completion by TLC, the crude reaction was washed with 1M 
HCl (2 × 10 mL), water (10 mL) and brine (10 mL) to afford the title product as an orange solid 
(281 mg, 100% yield).  M.p. 111 - 114oC (from CH2Cl2);  Rf = 0.27 (3:1 petroleum ether: ethyl 
acetate);  1H NMR (300 MHz, CDCl3): δH = 8.95 (1H, br s, NH), 7.79-7.72 (1H, m, Ar), 7.66 (1H, d, 
J = 8.0 Hz, Ar), 7.56 – 7.50 (1H, m, Ar)7.49 – 7.39 (3H, m, Ar), 7.25 (1H, td, J = 7.5, 1.0 Hz, Ar), 
7.16 (1H, td, J = 7.5, 1.0 Hz, Ar), 6.87 (1H, dd, J = 2.0, 1.0 Hz, Ar), 2.79 (3H, s, CH3);  13C NMR (75 
MHz, CDCl3): δC = 145.73 (Ar, Cq), 136.89 (Ar, Cq), 133.07 (Ar, Cq), 130.20 (Ar, CH), 129.36 (Ar, 
CH), 128.28 (Ar, Cq), 128.23 (Ar, CH), 126.12 (Ar, Cq), 124.26 (Ar, CH), 123.17 (Ar, CH), 120.96 (Ar, 
CH), 120.58 (Ar, CH), 111.38 (Ar, CH), 103.38 (Ar, CH), 37.60 (CH3);  IR (neat, cm-1) ν = 1358 (S=O 
stretch), 1154 (S=O stretch);  MS (ESI): m/z 288 ([M+H]+);  HRMS found: [M+H]+ 288.0691, 
C15H13NO3S+H+ requires 288.0689. 
8.2.13 Procedure for the synthesis of 2-(1H-indol-2-yl)phenyl benzoate (157) 
N
H
O
O
N
H
HO O
Cll
Ett3N
DMAP
rr
.
.tt
.
.,,
 
 18
 
h
CH2Cll24
157  
Compound 4 (0.97 mmol, 202 mg), benzoyl chloride (1.16 mmol, 135 µL), triethylamine (1.46 
mmol, 203 µL) and DMAP (0.1 mmol, 12 mg) was stirred in CH2Cl2 (10 mL) at room temperature 
for 18 hours.  Upon completion by TLC, the crude reaction was washed with 1M HCl (2 × 10 mL), 
water (10 mL) and brine (10 mL).  The crude reaction was purified via preparative liquid 
chromatography on silica gel (19:1 to 9:1 petroleum ether: ethyl acetate) to afford the title 
product as a yellow solid (141 mg, 47% yield).  M.p. 148 - 168 oC (decomposes);  Rf = 0.18 (9:1 
petroleum ether: ethyl acetate);  1H NMR (300 MHz, CDCl3): δH = 8.60 (1H, s, NH), 8.23 (2H, d, J 
= 7.5 Hz, Ar), 7.79 – 7.03 (11H, m, Ar), 6.83 (1H, s, Ar);  13C NMR (75 MHz, CDCl3): δC = 165.24 
(C=O), 147.66 (Ar, Cq), 136.54 (Ar, Cq), 134.09 (Ar, CH), 133.73 (Ar, Cq), 130.29 (Ar, CH), 129.27 
(Ar, Cq), 129.08 (Ar, CH), 128.96 (Ar, CH), 128.80 (Ar, CH), 128.61 (Ar, Cq), 126.80 (Ar, CH), 125.85 
(Ar, Cq), 123.78 (Ar, CH), 122.50 (Ar, CH), 120.79 (Ar, CH), 120.14 (Ar, CH), 110.96 (Ar, CH), 102.80 
(Ar, CH);  IR (neat, cm-1) ν = 1725 (C=O stretch), 1260 (C-O stretch); MS (ESI): m/z 314 ([M+H]+);  
HRMS found: [M+H]+ 314.1184, C21H15NO2+H requires 314.1176. 
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8.2.14 Procedure for the synthesis of 2-(1H-indol-2-yl)phenyl acetate (158) 
N
H
HO
N
H
O
O
Acetic
 
Acid
TEA
DMAP
r.t.,
 
16
 
h
CH2Cl24 158  
2-(1H-Indol-2-yl)phenol (101.7 mg, 0.59 mmol), acetic acid (0.06 mL, 0.54 mmol), triethylamine 
(54 µL) and DMAP (6 mg, 0.05 mmol) were added to CH2Cl2 (5 mL) and stirred at room 
temperature for 16 h.  The reaction was washed with 1 M HCl (3 × 5 mL), water (1 × 5 mL) and 
brine (1 × 5 mL), dried (MgSO4), filtered and the solvent was removed in vacuo.  The reaction 
was purified by flash column chromatography on silica gel (5:1 petroleum ether: ethyl acetate) 
to yield the title product as an off-white solid (84.3 mg, 71% yield).  M.p. 112-127 oC; Rf = 0.23 
(5:1 petroleum ether: ethyl acetate); 1H NMR (300 MHz, CDCl3): δH = 8.50 (1H, s, NH), 7.70-7.62 
(2H, m, Ar), 7.43-7.32 (3H, m, Ar), 7.26-7.09 (3H, m, Ar), 6.78-6.82 (1H, m, Ar), 2.31 (3H, s, CH3); 
13C NMR (75 MHz, CDCl3): δC = 169.42 (C=O), 147.58 (Ar), 136.59 (Ar), 133.92 (Ar), 129.28 (Ar), 
128.88 (Ar), 128.71 (Ar), 126.81 (Ar), 125.86 (Ar), 123.67 (Ar), 122.65 (Ar), 120.88 (Ar), 120.32 
(Ar), 111.00 (Ar), 102.73 (Ar), 21.40 (CH3); IR (neat, cm-1) ν = 3357 (N-H stretch), 1735 (C=O 
stretch), 1368 (aromatic C-C stretch), 1220 (C-O stretch);  MS (ESI): m/z 252 ([M+H]+);  HRMS 
found: [M+H]+ 252.1021, C16H13NO2+H+ requires 252.1019. 
8.2.15 Procedure for the synthesis of 2-(1H-indol-2-yl)phenyl heptanoate (159) 
N
H
O
O
N
H
HO
O
Cll
Ett3N
DMAP
rr
.
.tt
.
.,,
 
 18
 
 h
CH2Cll24
159  
Compound 4 (0.92 mmol, 192 mg), heptanoyl chloride (1.10 mmol, 171 µL), triethylamine (1.38 
mmol, 192 µL) and DMAP (0.1 mmol, 12 mg) was stirred in CH2Cl2 (10 mL) at room temperature 
for 18 hours.  Upon completion by TLC, the crude reaction was washed with 1M HCl (2 × 10 mL), 
water (10 mL) and brine (10 mL).  The crude reaction was purified via preparative liquid 
chromatography on silica gel (19:1 to 9:1 petroleum ether: ethyl acetate) to afford the title 
product as a yellow solid (225 mg, 76% yield).  M.p. 51 - 54 oC;  Rf = 0.15 (9:1 petroleum ether: 
ethyl acetate);  1H NMR (300 MHz, CDCl3): δH = 8.53 (1H, br s, NH), 7.70 – 7.61 (2H, m, Ar), 7.41 
– 7.27 (3H, m, Ar), 7.25 – 7.10 (3H, m, Ar), 6.81 – 6.76 (1H, m, Ar), 2.59 (2H, t, J = 7.5 Hz, CH2), 
1.70 (2H, pent, J = 7.5 Hz, CH2), 1.39 – 1.19 (6H, m, 3 × CH2), 0.87 (3H, t, J = 6.5 Hz, CH3);  13C NMR 
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(75 MHz, CDCl3): δC = 172.36 (C=O), 147.64 (Ar, Cq), 136.54 (Ar, Cq), 133.96 (Ar, Cq), 129.35 (Ar, 
CH), 128.82 (Ar, CH), 128.65 (Ar, Cq), 126.65 (Ar, CH), 125.89 (Ar, Cq), 123.65 (Ar, CH), 122.55 (Ar, 
CH), 120.81 (Ar, CH), 120.23 (Ar, CH), 110.97 (Ar, CH), 102.64 (Ar, CH), 34.66 (CH2), 31.53 (CH2), 
28.88 (CH2), 24.90 (CH2), 22.54 (CH2), 14.14 (CH3);  IR (neat, cm-1) ν = 1145 (C-O stretch), 1746 
(C=O stretch), 2928 (C-H stretch);  MS (ESI): m/z 322 ([M+H]+);  HRMS found: [M+H]+ 322.1805, 
C21H23NO2+H requires 322.1802. 
8.2.16 Procedure for the synthesis of 2-(1H-indol-3-yl)phenol (160) 
O
OH
O
O
O
O
Me
H2SO4
 
(cat
.
)
r.t.,
 
18
 
h
MeOH
 
2-Benzyloxyphenylacetic acid (983 mg, 4.06 mmol) was stirred in methanol (45 mL) and sulfuric 
acid (2 drops) at room temperature for 72 hours to yield methyl 2-(2-(benzyloxy)phenyl)acetate 
as a pale red viscous oil. Rf = 0.60 (3:1 petroleum ether: ethyl acetate); 1H NMR (300 MHz, CDCl3): 
δH = 7.45 – 7.29 (5H, m, Ar), 7.29 – 7.18 (2H, m, Ar), 6.94 (2H, m, Ar), 5.08 (2H, s, O-CH2-Ar), 3.70 
(2H, s, Ar-CH2-COOMe), 3.64 (3H, s, CH3). 
O
O
O
Me
O
OH
LiAlH4
r.t.,
 
90
 mins
THF
 
(dry)
 
The crude methyl ester was reduced to the alcohol by stirring in THF (dry, 15 mL) at 0oC and 
adding LiAlH4 (308 mg, 8.11 mmol) under an atmosphere of nitrogen.  The ice bath was then 
removed, and the reaction was stirred at room temperature for 90 minutes.  The reaction was 
quenched with NaOH(aq) (10 mL, 0.1 M).  The crude product was extracted with ethyl acetate 
(3 × 10 mL), and the combined organic layers were dried over MgSO4 and filtered before being 
concentrated in vacuo to yield crude 2-(2-(benzyloxy)phenyl)ethanol as a pale yellow oil. Rf = 
0.22 (3:1 petroleum ether: ethyl acetate); 1H NMR (300 MHz, CDCl3): δH = 7.49 – 7.32 (5H, m, 
Ar), 7.28 – 7.19 (2H, m, Ar), 7.00 - 6.91 (2H, m, Ar), 5.10 (2H, s, Ar-CH2-OAr), 3.87 (2H, t, J = 6.5, 
CH2-OH), 2.98 (2H, t, J = 6.5 Hz, Ar-CH2-CH2OH), 1.95 (1H, br s, OH). 
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O
OH
O
O
O
O
Pyridinium
 chlorochromate
84 : 16
r.t.,
 
22
 
h
CH2Cl2
 
The crude alcohol was oxidised to the aldehyde by stirring with pyridinium chlorochromate 
(1.31 g, 6.08 mmol) in CH2Cl2 (40 mL) in the presence of crushed molecular sieves (650 mg) at 
room temperature for 22 hours.  The solvent was removed in vacuo, and the crude reaction was 
dissolved in diethyl ether (40 mL), before being filtered through Celite®.  The crude reaction was 
purified by flash column chromatography (19:1 petroleum ether: ethyl acetate) to yield 0.70 g 
of an 84:16 ratio of products,[306] which included 468 mg (51% yield over 3 steps) of the major 
product 2-(2-(benzyloxy)phenyl)acetaldehyde as a pale yellow oil.  Rf = 0.61 (3:1 petroleum 
ether: ethyl acetate); 1H NMR (300 MHz, CDCl3): δH = 9.72 (1H, t, J = 2.0 Hz, CHO), 7.45 – 7.24 
(6H, m, Ar), 7.20 - 7.14 (1H, m, Ar), 7.00 - 6.93 (2H, m, Ar), 5.08 (2H, s, O-CH2-Ar), 3.70 (2H, d, J 
= 2.0 Hz, CH2-CHO). 
O
O
N
H
O
TssOH
mm
.
.ww
.
.
 
200
 ooC
20
 
 mmiinnss
NeeaattNH
NH2
 
The mixture of aldehydes (0.70g, of which 468 mg, 2.07 mmol was the pictured aldehyde) was 
added to a microwave vial with phenyl hydrazine (336 mg, 3.11 mmol) and p-toluenesulfonic 
acid (40 mg, 0.21 mmol) and heated at 200 oC for 20 minutes.  The crude product was purified 
by flash column chromatography on silica gel (19:1  9:1 petroleum ether: ethyl acetate) to 
yield 3-(2-(benzyloxy)phenyl)-1H-indole (200 mg, 32% yield).  1H NMR (300 MHz, CDCl3): δH = 
8.12 (1H, br s, NH), 7.95 (1H, d, J = 7.5 Hz, Ar), 7.79 (1H, dd, J = 7.5, 1.5 Hz, Ar), 7.53 (1H, d, J = 
2.5 Hz, Ar), 7.42 – 7.11 (11H, m, Ar), 5.14 (2H, s, CH2). 
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r.t.,
 
24
 
h
MeOH
160  
Methanol (10 mL) was added to a two-necked flask containing 3-(2-(benzyloxy)phenyl)-1H-
indole (200 mg, 0.67 mmol) and palladium on carbon (20 mg, 10 wt%).  The flask was evacuated 
and backfilled with nitrogen twice, before being evacuated and backfilled with hydrogen twice.  
The reaction was then stirred at room temperature under an atmosphere of hydrogen for 24 
hours, and the crude product was filtered through Celite® and purified by flash column 
chromatography on silica gel (4:1  3:1 petroleum ether: ethyl acetate) to yield 2-(1H-indol-3-
yl)phenol (119 mg, 85% yield) as a thick orange oil.  Rf = 0.29 (3:1 petroleum ether: ethyl acetate), 
0.12 (4:1 petroleum ether: ethyl acetate);  1H NMR (300 MHz, CDCl3): δH = 8.31 (1H, br s, NH), 
7.73 (1H, d, J = 8 Hz, Ar), 7.50 (1H, dd, J = 7.5, 1.5 Hz, Ar), 7.45 – 7.31 (3H, m, Ar), 7.31 – 7.20 (2H, 
m, Ar), 7.19 – 7.08 (2H, m, Ar), 5.69 (1H, br s, OH);  13C NMR (75 MHz, CDCl3): δC = 153.22 (Ar, 
Cq), 136.34 (Ar, Cq), 130.89 (Ar, CH), 128.57 (Ar, CH), 126.21 (Ar, Cq), 123.43 (Ar, CH), 122.91 (Ar, 
CH), 121.09 (Ar, Cq), 120.74 (Ar, CH), 120.54 (Ar, CH), 119.74 (Ar, CH), 115.45 (Ar, CH), 111.66 
(Ar, CH); MS (ESI): m/z  208 ([M-H]-);  HRMS found: [M+H]+ 210.0913, C14H11NO+H+ requires 
210.0913. 
8.2.17 Procedure for the synthesis of 2-(naphthelen-7-yl) phenol (168)[307] 
Br B
OH
OH
OH OHDIPA
Pd(OAc)2
H2O 168  
To a flask containing water (5 mL), was added 2-bromonaphthalene (331 mg, 1.6 mmol), 
2-hydroxyphenylboronic acid (500 mg, 2.4 mmol), diisopropylamine (DIPA, 0.45 mL, 3.2 mmol) 
and palladium (II) acetate (12.3 mg, 0.25 mol%).  The reaction was heated to reflux for 3.5 hours, 
and was allowed to cool to room temperature before being diluted with brine (40 mL) and 
extracted with ethyl acetate (5 × 20 mL).  The reaction was filtered through Celite®, and the 
filtrate dried (MgSO4) and filtered.  The crude reaction was purified via flash column 
chromatography on silica gel (5:1 petroleum ether: ethyl acetate) to afford the title compound 
as a pale yellow solid (288 mg, 82% yield).  M.p. 93-96 oC;  Rf = 0.37 (5:1 petroleum ether: ethyl 
acetate);  1H NMR (300 MHz, CDCl3): δH = 8.03-7.97 (2H, m, Ar), 7.96-7.88 (2H, m, Ar), 7.66-7.54 
(3H, m, Ar), 7.43-7.30 (2H, m, Ar), 7.13 (2H, m, Ar), 5.42 (1H, s, OH);  13C NMR (75 MHz, CDCl3): 
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δC = 152.66 (Ar, Cq), 134.57 (Ar, Cq), 133.66 (Ar, Cq), 132.77 (Ar, Cq), 130.25 (Ar, CH), 129.35 (Ar, 
CH), 129.20 (Ar, CH), 128.15 (Ar, Cq), 128.13 (Ar, CH), 127.94 (Ar, CH), 127.88 (Ar, CH), 127.23 
(Ar, CH), 126.72 (Ar, CH), 126.52 (Ar, CH), 121.07 (Ar, CH), 116.02 (Ar, CH);  IR (neat, cm-1) ν = 
3520 (OH stretch), 750 (Aromatic C-C bend);  MS (EI): m/z 220 (M);  HRMS found: [M+H]+ 
221.0960, C16H12O+H+ requires 221.0961.  
8.2.18 Procedure for the synthesis of 2-(2-hydroxyphenyl)-3-methyl-3H-indol-3-ol (198) 
OOH
N
H
NH2 N
H HO
TsOH
m.w. 200
 oC
20
 mins
Neat
186  
Method 1: 
2′-Hydroxypropiophenone (93.7 mg, 0.87 mmol), phenylhydrazine (200.8 mg, 1.34 mmol) and 
p-toluenesulfonic acid (18.6 mg, 0.10 mmol) were heated under microwave irradiation at 200°C 
for 20 minutes.  The crude reaction product was purified via preparative liquid chromatography 
(petroleum ether  5:1 petroleum ether: ethyl acetate) to yield 2-(3-methyl-1H-indol-2-
yl)phenol as a highly viscous yellow oil (143 mg, 74% yield). 
Method 2:[308] 
2’-Hydroxypropiophenone (10 mmol, 1.50 g), phenylhydrazine (10 mmol, 1.08 g) and acetic acid 
(4 drops) were stirred in ethanol (10 mL) at reflux for 2 hours.  The reaction was then cooled to 
room temperature, and the ethanol was removed in vacuo.  Polyphosphoric acid (5.5 g) was 
then added, and the reaction was heated at 170oC for 30 mins.  The reaction was cooled to room 
temperature, and diluted with water (100 mL), and neutralised with sodium hydroxide (1 M).  
The crude reaction was extracted with CH2CH2 (2 × 50 mL), dried over MgSO4 and filtered.  The 
crude reaction was purified via preparative liquid chromatography (4:1 petroleum ether: ethyl 
acetate) to afford 2-(3-methyl-1H-indol-2-yl)phenol as a highly viscous yellow oil (1.61g, 72% 
yield). 
1H NMR (300 MHz, CDCl3): δH = 8.06 (1H, br s, NH), 7.64 (1H, d, J = 7.5 Hz, Ar), 7.41 – 7.30 (3H, 
m, Ar), 7.26 (1H, td, J = 7.5, 1.5 Hz, Ar), 7.19 (1H, td, J = 7.5, 1.0 Hz, Ar), 7.08 – 7.00 (2H, m, Ar), 
5.55 (1H, br s, OH), 2.33 (3H, s, CH3); 13C NMR (75 MHz, CDCl3): δC = 153.45 (Cq, Ar), 136.56 (Cq 
Ar), 130.52 (CH, Ar), 130.15 (CH, Ar), 129.47 (Cq, Ar), 129.40 (Cq, Ar), 122.84 (CH, Ar), 120.81 (CH, 
Ar), 119.91 (CH, Ar), 119.23 (Cq, Ar), 119.16 (CH, Ar), 115.95 (CH, Ar), 111.09 (CH, Ar), 110.70 (Cq, 
Ar), 9.48 (CH3);  IR (neat, cm-1) ν = 3399 (OH stretch), 744 (Ar C-H bend);  MS (EI): m/z 223 ([M]+). 
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186 198  
The title product was formed by the degradation of 2-(3-methyl-1H-indol-2-yl)phenol in air, and 
was purified by recrystallization (ethyl acetate and petroleum ether).  M.p. 135-136 oC;  Rf = 0.28 
(7:1 petroleum ether: ethyl acetate);  1H NMR (300 MHz, CDCl3): δH = 13.59 (1H, br s, Ar-OH), 
8.20 (1H, dd, J = 8.5, 1.5 Hz, Ar), 7.52 (1H, d, J = 7Hz, Ar), 7.47 – 7.28 (4H, m, Ar), 7.01 – 6.93 (2H, 
m, Ar), 2.78 (1H, br s, OH), 1.78 (3H, s, CH3);  13C NMR (75 MHz, CDCl3): δC = 181.85 (Ar, Cq), 161.65 
(Ar, Cq), 149.95 (Ar, Cq), 141.11 (Ar, Cq), 133.47 (Ar, CH), 129.94 (Ar, CH), 129.76 (Ar, CH), 126.85 
(Ar, CH), 121.97 (Ar, CH), 120.33 (Ar, CH), 118.87 (Ar, CH), 117.83 (Ar, CH), 114.89 (C-PhOH), 
84.73 (C-CH3), 26.25 (CH3);  IR (neat, cm-1) ν = 3414 (O-H stretch), 1090 (C-OH stretch), 741 (C-H 
bend);  MS (EI): m/z  239 ([M]+);  HRMS found: [M-H+] 238.0875, C15H13NO2-H+ requires 238.0874; 
Anal. Calcd for C15H13NO2: C, 75.3 %; H, 5.5 %; N, 5.8 %. Found: C, 75.0 %; H, 5.5 %; N, 5.8 %.  XRD 
data is shown in Appendix 8. 
8.2.19 Procedure for the synthesis of 2-(1H-indol-2-yl)-4-methylphenol (244) 
OOH
N
H
NH2 N
H HO
TsOH
m.w. 200
 oC
20
 mins
Neat 244  
Phenylhydrazine (108 mg, 1.00 mmol), 2-hydroxy-5-methylacetophenone (216 mg, 1.44 mmol) 
and p-toluenesulfonic acid (20 mg, 0.10 mmol) were heated under microwave irradiation at 
200°C for 20 minutes.  The crude reaction was purified via flash column chromatography on 
silica gel (5:1 petroleum ether: ethyl acetate) to afford the title compound as a dark solid (68 
mg, 31% yield).  Rf = 0.09 (5:1 petroleum ether: ethyl acetate);  1H NMR (300 MHz, CDCl3): δH = 
9.28 (1H, br s, NH), 7.65 (1H, d, J = 8.0 Hz, Ar), 7.51 (1H, d, J = 1.5 Hz, Ar), 7.42 (1H, d, J = 8.0 Hz, 
Ar), 7.20 (1H, td, J = 7.5, 1.0 Hz, Ar), 7.13 (1H, td, J = 7.5, 1.0 Hz, Ar), 7.01 (1H, dd, J – 8.0, 2.0 Hz, 
Ar), 6.78 – 6.88 (2H, m, Ar), 5.43 (1H, br s, OH), 2.25 (3H, s, CH3);  13C NMR (100 MHz, CDCl3): δC 
= 150.10 (Cq, Ar), 136.62 (Cq, Ar), 135.27 (Cq, Ar), 130.87 (Cq, Ar), 129.61 (CH, Ar), 128.74 (CH, 
Ar), 128.65 (Cq, Ar), 122.27 (CH, Ar), 120.55 (CH, Ar), 120.22 (CH, Ar), 119.01 (Cq, Ar), 116.64 (CH, 
Ar), 111.13 (CH, Ar), 100.23 (CH, Ar), 20.70 (CH3); MS (EI): m/z 224 ([M+H]+);  HRMS found: [M-H]- 
222.0924, C15H13NO-H+ requires 222.0924.
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APPENDICIES 
 
 A2 
 
Appendix 1 – Raw data and calculations used in the determination of 
appropriate microwave irradiation time in the microwave-assisted Fischer 
indole synthesis of 2-arylindoles 
As discussed in Section 4.4.3, a method for the microwave-assisted Fischer indole synthesis was 
required.  The methodology was developed while synthesising compound 186 (Figure 96). 
N
H HO
186  
Figure 96 - Compound 186 
Reactions were run at 160 oC and 200 oC for between one and 50 minutes, and the product yield 
was determined by GC-MS, using 2-phenylindole as an internal standard.  The relative peak area 
of compound 186 to 2-phenylindole was found to be 1.34.  The raw data for the methodological 
work on this reaction is shown in Table 29 and Table 30. 
T = 160 oC Peak Area 
Normalisation 
Factor 
Normalised Area  
Time (mins) Standard Product Standard Product Yield (%) 
1 1.39×109 3.93×107 1.34 1.39×109 5.27×107 3 
2 1.15×109 6.31×107 1.34 1.15×109 8.46×107 5 
5 1.24×109 1.42×108 1.34 1.24×109 1.90×107 11 
10 1.22×109 2.05×108 1.34 1.22×109 2.75×108 17 
20 1.39×109 4.25×108 1.34 1.39×109 5.70×108 31 
Table 29 - Table of peak areas from GC-MS, and the yield calculation at 160 oC 
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T = 200 oC Peak Area 
Normalisation 
Factor 
Normalised Area  
Time (mins) Standard Product Standard Product Yield (%) 
1 2.36×109 8.70×108 1.34 2.36×109 1.17×109 49 
2 2.73×109 1.33×109 1.34 2.73×109 1.78×109 65 
5 2.99×109 1.62×109 1.34 2.99×109 2.17×109 73 
10 3.40×109 1.98×109 1.34 3.40×109 2.65×109 78 
20 2.06×109 1.33×109 1.34 2.06×109 1.78×109 86 
30 7.76×108 5.18×108 1.34 7.76×108 6.94×108 90 
40 9.17×108 5.94×108 1.34 9.17×108 7.96×108 87 
50 1.07×108 7.40×108 1.34 1.07×109 9.92×108 93 
Table 30 - Table of peak areas from GC-MS, and the yield calculation at 200 oC 
 
  
 
A4 
Appendix 2 – Analogues of compound 4 found as part of the similarity search 
Structure ZINC Identifier Similarity Shape Electronic 
Isomers and 
pseudoisomers 
Different 
core 
Very 
different 
No relevant 
functional group 
N
H
O
N
 
ZINC45235565 0.765 0.633 0.898    × 
N+
OH
O
-
 
ZINC00159358 0.766 0.660 0.873   ×  
N
 
ZINC01025941 0.766 0.607 0.925    × 
N
 
ZINC02144604 0.766 0.607 0.926    × 
NH2
N
 
ZINC37401152 0.766 0.603 0.930  ×   
N
H
N
H2N
 
ZINC00144326 0.767 0.639 0.895  ×   
  
 
A5 
Structure ZINC Identifier Similarity Shape Electronic 
Isomers and 
pseudoisomers 
Different 
core 
Very 
different 
No relevant 
functional group 
N
N
HO
 
ZINC01391331 0.767 0.617 0.918  ×   
O
O
 
ZINC00397633 0.767 0.595 0.940    × 
H
N
N
NH2
H2N
 
ZINC00236875 0.768 0.611 0.924  ×   
O
NH2  
ZINC02538818 0.768 0.617 0.919  ×   
N
 
ZINC71711321 0.768 0.617 0.919    × 
N
H
O
 
ZINC13403054 0.768 0.645 0.890    × 
  
 
A6 
Structure ZINC Identifier Similarity Shape Electronic 
Isomers and 
pseudoisomers 
Different 
core 
Very 
different 
No relevant 
functional group 
N
N
N
 
ZINC13194625 0.768 0.638 0.898    × 
H
N
N
 
ZINC00507751 0.769 0.616 0.921    × 
H
N
N
H2N  
ZINC00122913 0.769 0.618 0.919  ×   
O
OH
 
ZINC03847971 0.769 0.591 0.947    × 
N
O
S
 
ZINC00478097 0.769 0.601 0.937    × 
SNH
O  
ZINC65339301 0.769 0.600 0.938  ×   
  
 
A7 
Structure ZINC Identifier Similarity Shape Electronic 
Isomers and 
pseudoisomers 
Different 
core 
Very 
different 
No relevant 
functional group 
H
N O
 
ZINC65339268 0.769 0.624 0.914  ×   
H
N
NN+
O
-
 
ZINC46085466 0.770 0.598 0.941    × 
N
H
O
 
ZINC32099770 0.770 0.641 0.899  ×   
H
N
N
HO
NH2  
ZINC00246170 0.770 0.618 0.921  ×   
OH
+H3N
 
ZINC01716698 0.770 0.670 0.870   ×  
  
 
A8 
Structure ZINC Identifier Similarity Shape Electronic 
Isomers and 
pseudoisomers 
Different 
core 
Very 
different 
No relevant 
functional group 
NN
H
F
 
ZINC95835619 0.770 0.638 0.902    × 
H
N
N
HO
 
ZINC79387317 0.770 0.618 0.923    × 
H
N
 
ZINC23625305 0.771 0.599 0.942    × 
N
H
O
 
ZINC65339264 0.771 0.600 0.942  ×   
N
H
NCl
H2N
 
ZINC40450030 0.771 0.618 0.924  ×   
N
HO  
ZINC00056346 0.771 0.593 0.949  ×   
  
 
A9 
Structure ZINC Identifier Similarity Shape Electronic 
Isomers and 
pseudoisomers 
Different 
core 
Very 
different 
No relevant 
functional group 
N
H
N
N+
O-
O
 
ZINC00188622 0.771 0.645 0.897    × 
O
NH
O  
ZINC65490232 0.771 0.601 0.941  ×   
O
N
H
F
OH
 
ZINC06567825 0.771 0.575 0.968   ×  
HO
O
 
ZINC04824058 0.772 0.622 0.921    × 
H
N
N
N  
ZINC66091588 0.772 0.636 0.908    × 
H
N
N
HO  
ZINC03881190 0.772 0.623 0.920  ×   
  
 
A10 
Structure ZINC Identifier Similarity Shape Electronic 
Isomers and 
pseudoisomers 
Different 
core 
Very 
different 
No relevant 
functional group 
N
O  
ZINC00364176 0.772 0.606 0.939    × 
N
S
S
 
ZINC00329431 0.772 0.607 0.937    × 
O
O
 
ZINC00080737 0.772 0.682 0.863    × 
H
N
N
N  
ZINC13284363 0.773 0.628 0.918    × 
O
N
OOH  
ZINC00148440 0.775 0.609 0.941  ×   
  
 
A11 
Structure ZINC Identifier Similarity Shape Electronic 
Isomers and 
pseudoisomers 
Different 
core 
Very 
different 
No relevant 
functional group 
O
N
 
ZINC00559647 0.776 0.624 0.928    × 
N
NH2
 
ZINC12350724 0.777 0.611 0.943  ×   
N+N
H  
ZINC00393231 0.777 0.665 0.889    × 
H
N
N+
 
ZINC01705340 0.778 0.646 0.909    × 
N
H
NH3
+
 
ZINC14001405 0.778 0.676 0.881    × 
O
HN
 
ZINC05480960 0.778 0.609 0.947    × 
  
 
A12 
Structure ZINC Identifier Similarity Shape Electronic 
Isomers and 
pseudoisomers 
Different 
core 
Very 
different 
No relevant 
functional group 
O
H2N
 
ZINC00122320 0.778 0.638 0.918  ×   
N N
 
ZINC34268568 0.778 0.635 0.922    × 
ON  
ZINC15084532 0.779 0.616 0.941    × 
N
H
N
N
 
ZINC39232949 0.779 0.650 0.908    × 
NH
O
N
H
 
ZINC04086135 0.779 0.658 0.901 ×    
N
H
N
OH  
ZINC00166610 0.779 0.665 0.893  ×   
H
N
O
O
-
 
ZINC05775431 0.779 0.695 0.864    × 
  
 
A13 
Structure ZINC Identifier Similarity Shape Electronic 
Isomers and 
pseudoisomers 
Different 
core 
Very 
different 
No relevant 
functional group 
N
H
N
H2N
 
ZINC19486558 0.780 0.615 0.945  ×   
H
N N
 
ZINC00050693 0.781 0.642 0.920    × 
S
NH
O  
ZINC38918044 0.782 0.597 0.967  ×   
O
NH
H2N
 
ZINC02505847 0.783 0.623 0.943   ×  
N
N
OH
 
ZINC05837089 0.783 0.666 0.901  ×   
N
H
N
O
 
ZINC02534051 0.784 0.653 0.915    × 
  
 
A14 
Structure ZINC Identifier Similarity Shape Electronic 
Isomers and 
pseudoisomers 
Different 
core 
Very 
different 
No relevant 
functional group 
N
H
N
H
Cl
 
ZINC66055026 0.784 0.625 0.942    × 
N
H
N
 
ZINC22015465 0.784 0.629 0.940    × 
O
OH
 
ZINC00406909 0.785 0.649 0.920   ×  
S+
N
H
 
ZINC05105345 0.785 0.674 0.895    × 
H
N
O
O
-
 
ZINC00103501 0.786 0.706 0.866    × 
S
N
OH  
ZINC65339297 0.786 0.603 0.970  ×   
  
 
A15 
Structure ZINC Identifier Similarity Shape Electronic 
Isomers and 
pseudoisomers 
Different 
core 
Very 
different 
No relevant 
functional group 
N NH  
ZINC32233020 0.787 0.635 0.940    × 
O
OH
H2N
 
ZINC39119558 0.788 0.650 0.925  ×   
N
N
F  
ZINC33884628 0.788 0.608 0.967    × 
O
HN
 
ZINC05480972 0.789 0.629 0.948    × 
NH+
H
N
 
ZINC22015465 0.789 0.645 0.933    × 
O
N
H
F
 
ZINC01518176 0.789 0.652 0.926    × 
  
 
A16 
Structure ZINC Identifier Similarity Shape Electronic 
Isomers and 
pseudoisomers 
Different 
core 
Very 
different 
No relevant 
functional group 
N
H
N
HO
 
ZINC03845012 0.790 0.635 0.946  ×   
N
H
N
N
 
ZINC05117514 0.792 0.593 0.991    × 
N
HH2N  
ZINC00501252 0.792 0.681 0.903 ×    
N
H
N
HN
NH2
 
ZINC13285077 0.792 0.639 0.945  ×   
N
H
NH3
+
 
ZINC15445928 0.793 0.693 0.893    × 
N
H
N
 
ZINC40448330 0.793 0.645 0.942    × 
  
 
A17 
Structure ZINC Identifier Similarity Shape Electronic 
Isomers and 
pseudoisomers 
Different 
core 
Very 
different 
No relevant 
functional group 
N
NH2
 
ZINC35325036 0.794 0.684 0.903 ×    
N
H
SNH2N  
ZINC05777096 0.794 0.642 0.947    × 
N
H
N
 
ZINC01519035 0.794 0.646 0.942    × 
N
H
S
O
 
ZINC19724840 0.795 0.647 0.942    × 
N
H
HN
O
 
ZINC03944854 0.796 0.674 0.918 ×    
N
HO  
ZINC08707999 0.797 0.689 0.904    × 
  
 
A18 
Structure ZINC Identifier Similarity Shape Electronic 
Isomers and 
pseudoisomers 
Different 
core 
Very 
different 
No relevant 
functional group 
N
H
N
 
ZINC95831280 0.797 0.671 0.923    × 
H
N
N
H+  
ZINC40448330 0.798 0.663 0.932    × 
H
N
F
F  
ZINC01516739 0.798 0.673 0.923    × 
N
H
N
H  
ZINC98233994 0.799 0.658 0.939    × 
H
N N
 
ZINC00050695 0.799 0.657 0.941    × 
H
N
F
F
 
ZINC01518212 0.800 0.654 0.946    × 
N
H
N
 
ZINC00050716 0.801 0.659 0.942    × 
N
 
ZINC39241206 0.806 0.616 0.996    × 
  
 
A19 
Structure ZINC Identifier Similarity Shape Electronic 
Isomers and 
pseudoisomers 
Different 
core 
Very 
different 
No relevant 
functional group 
HN
HN
O
 
ZINC01626613 0.808 0.718 0.898 ×    
H
N
H2N  
ZINC03844886 0.810 0.699 0.921 ×    
N
H
OH
 
ZINC08752894 0.812 0.706 0.919    × 
H
N NH2
 
ZINC34543816 0.818 0.691 0.945 ×    
N
N  
ZINC02495043 0.820 0.693 0.946    × 
N
H
H2N
 
ZINC33978742 0.820 0.672 0.968 ×    
H
N
OH
 
ZINC37632465 0.821 0.698 0.944 ×    
  
 
A20 
Structure ZINC Identifier Similarity Shape Electronic 
Isomers and 
pseudoisomers 
Different 
core 
Very 
different 
No relevant 
functional group 
N
H
NH2
 
ZINC35325033 0.822 0.699 0.945 ×    
N
H
HO
 
ZINC89203406 0.823 0.701 0.945 ×    
H
N
NH2
 
ZINC01708901 0.825 0.703 0.946 ×    
H
N
NH2
 
ZINC01663940 0.826 0.708 0.945 ×    
N
H
F
 
ZINC01518159 0.828 0.713 0.944    × 
N
HHO  
ZINC12356961 0.835 0.725 0.944 ×    
N
HNH2  
ZINC00154770 0.874 0.752 0.996 ×    
 
 A21 
 
Appendix 3 – Determination of enthalpic values: a worked example 
This appendix describes the full process for the determination of enthalpic values used in this 
thesis, using compound 4 as a worked example. 
Generating 3D structures of likely ionisation states 
To begin with, the likely ionisation states of each compound needed to be determined, and an 
approximate 3D structure for each of these ionisation states would be required as a starting 
point for the following step.  To do this, 2D structures were imported into LigPrep from 
ChemDraw as .cdx files, which would then output probable ionisation states at a specified pH of 
7.0 for each compound as 3D structures (Figure 97). 
N
H HO    
Figure 97 - The process of generating the 3D structures of likely ionisation state(s).  Construction of 2D 
structure in Chemdraw (left) and the outputted 3D structure of the likely ionisation state(s) (right) 
In the case of multiple ionisation states being generated, all potential ionisation states within 
20 kcal mol-1 of the lowest energy state (as determined by LigPrep) were taken forward. 
Generating plausible conformers as a starting point for the optimisation step 
Now that the most probable ionisation states of each compound are known, the process of 
optimising their geometry can begin.  The first part of this process is producing a number of 
reasonable conformers from which the geometry optimisation can begin.  Multiple conformers 
were used as starting points in order to improve the chances of finding the global minima. 
MacroModel was used to generate these conformers from the 3D structures outputted by 
LigPrep, as shown in Figure 98, and any conformer within 15 kcal mol-1 of the lowest energy 
conformer (as determined by MacroModel) were taken forward as starting points in the 
geometry optimisation steps.  Typically, between one and five conformers taken forward to the 
next step.  In the case of compound 4, four conformers were found, three of which were within 
15 kcal mol-1 of the lowest energy conformation.  Therefore, these three conformers were used 
as starting points in the geometry optimisation steps. 
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Figure 98 - The three conformers of compound 4 taken forward as starting points in the geometry 
optimisation steps 
These conformers were used as starting points for the neutral and radical cationic species.  For 
the radical and anionic species, the relevant proton was manually removed. 
Geometry optimisation 
The geometries of the neutral, radical cationic, anionic and radical species from the previous 
step were optimised using Jaguar.  Whether true minima had been found was determined by 
the absence of imaginary frequencies.  If imaginary frequencies were found, they were manually 
removed, and the optimisation was restarted.   The energy and geometry of each species was 
taken to be that of the lowest energy conformer (Figure 99). 
  
Neutral          Radical 
  
      Anionic       Radical Cationic 
Figure 99 - The optimised geometries of the neutral, radical, anionic and radical cationic forms of 
compound 4 
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Calculation of enthalpic values 
The enthalpic values were calculated as follows: 
BDE = H(R●) + H(H●) – H(RH) 
AIP = H(RH+●) + H(e-) – H(RH) 
PDE = H(R●) + H(H+) – H(RH+●) 
PA = H(R-) + H(H+) – H(RH) 
ETE = H(R●) + H(e-) – H(R-) 
where “H” indicates the enthalpy of a species.  The enthalpy of the hydrogen radical was 
calculated as -325.4 kcal mol-1, and literature values for the enthalpies of the proton and 
electron were used.[309]
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Appendix 4 – Total BDE, AIP, PDE, PA and ETE data 
  Absolute Relative to Compound 4 
Structure Compound BDE AIP PDE PA ETE BDE AIP PDE PA ETE 
N
H HO  
4 77.1 173.4 231.3 327.0 77.7 0.0 0.0 0.0 0.0 0.0 
N
H
N
H2N  
228 97.3 176.5 248.4 344.0 80.9 20.1 3.1 17.1 16.9 3.2 
N
H
N
O
 
262 71.5 175.5 223.6 326.6 72.5 -5.6 2.1 -7.7 -0.4 -5.2 
N
N
OH
 
227 72.7 189.9 210.4 327.8 72.5 -4.4 16.5 -21.0 0.8 -5.2 
S HN
O  
258 95.6 187.9 235.3 338.8 84.4 18.5 14.5 4.0 11.8 6.7 
H
N O
 
259 97.1 187.9 236.7 342.4 82.3 19.9 14.5 5.4 15.4 4.6 
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  Absolute Relative to Compound 4 
Structure Compound BDE AIP PDE PA ETE BDE AIP PDE PA ETE 
NH
O
 
260 95.1 180.6 242.1 340.5 82.2 18.0 7.2 10.8 13.5 4.5 
S NH
O  
213 93.4 179.3 241.7 336.5 84.5 16.3 5.9 10.4 9.5 6.8 
S HN
O
 
257 73.2 176.5 224.3 319.6 81.2 -4.0 3.1 -7.0 -7.4 3.5 
S N
HO
 
256 81.7 182.6 226.8 328.2 81.2 4.6 9.2 -4.6 1.1 3.5 
N
H
N
OH
 
212 73.0 169.8 230.8 338.5 62.1 -4.1 -3.6 -0.5 11.5 -15.6 
N
H
NH
O
 
211 102.1 184.9 244.8 345.2 84.5 24.9 11.5 13.5 18.2 6.8 
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  Absolute Relative to Compound 4 
Structure Compound BDE AIP PDE PA ETE BDE AIP PDE PA ETE 
N
H
NH
O
 
211 95.5 --- --- 333.2 89.9 18.4 --- --- 6.2 12.2 
N
H
OH
 
255 82.1 173.1 236.6 335.5 74.2 5.0 -0.3 5.3 8.5 -3.5 
N
H
HO
 
210 82.8 177.5 232.9 348.9 61.4 5.6 4.1 1.5 21.9 -16.2 
N
H OH  
209 87.9 177.7 237.8 339.4 76.1 10.7 4.3 6.5 12.4 -1.6 
N
HO
OH
 
198 92.3 188.9 231.0 331.3 88.6 15.2 15.5 -0.3 4.3 10.9 
N
H HO  
149 90.2 177.4 240.4 345.4 72.4 13.1 4.0 9.1 18.3 -5.2 
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  Absolute Relative to Compound 4 
Structure Compound BDE AIP PDE PA ETE BDE AIP PDE PA ETE 
N
HO
O
O  
217 90.0 193.2 224.4 340.4 77.2 12.9 19.8 -6.9 13.4 -0.5 
N
H
N
HO  
214 87.1 187.3 227.5 330.6 84.2 10.0 13.9 -3.8 3.6 6.5 
N
H
HO
 
261 83.2 181.5 229.3 331.9 78.9 6.1 8.1 -2.0 4.8 1.2 
OH
OH  
Catechol 77.4 200.6 204.4 339.5 65.4 0.3 27.2 -26.9 12.5 -12.2 
N
HO  
236 86.3 180.7 233.2 338.7 75.2 9.1 7.3 1.8 11.6 -2.5 
N
H HO  
186 77.8 172.0 233.4 329.4 76.1 0.7 -1.4 2.1 2.3 -1.6 
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  Absolute Relative to Compound 4 
Structure Compound BDE AIP PDE PA ETE BDE AIP PDE PA ETE 
N
H HO  
240 76.8 170.6 233.8 327.5 77.0 -0.3 -2.8 2.5 0.5 -0.7 
N
H HO  
238 77.0 171.5 233.1 327.8 76.8 -0.1 -1.9 1.8 0.8 -0.9 
N
H HO  
241 76.5 169.4 234.7 328.0 76.1 -0.7 -4.0 3.4 1.0 -1.6 
N
H HO  
239 76.9 171.7 232.8 327.4 77.1 -0.2 -1.7 1.5 0.4 -0.6 
N
H HO  
243 75.9 172.1 231.5 327.0 76.5 -1.2 -1.3 0.1 0.0 -1.2 
N
H HO  
242 76.3 170.2 233.7 327.8 76.1 -0.8 -3.2 2.4 0.8 -1.6 
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  Absolute Relative to Compound 4 
Structure Compound BDE AIP PDE PA ETE BDE AIP PDE PA ETE 
N
H HO  
244 75.6 171.4 231.8 328.1 75.1 -1.5 -2.0 0.5 1.1 -2.6 
N
H HO  
237 79.4 175.9 231.1 329.4 77.6 2.3 2.5 -0.2 2.4 -0.1 
N
HOF  
245 84.5 187.3 224.8 335.1 77.1 7.4 13.9 -6.6 8.0 -0.6 
N
H HO
F
 
253 76.2 173.9 229.9 325.0 78.8 -0.9 0.5 -1.4 -2.0 1.1 
N
H HO
F
 
250 77.4 175.7 229.3 324.3 80.7 0.3 2.3 -2.0 -2.8 3.0 
N
H HO
F
 
249 77.6 177.4 227.8 324.1 81.1 0.4 4.0 -3.6 -2.9 3.4 
  
 
A30 
  Absolute Relative to Compound 4 
Structure Compound BDE AIP PDE PA ETE BDE AIP PDE PA ETE 
N
H HO
F
 
251 76.7 174.3 230.0 324.7 79.6 -0.4 0.9 -1.4 -2.3 1.9 
N
H HOF  
247 78.3 177.0 228.9 325.3 80.5 1.2 3.6 -2.4 -1.7 2.9 
N
H HO F  
246 78.7 176.8 229.5 325.2 81.0 1.6 3.4 -1.8 -1.8 3.3 
N
H HO
F
 
252 76.6 175.5 228.7 322.5 81.6 -0.5 2.1 -2.6 -4.5 3.9 
N
H HO
F
 
254 75.8 176.8 226.7 324.3 79.1 -1.3 3.4 -4.7 -2.7 1.4 
N
H HO
F
 
248 77.8 176.7 228.7 323.9 81.4 0.7 3.3 -2.6 -3.1 3.7 
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  Absolute Relative to Compound 4 
Structure Compound BDE AIP PDE PA ETE BDE AIP PDE PA ETE 
N
H HO
 
263 91.2 176.9 242.0 339.9 78.9 14.1 3.5 10.6 12.8 1.2 
N
H HO  
263 90.6 176.6 241.7 339.6 78.6 13.5 3.2 10.4 12.6 0.9 
OH
O
 
218 85.9 189.1 224.4 344.6 68.9 8.8 15.7 -6.9 17.5 -8.8 
OH
OH  
Hydroquinone 82.1 193.1 216.6 350.1 59.6 4.9 19.7 -14.7 23.0 -18.1 
OH
 
168 86.6 184.9 229.3 339.7 74.5 9.5 11.5 -2.0 12.7 -3.2 
N
H H2N  
152 84.8 172.8 239.6 344.4 67.9 7.6 -0.6 8.2 17.4 -9.8 
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  Absolute Relative to Compound 4 
Structure Compound BDE AIP PDE PA ETE BDE AIP PDE PA ETE 
O
N
HO  
166 98.0 193.6 232.1 345.1 80.5 20.9 20.2 0.7 18.1 2.8 
S
N
HO  
167 92.5 191.3 228.8 336.2 83.9 15.3 17.9 -2.5 9.2 6.2 
OH
OH
O
 
Salicylic acid 94.0 210.0 211.7 347.0 74.6 16.9 36.6 -19.7 20.0 -3.1 
OH
NO2
 
2-Nitrophenol 101.1 223.1 205.5 337.4 91.3 23.9 49.7 -25.8 10.3 13.6 
OH
NH2
O
 
Salicylamide 91.6 202.2 217.0 335.0 84.2 14.5 28.8 -14.3 8.0 6.5 
OH
 
2-Methylphenol 85.5 201.5 211.6 347.6 65.5 8.4 28.1 -19.7 20.6 -12.2 
OH
 
Phenol 87.7 209.1 206.3 349.3 66.0 10.6 35.7 -25.0 22.3 -11.7 
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  Absolute Relative to Compound 4 
Structure Compound BDE AIP PDE PA ETE BDE AIP PDE PA ETE 
OH
O
 
Guaiacol 86.8 193.5 220.8 353.3 61.1 9.6 20.1 -10.5 26.2 -16.6 
OH
OH  
136 79.5 185.3 221.8 350.2 56.9 2.4 11.9 -9.5 23.1 -20.8 
OH
 
169 87.0 193.9 220.7 342.4 72.3 9.9 20.5 -10.6 15.3 -5.4 
N
H
OH
 
160 82.9 175.4 235.1 343.8 66.8 5.8 2.0 3.8 16.7 -10.9 
OH  
235 85.1 191.0 221.7 343.1 69.5 8.0 17.6 -9.6 16.1 -8.2 
CH3
OH
 
Methanol 102.0 258.6 171.0 381.2 48.5 24.9 85.2 -60.3 54.1 -29.2 
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Appendix 5 – The PrestoBlue assay procedure 
The U87 and SVG p12 cells (obtained from ECACC) were maintained in Minimum Essential 
Medium (MEM) supplemented with 10% (v/v) foetal bovine serum (FBS), 2mM L-glutamine, 1 
mM sodium pyruvate and 1% (v/v) non-essential amino acids (NEAA) (Lonza) in a 37 oC 
humidified incubator supplied with 5% CO2. The cells were trypsinised before being seeded at a 
density of 103 cells/well (81 µL) into 96-well plates and incubated in growth media for 24 hours, 
before being treated with a solution of the compound (9 µL, preloaded in and containing ≤0.5% 
absolute DMSO) in triplicate and left for incubation for a further 24 hours. At this point, 10 µL of 
the pre-warmed PrestoBlue solution was added to each well, and incubated for 60 minutes. 
After 60 minutes, the absorbance was recorded at 612 nm using an XFluor4 GENios Pro plate 
reader.  Half of the maximal effective concentration (EC50) compared to untreated vehicle 
controls containing ≤0.5% absolute DMSO was calculated by nonlinear regression analysis.  
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Appendix 6 – SRB Assay Procedure 
Short-term cell cultures (IN1472, IN1528, IN1760) were prepared from approximately 10mg of 
adult GBM biopsy tissue and maintained in Hams F10 nutrient mix [Invitrogen, Paisley UK] 
containing 10% foetal calf serum in a 37 °C non-CO2 incubator as previously described.[310] 
Passages of 10 to 14 were employed for the current study. In addition, we also employed U251 
and U87 which are established glioblastoma cell lines cultured under similar conditions. 
Treated cells were assessed for their capacity to proliferate following treatment 
with compounds using sulphorhodamine B (SRB) assay.[311] Briefly, 3000 cells were seeded per 
well in a 96 well plate and allowed to reach exponential growth (48 hours). Compounds 
were dissolved in DMSO [Sigma Aldrich; UK] and cells were treated for 72 hours with serial 
dilutions of the drug.  The culture medium was removed and the cells fixed in 
10% trichloroacetic acid [Sigma Aldrich; UK] on ice for 30 min followed by washing in water and 
air-drying. Cells were stained with 0.4% sulforhodamine B [Sigma Aldrich; UK] prepared in 1% 
acetic acid for 15-20 mins, washed in 1% acetic acid and air-dried. The dye was solubilized in 
100 µL of 10mM Tris (not buffered) and read at 560nm [Dynatech MR5000] for quantification. 
Analysis- Sigmoidal Dose Response (Variable Slope) (Non-Linear Fit) 
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Appendix 7 – Comparisons between EC50 values and radical-forming 
enthalpic values 
This appendix contains the comparisons between EC50 values of compounds against the radical-
forming enthalpic values BDE, AIP, PDE, PA and ETE.  All enthalpic values are given in kcal mol-1, 
and all EC50 values are given in μM.  The data is arranged as one graph per cell culture. 
Raw data 
Batch 1 
EC50 values / μM 
U87 U251 IN1472 IN1528 IN1760 
4 233.1 337.7 332.4 497.1 465.6 
152 354.6 537.5 527.1 690.9 4791.1 
 
Batch 2 
EC50 values / μM 
U87 U251 IN1472 IN1528 IN1760 
Phenol 930 2420 1990 1000 7350 
Salicylamide 850 2420 1430 1190 8660 
2-Nitrophenol 950 2270 190 1500 6560 
2-Methylphenol 740 1960 1530 1040 3800 
Guaiacol 570 4230 1520 1170 1660 
Aspirin 780 3240 1640 1320 2910 
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Batch 3 
EC50 values / μM 
U251 IN1528 IN1760 
4 300 760 100 
Phenol 5110 5170 1170 
2-Methylphenol 3110 1550 4500 
Aspirin7 1110 5970 1200 
Hydroquinone 220 67540 1310 
 
Batch 4 
EC50 values / μM 
U251 IN1528 IN1760 
4 310 1190 18430 
166 3690 14080 8798008 
167 1610 9710 - 
168 240 490 4970 
 
                                                          
7 Although EC50 data is for aspirin, the enthalpic values used were calculated for deacetylated active agent 
(salicylic acid) 
8 Anomalous data – not included in analysis 
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Batch 5 
EC50 values / μM 
U251 IN1528 IN1760 
4 60 270 60 
Phenol 80 450 750 
198 110 120 50 
244 30 10 10 
169 350 210 370 
217 680 530 1110 
214 50 20 20 
235 250 70 90 
160 40 300 90 
149 7 420 150 
218 6 70 340 
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Comparisons between EC50 values and BDE values 
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Comparisons between EC50 values and AIP values 
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Comparisons between EC50 values and PDE values 
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Comparisons between EC50 values and PA values 
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Comparisons between EC50 values and ETE values 
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Comparisons between the activity of simple ortho-substituted phenols and their 
calculated enthalpic values 
  U87 U251 IN1472 IN1528 IN1760 
BDE 
Trendline 
y = -40.0x -
24.8 
y = 6.10x 
+112.0 
y = 12.7x 
+123.0 
y = -81.8x -
160.6 
y = -7.34x 
+64.3 
R2 0.315 0.016 0.700 0.844 0.121 
AIP 
Trendline 
y = -100.0x -
83.4 
y = 37.0x + 
333.1 
y = 19.8x 
+266.9 
y = -94.9x - 
85.3 
y = -19.3x 
+136.1 
R2 0.659 0.198 0.564 0.379 0.281 
PDE 
Trendline 
y = 60.1x 
+386.3 
y = -30.8x 
+106.5 
y = -7.04x 
+190.7 
y = 13.0x 
+252.3 
y = 12.0x 
+255.9 
R2 0.677 0.394 0.204 0.020 0.308 
PA 
Trendline 
y = 56.2x + 
507.9 
y = -30.6x 
+240.3 
y = -10.5x 
+312.8 
y = 57.1x 
+520.5 
y = 19.2x 
+414.9 
R2 0.412 0.269 0.317 0.271 0.548 
ETE 
Trendline 
y = -96.2x - 
205.1 
y = 36.7x 
+199.5 
y = 23.3x 
+144.8 
y = -138.9x - 
353.5 
y = -26.5x -
22.9 
R2 0.438 0.141 0.561 0.583 0.380 
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Appendix 8 – XRD data for decomposition of 2-(3-methyl-1H-indol-2-
yl)phenol 
It was observed that on standing over a period of a few days, compound 186, a thick yellow oil, 
had crystallised into a pale yellow solid, and on doing so had changed by 1H NMR.  The resultant 
product was purified by recrystallization (ethyl acetate and petroleum ether) to form large 
amber crystals.  The crystal structure of the product was obtained by the EPSRC UK National 
Crystallography Service at the University of Southampton.[231]  
N
H HO
N
HO
OH
186 198  
Scheme 65 - Formation of compound 198 
Formula: C15H13NO2; Mr = 239.26; crystal dimensions: 0.090 × 0.090 × 0.030 mm; crystal system; 
triclinic; space group: P-1; a = 7.4707(3) Å, b = 8.5536(3) Å, c = 9.2611(3) Å, α = 96.251(3)o, β = 
97.624(3)o, γ = 98.134(3)o; Volume = 575,73(4) Å3; Z = 2; ρcalcd = 1.380 Mg/m3; μ = 0.092 mm-1; 
Mo Kα radiation, λ = 0.71073 Å; T = 100(2) K; 2Θmax = 54.95o; 10399/2622 
measured/independent reflections; Rint: 0.0216; R = 0.0392, wR = 0.0997; Δρmax = 0.378 eÅ−3, 
Δρmin = −0.206 eÅ−3.  Orange block crystals gave good diffraction.  The data were collected on a 
Rigaku AFC12 goniometer equipped with an enhanced sensitivity (HG) Saturn 724+ detector 
mounted at the window of an FR-E+ SuperBright molybdenum rotating anode generator with 
VHF Varimax optics (70 μm focus).  Cell determination and data collection was carried out using 
CrystalClear-SM Expert 3.1 b27 (Rigaku, 2013).  Data reduction, cell refinement and absorption 
correction was carried out using CrysAlisPro 1.171 (Oxford Diffraction, 2015).  Structure solution 
was carried out using SUPERFLIP.[312]  Structure refinement was carried out using SHELXL-
2014.[313]  Graphics were generated using enCIFer (International Union of Crystallography, 2014). 
N
OH
OHMe
(±)
198  
Figure 100 - Skeletal structure of compound 198 (left) alongside its crystal structure (right) 
